

[19] Patents Registry
The Hong Kong Special Administrative Region
香港特別行政區
專利註冊處

[11] 1251611 B
EP 3312282 B1

[12] **STANDARD PATENT (R) SPECIFICATION**
轉錄標準專利說明書

[21]	Application no. 申請編號 18110838.5	[51]	Int. Cl. C12N 15/82 (2006.01) C07K 14/78 (2006.01) A01H 5/00 (2018.01)
[22]	Date of filing 提交日期 23.08.2018		

[54] COLLAGEN PRODUCING PLANTS AND METHODS OF GENERATING AND USING SAME
生產膠原的植物及其生成和使用方法

[30]	Priority 優先權 29.09.2004 US 613719P	[73]	Proprietor 專利所有人 COLLPLANT LTD. 3 SAPIR STREET 74140 NES ZIONA ISRAEL
[43]	Date of publication of application 申請發表日期 01.02.2019		
[45]	Date of publication of grant of patent 批予專利的發表日期 19.06.2020	[72]	Inventor 發明人 SHOSEYOV, Oded STEIN, Hanan
EP Application no. & date 歐洲專利申請編號及日期 EP 17205280.5 28.09.2005		[74]	Agent and / or address for service 代理人及/或送達地址 CHINA PATENT AGENT (HONG KONG) LIMITED 22/F, Great Eagle Centre, 23 Harbour Road Wanchai HONG KONG
EP Publication no. & date 歐洲專利申請發表編號及日期 EP 3312282 25.04.2018			
Date of grant in designated patent office 指定專利當局批予專利日期 03.07.2019			



EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
03.07.2019 Bulletin 2019/27

(51) Int Cl.:
C12N 15/82 ^(2006.01) **C07K 14/78** ^(2006.01)
A01H 5/00 ^(2018.01)

(21) Application number: **17205280.5**

(22) Date of filing: **28.09.2005**

(54) **COLLAGEN PRODUCING PLANTS AND METHODS OF GENERATING AND USING SAME**

KOLLAGENPRODUZIERENDE PFLANZEN UND VERFAHREN ZUR ERZEUGUNG UND
VERWENDUNG DAVON

PLANTES PRODUISANT DU COLLAGENE ET PROCEDES DE GENERATION ET D'UTILISATION
DE CELLES-CI

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**

(30) Priority: **29.09.2004 US 613719 P**

(43) Date of publication of application:
25.04.2018 Bulletin 2018/17

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
**16171177.5 / 3 088 528
14185576.7 / 2 816 117
10168971.9 / 2 357 241
05789469.3 / 1 809 751**

(73) Proprietor: **CollPlant Ltd.**
74140 Nes Ziona (IL)

(72) Inventors:
• **SHOSEYOV, Oded**
9979700 Karme Yosef (IL)
• **STEIN, Hanan**
74057 Nes-Ziona (IL)

(74) Representative: **Dennemeyer & Associates S.A.**
Postfach 70 04 25
81304 München (DE)

(56) References cited:
WO-A-01/29242 WO-A-01/34647
US-A1- 2004 018 592 US-B1- 6 617 431

- **OLSEN DAVID ET AL: "Recombinant collagen and gelatin for drug delivery.", ADVANCED DRUG DELIVERY REVIEWS, vol. 55, no. 12, 28 November 2003 (2003-11-28), pages 1547-1567, XP002368792, ISSN: 0169-409X**
- **MERLE C ET AL: "Hydroxylated human homotrimeric collagen I in Agrobacterium tumefaciens-mediated transient expression and in transgenic tobacco plant", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 515, no. 1-3, 27 March 2002 (2002-03-27), pages 114-118, XP004347752, ISSN: 0014-5793**
- **PERRET S ET AL: "Prolyl hydroxylation of collagen type I is required for efficient binding to integrin [alpha]1[beta]1 and platelet glycoprotein VI but not to [alpha]2[beta]1", JOURNAL OF BIOLOGICAL CHEMISTRY 20030808 AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY INC. US, vol. 278, no. 32, 8 August 2003 (2003-08-08), pages 29873-29879, XP002626606, DOI: DOI:10.1074/JBC.M304073200**
- **OLSEN D R ET AL: "Production of human type I collagen in yeast reveals unexpected new insight into the molecular assembly of collagen trimers", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, vol. 276, no. 26, 29 June 2001 (2001-06-29), pages 24038-24043, XP002969135, ISSN: 0021-9258, DOI: DOI:10.1074/JBC.M101613200**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- HULMES D J S: "Building collagen molecules, fibrils, and suprafibrillar structures", JOURNAL OF STRUCTURAL BIOLOGY 2002 US LNKD-DOI:10.1006/JSBI.2002.4450, vol. 137, no. 1-2, 2002, pages 2-10, XP002626609, ISSN: 1047-8477
- RUGGIERO F ET AL: "Triple helix assembly and processing of human collagen produced in transgenic tobacco plants", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 469, no. 1, 3 March 2000 (2000-03-03) , pages 132-136, XP004261062, ISSN: 0014-5793
- NOKELAINEN MINNA ET AL: "High-level production of human type I collagen in the yeast *Pichia pastoris*", YEAST, vol. 18, no. 9, 30 June 2001 (2001-06-30), pages 797-806, XP008159810, ISSN: 0749-503X
- HIETA REIJA ET AL: "Cloning and characterization of a low molecular weight prolyl 4-hydroxylase from *Arabidopsis thaliana*. Effective hydroxylation of proline-rich, collagen-like, and hypoxia-inducible transcription factor alpha-like peptides", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 26, 28 June 2002 (2002-06-28), pages 23965-23971, XP002368907, ISSN: 0021-9258
- MATSUOKA K ET AL: "CIS-ELEMENTS OF PROTEIN TRANSPORT TO THE PLANT VACUOLES", JOURNAL OF EXPERIMENTAL BOTANY, OXFORD UNIVERSITY PRESS, GB, vol. 50, no. 331, 1 February 1999 (1999-02-01), pages 165-174, XP001188956, ISSN: 0022-0957, DOI: DOI:10.1093/JEXBOT/50.331.165
- MARTY FRANCIS: "Plant vacuoles", PLANT CELL, vol. 11, no. 4, April 1999 (1999-04), pages 587-599, XP002640272, ISSN: 1040-4651
- YOSHIDA K ET AL: "The plant vesicular transport engineering for production of useful recombinant proteins", JOURNAL OF MOLECULAR CATALYSIS B: ENZYMATIC 20040601 ELSEVIER NL, vol. 28, no. 4-6, 1 June 2004 (2004-06-01) , pages 167-171, XP002640279, DOI: DOI:10.1016/J.MOLCATB.2004.01.017
- NAKAMURA K ET AL: "PROTEIN TARGETING TO THE VACUOLE IN PLANT CELLS", PLANT PHYSIOLOGY, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, USA, vol. 101, 1993, pages 1-05, XP002038306, ISSN: 0032-0889, DOI: 10.1104/PP.101.1.1
- HORVATH HENRIETTE ET AL: "The production of recombinant proteins in transgenic barley grains", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, NATIONAL ACADEMY OF SCIENCES, US, vol. 97, no. 4, 15 February 2000 (2000-02-15), pages 1914-1919, XP002173225, ISSN: 0027-8424, DOI: 10.1073/PNAS.030527497

Description

[0001] The present disclosure relates to collagen producing plants and methods of generating and using same. More particularly, the present disclosure relates to a novel approach for generating plants capable of producing high levels of hydroxylated collagen chains which are capable of forming native triple helix type I collagen fibers.

[0002] Collagens are the main structural proteins responsible for the structural integrity of vertebrates and many other multicellular organisms. Type I collagen represents the prototypical fibrillar collagen and is the major collagen type in most tissues.

[0003] Type I collagen is the predominant collagen component of bone and tendon and is found in large amounts in skin, aorta, and lung. Type I collagen fibers provide great tensile strength and limited extensibility. The most abundant molecular form of type I collagen is a heterotrimer composed of two different alpha chains [$\alpha 1(I)$]₂ and $\alpha 2(1)$ (Inkinen, 2003). All fibrillar collagen molecules contain three polypeptide chains constructed from a repeating Gly-X-Y triplet, where X and Y can be any amino acid but are frequently the imino acids proline and hydroxyproline.

[0004] Fibril forming collagens are synthesized as precursor procollagens containing globular N- and C-terminal extension propeptides. The biosynthesis of procollagen is a complex process involving a number of different post-translational modifications including proline and lysine hydroxylation, N-linked and O-linked glycosylation and both intra- and inter-chain disulphide-bond formation. The enzymes carrying out these modifications act in a coordinated fashion to ensure the folding and assembly of a correctly aligned and thermally stable triple-helical molecule.

[0005] Each procollagen molecule assembles within the rough endoplasmic reticulum from the three constituent polypeptide chains. As the polypeptide chain is co-translationally translocated across the membrane of the endoplasmic reticulum, hydroxylation of proline and lysine residues occurs within the Gly-X-Y repeat region. Once the polypeptide chain is fully translocated into the lumen of the endoplasmic reticulum the C-propeptide folds. Three pro-alpha chains then associate via their C-propeptides to form a trimeric molecule allowing the Gly-X-Y repeat region to form a nucleation point at its C- terminal end, ensuring correct alignment of the chains. The Gly-X-Y region then folds in a C-to-N direction to form a triple helix.

[0006] The temporal relationship between polypeptide chain modification and triple-helix formation is crucial as hydroxylation of proline residues is required to ensure stability of the triple helix at body temperature, once formed, the triple helix no longer serves as a substrate for the hydroxylation enzyme. The C-propeptides (and to a lesser extent the N-propeptides) keep the procollagen soluble during its passage through the cell (Bulleid et al., 2000). Following or during secretion of procollagen molecules into the extracellular matrix, propeptides are removed by procollagen N- and C-proteinases, thereby triggering spontaneous self-assembly of collagen molecules into fibrils (Hulmes, 2002). Removal of the propeptides by procollagen N- and C-proteinases lowers the solubility of procollagen by >10000-fold and is necessary and sufficient to initiate the self-assembly of collagen into fibers. Crucial to this assembly process are short non triple-helical peptides called telopeptides at the ends of the triple-helical domain, which ensure correct registration of the collagen molecules within the fibril structure and lower the critical concentration for self-assembly (Bulleid et al., 2000). In nature, the stability of the triple-helical structure of collagen requires the hydroxylation of prolines by the enzyme prolyl-4-hydroxylase (P4H) to form residues of hydroxyproline within a collagen chain.

[0007] Plants expressing collagen chains are known in the art, see for example, U.S. Pat. No. 6,617,431 and (Merle et al., 2002, Ruggiero et al., 2000). Although plants are capable of synthesizing hydroxyproline-containing proteins the prolyl hydroxylase that is responsible for synthesis of hydroxyproline in plant cells exhibits relatively loose substrate sequence specificity as compared with mammalian P4H and thus, production of collagen containing hydroxyproline only in the Y position of Gly -X-Y triplets requires plant co-expression of collagen and P4H genes (Olsen et al, 2003).

[0008] An attempt to produce human collagens that rely on the hydroxylation machinery naturally present in plants resulted in collagen that is poor in proline hydroxylation (Merle et al., 2002). Such collagen melts or loses its triple helical structure at temperatures below 30 °C. Co-expression of collagen and prolyl-hydroxylase results with stable hydroxylated collagen that is biologically relevant for applications at body temperatures (Merle et al., 2002).

[0009] Lysyl hydroxylase (LH, EC 1.14.11.4), galactosyltransferase (EC 2.4.1.50) and glucosyltransferase (EC 2.4.1.66) are enzymes involved in posttranslational modifications of collagens. They sequentially modify lysyl residues in specific positions to hydroxylysyl, galactosylhydroxylysyl and glucosylgalactosyl hydroxylysyl residues. These structures are unique to collagens and essential for their functional activity (Wang et al, 2002). A single human enzyme, Lysyl hydroxylase 3 (LH3) can catalyze all three consecutive steps in hydroxylysine linked carbohydrate formation (Wang et al, 2002).

[0010] Hydroxylysins of a human collagen expressed in tobacco form less than 2 % of the hydroxylysins found in a bovine collagen (0.04 % of residues / 1.88 % of residues). This suggests that plant endogenous Lysyl hydroxylase is unable to sufficiently hydroxylate lysines in collagen.

[0011] WO 0134647 and US 2004018592 provide animal collagens and gelatins and compositions thereof, and methods of producing the same.

[0012] OLSEN DAVID ET AL, relates to "Recombinant collagen and gelatin for drug delivery.", ADVANCED DRUG

DELIVERY REVIEWS, (20031128), vol. 55, no. 12, ISSN 0169-409X, pages 1547 - 1567.

[0013] MERLE C ET AL, relates to "Hydroxylated human homotrimeric collagen I in Agrobacterium tumefaciens-mediated transient expression and in transgenic tobacco plant", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (20020327), vol. 515, no. 1-3, ISSN 0014-5793, pages 114 - 118.

[0014] While reducing the present disclosure to practice, the present inventors uncovered that efficient hydroxylation of collagen chains relies upon sequestering of the collagen chain along with an enzyme capable of correctly modifying this polypeptide.

SUMMARY OF THE INVENTION

[0015] The present invention relates to a method of producing collagen in a plant or an isolated plant cell comprising expressing in the plant or the isolated plant cell at least one type of a collagen alpha chain which comprises a signal peptide for targeting to a vacuole and exogenous P4H which comprises a signal peptide for targeting to a vacuole in a manner enabling accumulation of said at least one type of said collagen alpha chain and said exogenous P4H in a subcellular compartment devoid of endogenous P4H activity, thereby producing the collagen in the plant.

[0016] Preferably, it comprises expressing exogenous LH3 in said subcellular compartment devoid of endogenous P4H activity.

Preferably, said exogenous P4H is devoid of an ER retention sequence. Preferably, said at least one type of said collagen alpha chain includes a C-terminus and/or an N-terminus propeptide.

Preferably, the plant is selected from the group consisting of tobacco, maize, alfalfa, rice, potato, soybean, tomato, wheat, barley, canola, carrot and cotton.

Preferably, said exogenous P4H is human P4H.

Preferably, the plant is subjected to a stress condition.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The disclosure is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred aspects of the present disclosure only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the disclosure. In this regard, no attempt is made to show structural details of the disclosure in more detail than is necessary for a fundamental understanding of the disclosure, the description taken with the drawings making apparent to those skilled in the art how the several forms of the disclosure may be embodied in practice.

[0018] In the drawings:

FIGs. 1a-d illustrate construction of various expression cassettes and vectors used to transform test plants. All of the coding sequences synthesized as a part of the present study were optimized for expression in tobacco.

FIG. 2 illustrates various co-transformations approaches. Each expression cassette is represented by the short name of the coding sequence. The coding sequences are specified in table 1. Each co-transformation was performed by two pBINPLUS binary vectors. Each rectangle represents a single pBINPLUS vector carrying one, two or three expression cassettes. Promoter and terminators are specified in Example 1.

FIG. 3 is a multiplex PCR screening of transformants showing plants that are positive for Collagen alpha 1 (324bp fragment) or Collagen alpha 2 (537bp fragment) or both.

FIG. 4 is western blot analysis of transgenic plants generated by co-transformations 2, 3 and 4. Total soluble proteins were extracted from tobacco co-transformants #2, #3 and #4 and tested with anti-Collagen I antibody (#AB745 from Chemicon Inc.). Size markers were #SM0671 from Fermentas Inc. W.T. is a wild type tobacco. Positive collagen bands are visible in plants that are PCR positive for collagen type I alpha 1 or alpha 2 or both. Positive control band of 500ng collagen type I from human placenta (#CC050 from Chemicon Inc., extracted from human placenta by pepsin digestion) represents about 0.3% of the total soluble proteins (about 150µg) in the samples from the transgenic plants. The larger band at about 140 kDa in the human collagen sample is a procollagen with its C-propeptide as detected by anti carboxy-terminal pro-peptide of collagen type I antibody (#MAB1913 from Chemicon Inc.). The smaller band at about 120 kDa in the human collagen sample is a collagen without propeptides. Due to their unusual composition proline rich proteins (including collagen)s consistently migrate on polyacrylamid gels as bands with molecular mass higher than expected. Therefore the collagen chains without propeptides with a molecular weight of about 95kDa migrate as a band of about 120kDa.

FIG. 5 is a western blot analysis of transgenic plant generated by co-transformation #8 (carrying appoplast signals translationally fused to the collagen chains). Total soluble proteins were extracted from transgenic tobacco leaves and tested with anti-Collagen I antibody (#AB745 from Chemicon Inc.) Positive collagen alpha 2 band is visible in

plant 8-141. Collagen type I from human placenta (#CC050 from Chemicon Inc.) served as control.

FIGs. 6a-b illustrate collagen triple helix assembly and thermal stability as qualified by heat treatment and Trypsin or Pepsin digestion. In Figure 6a - total soluble protein from tobacco 2-9 (expressing only col alpha1 and no P4H) and 3-5 (expressing both col alpha 1+2 and human P4H alpha and beta subunits) were subjected to heat treatment (15 minutes in 38 °C or 43 °C) followed by Trypsin digestion (20 minutes in R.T.) and tested with anti-Collagen I antibody in a Western blot procedure. Positive controls were samples of 500 ng human collagen I + total soluble proteins of w.t. tobacco. In Figure 6b - total soluble proteins were extracted from transgenic tobacco 13-6 (expressing collagen I alpha 1 and alpha 2 chains - pointed by arrows, human P4H alpha and beta subunits and human LH3) and subjected to heat treatment (20 minutes in 33 °C, 38 °C or 42 °C), immediately cooled on ice to prevent reassembly of triple helix and incubated with pepsin for 30 minutes in room temperature (about 22 °C) followed by testing with anti-Collagen I antibody ((#AB745 from Chemicon Inc.) in a standard Western blot procedure. Positive control was sample of ~50 ng human collagen I (#CC050 from Chemicon Inc., extracted from human placenta by pepsin digestion) which was added to total soluble proteins extracted from w.t. tobacco.

FIG. 7 illustrates Northern blot analysis conducted on wild type tobacco. Blots were probed with tobacco P4H cDNA.

FIG. 8 is a western blot analysis of transgenic plants generated by co-transformations 2, 3 and 13. Total soluble protein was extracted from tobacco co-transformants and tested with anti human P4H alpha and beta and anti-Collagen I antibodies.

DESCRIPTION OF THE PREFERRED ASPECTS

[0019] The present disclosure is of plants expressing and accumulating collagen which can be used to produce collagen and collagen fibers which display characteristics of mammalian collagen.

[0020] The principles and operation of the present disclosure may be better understood with reference to the drawings and accompanying descriptions.

[0021] Before explaining at least one aspect of the disclosure in detail, it is to be understood that the disclosure is not limited in its application to the details set forth in the following description or exemplified by the Examples. The disclosure is capable of other aspects or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

[0022] Collagen producing plants are known in the art. Although such plants can be used to produce collagen chains as well as collagen, such chains are incorrectly hydroxylated and thus self-assembly thereof, whether in planta or not, leads to collagen which is inherently unstable.

[0023] While reducing the present disclosure to practice, the present inventors have devised a plant expression approach which ensures correct hydroxylation of collagen chains and thus enables in-planta production of collagen which closely mimics the characteristics (e.g. temperature stability) of human type I collagen.

[0024] Thus, according to one aspect of the present disclosure there is provided a genetically modified plant which is capable of expressing at least one type of a collagen alpha chain and accumulating it in a subcellular compartment which is devoid of endogenous P4H activity.

[0025] As used herein, the phrase "genetically modified plant" refers to any lower (e.g. moss) or higher (vascular) plant or a tissue or an isolated cell thereof (e.g., of a cell suspension) which is stably or transiently transformed with an exogenous polynucleotide sequence. Examples of plants include Tobacco, Maize, Alfalfa, Rice, Potato, Soybean, Tomato, Wheat, Barley, Canola, Cotton, Carrot as well as lower plants such as moss.

[0026] As used herein, the phrase "collagen chain" refers to a collagen subunit such as the alpha 1 or 2 chains of collagen fibers, preferably type I fibers. As used herein, the phrase "collagen" refers to an assembled collagen trimer, which in the case of type I collagen includes two alpha 1 chains and one alpha 2 chain. A collagen fiber is collagen which is devoid of terminal propeptides C and N.

[0027] As is used herein, the phrase "subcellular compartment devoid of endogenous P4H activity" refers to any compartmentalized region of the cell which does not include plant P4H or an enzyme having plant-like P4H activity. Examples of such subcellular compartments include the vacuole, apoplast and cytoplasm as well as organelles such as the chloroplast, mitochondria and the like.

[0028] Any type of collagen chain can be expressed by the genetically modified plant of the present disclosure. Examples include Fibril-forming collagens (types I, II, III, V, and XI), networks forming collagens (types IV, VIII, and X), collagens associated with fibril surfaces (types IX, XII, and XIV), collagens which occur as transmembrane proteins (types XIII and XVII), or form 11-nm periodic beaded filaments (type VI). For further description please see Hulmes, 2002.

[0029] Preferably, the collagen chain expressed is an alpha 1 and/or 2 chain of type I collagen. The expressed collagen alpha chain can be encoded by any polynucleotide sequences derived from any mammal. Preferably, the sequences encoding collagen alpha chains are human and are set forth by SEQ ID NOs: 1 and 4.

[0030] Typically, alpha collagen chains expressed in plants may or may not include their terminal propeptides (i.e. propeptide C and propeptide N).

[0031] Ruggiero et al. (2000) note that processing of procollagen by plant proteolytic activity is different than normal processing in human and that propeptide C is removed by plant proteolytic activity although the cleavage site is unknown. Cleavage of the C propeptide may take place on a procollagen peptide before the assembly of trimmer (association of three C-Propeptides is essential for initiating the assembly of trimmers).

[0032] N-propeptide cleavage by plant proteolytic activity takes place in mature plants but not in plantlets. Such cleavage removes 2 amino acids from the N telopeptide (2 out of 17).

[0033] The C-propeptides (and to a lesser extent the N-propeptides) maintain the procollagen soluble during its passage through the animal cell (Bulleid et al., 2000) and are expected to have a similar effect in the plant cell. Following or during secretion of procollagen molecules into the extracellular matrix, propeptides are removed by procollagen N- and C-proteinases, thereby triggering spontaneous self-assembly of collagen molecules into fibrils (Hulmes, 2002). Removal of the propeptides by procollagen N- and C-proteinases lowers the solubility of procollagen by >10000-fold and is necessary and sufficient to initiate the self-assembly of collagen into fibers. Crucial to this assembly process are short non triple-helical peptides called telopeptides at the ends of the triple-helical domain, which ensure correct registration of the collagen molecules within the fibril structure and lower the critical concentration for self-assembly (Bulleid et al., 2000). Prior art describe the use of pepsin to cleave the propeptides during production of collagen (Bulleid et al 2000). However pepsin damages the telopeptides and as a result, pepsin-extracted collagen is unable to form ordered fibrillar structures (Bulleid et al 2000).

[0034] Protein disulfide isomerase (PDI) that form the beta subunit of human P4H was shown to bind to the C-propeptide prior to trimmer assembly thereby also acting as a molecular chaperone during chain assembly (Ruggiero et al, 2000). The use of human Procollagen I N-proteinase and Procollagen C-proteinase expressed in a different plants may generate collagen that is more similar to the native human collagen and can form ordered fibrillar structures.

[0035] In a case where N or C propeptides or both are included in the expressed collagen chain, the genetically modified plant of the present disclosure can also express the respective protease (i.e. C or N or both). Polynucleotide sequences encoding such proteases are exemplified by SEQ ID NOs: 18 (protease C) and 20 (Protease N). Such proteases can be expressed such that they are accumulated in the same subcellular compartment as the collagen chain.

[0036] Accumulation of the expressed collagen chain in a subcellular compartment devoid of endogenous P4H activity can be effected via any one of several approaches.

[0037] For example, the expressed collagen chain can include a signal sequence for targeting the expressed protein to a subcellular compartment such as the apoplast or an organelle (e.g. chloroplast). Examples of suitable signal sequences include the chloroplast transit peptide (included in Swiss-Prot entry P07689, amino acids 1- 57) and the Mitochondrion transit peptide (included in Swiss-Prot entry P46643, amino acids 1- 28). The Examples section which follows provides additional examples of suitable signal sequences as well as guidelines for employing such signal sequences in expression of collagen chains in plant cells.

[0038] Alternatively, the sequence of the collagen chain can be modified in a way which alters the cellular localization of collagen when expressed in plants.

[0039] As is mentioned hereinabove, the ER of plants includes a P4H which is incapable of correctly hydroxylating collagen chains. Collagen alpha chains natively include an ER targeting sequence which directs expressed collagen into the ER where it is post-translationally modified (including incorrect hydroxylation). Thus, removal of the ER targeting sequence will lead to cytoplasmic accumulation of collagen chains which are devoid of post translational modification including any hydroxylations.

[0040] Example 1 of the Examples section which follows describes generation of collagen sequences which are devoid of ER sequences.

[0041] Still alternatively, collagen chains can be expressed and accumulated in a DNA containing organelle such as the chloroplast or mitochondria. Further description of chloroplast expression is provided hereinbelow.

[0042] As is mentioned hereinabove, hydroxylation of alpha chains is required for assembly of a stable type I collagen. Since alpha chains expressed by the genetically modified plant of the present disclosure accumulate in a compartment devoid of endogenous P4H activity, such chains must be isolated from the plant, plant tissue or cell and in-vitro hydroxylated. Such hydroxylation can be achieved by the method described by Turpeenniemi-Hujanen and Myllyla (Concomitant hydroxylation of proline and lysine residues in collagen using purified enzymes in vitro. Biochim Biophys Acta. 1984 Jul 16;800(1):59-65).

[0043] Although such in-vitro hydroxylation can lead to correctly hydroxylated collagen chains, it can be difficult and costly to achieve.

[0044] To overcome the limitations of in-vitro hydroxylation, the genetically modified plant of the present disclosure preferably also co-expresses P4H which is capable of correctly hydroxylating the collagen alpha chain(s) [i.e. hydroxylating only the proline (Y) position of the Gly -X-Y triplets]. P4H is an enzyme composed of two subunits, alpha and beta. Both are needed to form an active enzyme while the Beta subunit also poses a chaperon function.

[0045] The P4H expressed by the genetically modified plant of the present disclosure is preferably a human P4H which is encoded by, for example, SEQ ID's NO:12 and 14. In addition, P4H mutants which exhibit enhanced substrate

specificity, or P4H homologues can also be used.

[0046] A suitable P4H homologue is exemplified by an *Arabidopsis* oxidoreductase identified by NCBI accession NP_179363. Pairwise alignment of this protein sequence and a human P4H alpha subunit conducted by the present inventors revealed the highest homology between functional domains of any known P4H homologs of plants.

[0047] Since P4H needs to co-accumulate with the expressed collagen chain, the coding sequence thereof is preferably modified accordingly (addition of signal sequences, deletions which may prevent ER targeting etc).

[0048] In mammalian cells, collagen is also modified by Lysyl hydroxylase, galactosyltransferase and glucosyltransferase. These enzymes sequentially modify lysyl residues in specific positions to hydroxyllysyl, galactosylhydroxyllysyl and glucosylgalactosyl hydroxyllysyl residues. A single human enzyme, Lysyl hydroxylase 3 (LH3) can catalyze all three consecutive steps in hydroxyllysine linked carbohydrate formation.

[0049] Thus, the genetically modified plant of the present disclosure preferably also expresses mammalian LH3. An LH3 encoding sequence such as that set forth by SEQ ID NO: 22 can be used for such purposes.

[0050] The collagen chain(s) and modifying enzymes described above can be expressed from a stably integrated or a transiently expressed nucleic acid construct which includes polynucleotide sequences encoding the alpha chains and/or modifying enzymes (e.g. P4H and LH3) positioned under the transcriptional control of plant functional promoters. Such a nucleic acid construct (which is also termed herein as an expression construct) can be configured for expression throughout the whole plant, defined plant tissues or defined plant cells, or at defined developmental stages of the plant. Such a construct may also include selection markers (e.g. antibiotic resistance), enhancer elements and an origin of replication for bacterial replication.

[0051] It will be appreciated that constructs including two expressible inserts (e.g. two alpha chain types, or an alpha chain and P4H) preferably include an individual promoter for each insert, or alternatively such constructs can express a single transcript chimera including both insert sequences from a single promoter. In such a case, the chimeric transcript includes an IRES sequence between the two insert sequences such that the downstream insert can be translated therefrom.

[0052] Numerous plant functional expression promoters and enhancers which can be either tissue specific, developmentally specific, constitutive or inducible can be utilized by the constructs of the present disclosure, some examples are provided hereinafter.

[0053] As used herein in the specification and in the claims section that follows the phrase "plant promoter" or "promoter" includes a promoter which can direct gene expression in plant cells (including DNA containing organelles). Such a promoter can be derived from a plant, bacterial, viral, fungal or animal origin. Such a promoter can be constitutive, i.e., capable of directing high level of gene expression in a plurality of plant tissues, tissue specific, i.e., capable of directing gene expression in a particular plant tissue or tissues, inducible, i.e., capable of directing gene expression under a stimulus, or chimeric, i.e., formed of portions of at least two different promoters.

[0054] Thus, the plant promoter employed can be a constitutive promoter, a tissue specific promoter, an inducible promoter or a chimeric promoter.

[0055] Examples of constitutive plant promoters include, without being limited to, CaMV35S and CaMV19S promoters, FMV34S promoter, sugarcane bacilliform badnavirus promoter, CsVMV promoter, *Arabidopsis* ACT2/ACT8 actin promoter, *Arabidopsis* ubiquitin UBQ1 promoter, barley leaf thionin BTH6 promoter, and rice actin promoter.

[0056] Examples of tissue specific promoters include, without being limited to, bean phaseolin storage protein promoter, DLEC promoter, PHS□ promoter, zein storage protein promoter, conglutin gamma promoter from soybean, AT2S1 gene promoter, ACT11 actin promoter from *Arabidopsis*, napA promoter from *Brassica napus* and potato patatin gene promoter.

[0057] The inducible promoter is a promoter induced by a specific stimuli such as stress conditions comprising, for example, light, temperature, chemicals, drought, high salinity, osmotic shock, oxidant conditions or in case of pathogenicity and include, without being limited to, the light-inducible promoter derived from the pea rbcS gene, the promoter from the alfalfa rbcS gene, the promoters DRE, MYC and MYB active in drought; the promoters INT, INPS, prxEa, Ha hsp17.7G4 and RD21 active in high salinity and osmotic stress, and the promoters hsr203J and str246C active in pathogenic stress.

[0058] Preferably the promoter utilized by the present disclosure is a strong constitutive promoter such that over expression of the construct inserts is effected following plant transformation.

[0059] It will be appreciated that any of the construct types used in the present disclosure can be co-transformed into the same plant using same or different selection markers in each construct type. Alternatively the first construct type can be introduced into a first plant while the second construct type can be introduced into a second isogenic plant, following which the transgenic plants resultant therefrom can be crossed and the progeny selected for double transformants. Further self-crosses of such progeny can be employed to generate lines homozygous for both constructs.

[0060] There are various methods of introducing nucleic acid constructs into both monocotyledonous and dicotyledonous plants (Potrykus, I., Annu. Rev. Plant. Physiol., Plant. Mol. Biol. (1991) 42:205-225; Shimamoto et al., Nature (1989) 338:274-276). Such methods rely on either stable integration of the nucleic acid construct or a portion thereof into the genome of the plant, or on transient expression of the nucleic acid construct in which case these sequences

are not inherited by a progeny of the plant.

[0061] In addition, several methods exist in which a nucleic acid construct can be directly introduced into the DNA of a DNA containing organelle such as a chloroplast.

[0062] There are two principle methods of effecting stable genomic integration of exogenous sequences such as those included within the nucleic acid constructs of the present disclosure into plant genomes:

(i) *Agrobacterium*-mediated gene transfer: Klee et al. (1987) *Annu. Rev. Plant Physiol.* 38:467-486; Klee and Rogers in *Cell Culture and Somatic Cell Genetics of Plants*, Vol. 6, Molecular Biology of Plant Nuclear Genes, eds. Schell, J., and Vasil, L. K., Academic Publishers, San Diego, Calif. (1989) p. 2-25; Gatenby, in *Plant Biotechnology*, eds. Kung, S. and Arntzen, C. J., Butterworth Publishers, Boston, Mass. (1989) p. 93-112.

(ii) direct DNA uptake: Paszkowski et al., in *Cell Culture and Somatic Cell Genetics of Plants*, Vol. 6, Molecular Biology of Plant Nuclear Genes eds. Schell, J., and Vasil, L. K., Academic Publishers, San Diego, Calif. (1989) p. 52-68; including methods for direct uptake of DNA into protoplasts, Toriyama, K. et al. (1988) *Bio/Technology* 6:1072-1074. DNA uptake induced by brief electric shock of plant cells: Zhang et al. *Plant Cell Rep.* (1988) 7:379-384. Fromm et al. *Nature* (1986) 319:791-793. DNA injection into plant cells or tissues by particle bombardment, Klein et al. *Bio/Technology* (1988) 6:559-563; McCabe et al. *Bio/Technology* (1988) 6:923-926; Sanford, *Physiol. Plant.* (1990) 79:206-209; by the use of micropipette systems: Neuhaus et al., *Theor. Appl. Genet.* (1987) 75:30-36; Neuhaus and Spangenberg, *Physiol. Plant.* (1990) 79:213-217; or by the direct incubation of DNA with germinating pollen, DeWet et al. in *Experimental Manipulation of Ovule Tissue*, eds. Chapman, G. P. and Mantell, S. H. and Daniels, W. Longman, London, (1985) p. 197-209; and Ohta, *Proc. Natl. Acad. Sci. USA* (1986) 83:715-719.

[0063] The *Agrobacterium* system includes the use of plasmid vectors that contain defined DNA segments that integrate into the plant genomic DNA. Methods of inoculation of the plant tissue vary depending upon the plant species and the *Agrobacterium* delivery system. A widely used approach is the leaf disc procedure which can be performed with any tissue explant that provides a good source for initiation of whole plant differentiation. Horsch et al. in *Plant Molecular Biology Manual A5*, Kluwer Academic Publishers, Dordrecht (1988) p. 1-9. A supplementary approach employs the *Agrobacterium* delivery system in combination with vacuum infiltration. The *Agrobacterium* system is especially viable in the creation of transgenic dicotyledenous plants.

[0064] There are various methods of direct DNA transfer into plant cells. In electroporation, protoplasts are briefly exposed to a strong electric field. In microinjection, the DNA is mechanically injected directly into the cells using very small micropipettes. In microparticle bombardment, the DNA is adsorbed on microprojectiles such as magnesium sulfate crystals, tungsten particles or gold particles, and the microprojectiles are physically accelerated into cells or plant tissues.

[0065] Following transformation plant propagation is exercised. The most common method of plant propagation is by seed. Regeneration by seed propagation, however, has the deficiency that due to heterozygosity there is a lack of uniformity in the crop, since seeds are produced by plants according to the genetic variances governed by Mendelian rules. Basically, each seed is genetically different and each will grow with its own specific traits. Therefore, it is preferred that the transformed plant be produced such that the regenerated plant has the identical traits and characteristics of the parent transgenic plant. Therefore, it is preferred that the transformed plant be regenerated by micropropagation which provides a rapid, consistent reproduction of the transformed plants.

[0066] Transient expression methods which can be utilized for transiently expressing the isolated nucleic acid included within the nucleic acid construct of the present disclosure include, but are not limited to, microinjection and bombardment as described above but under conditions which favor transient expression, and viral mediated expression wherein a packaged or unpackaged recombinant virus vector including the nucleic acid construct is utilized to infect plant tissues or cells such that a propagating recombinant virus established therein expresses the non-viral nucleic acid sequence.

[0067] Viruses that have been shown to be useful for the transformation of plant hosts include CaMV, TMV and BV. Transformation of plants using plant viruses is described in U.S. Pat. No. 4,855,237 (BGV), EP-A 67,553 (TMV), Japanese Published Application No. 63-14693 (TMV), EPA 194,809 (BV), EPA 278,667 (BV); and Gluzman, Y. et al., *Communications in Molecular Biology: Viral Vectors*, Cold Spring Harbor Laboratory, New York, pp. 172-189 (1988). Pseudovirus particles for use in expressing foreign DNA in many hosts, including plants, is described in WO 87/06261.

[0068] Construction of plant RNA viruses for the introduction and expression of non-viral exogenous nucleic acid sequences in plants is demonstrated by the above references as well as by Dawson, W. O. et al., *Virology* (1989) 172:285-292; Takamatsu et al. *EMBO J.* (1987) 6:307-311; French et al. *Science* (1986) 231:1294-1297; and Takamatsu et al. *FEBS Letters* (1990) 269:73-76.

[0069] When the virus is a DNA virus, the constructions can be made to the virus itself. Alternatively, the virus can first be cloned into a bacterial plasmid for ease of constructing the desired viral vector with the foreign DNA. The virus can then be excised from the plasmid. If the virus is a DNA virus, a bacterial origin of replication can be attached to the viral DNA, which is then replicated by the bacteria. Transcription and translation of this DNA will produce the coat protein which will encapsidate the viral DNA. If the virus is an RNA virus, the virus is generally cloned as a cDNA and inserted

into a plasmid. The plasmid is then used to make all of the constructions. The RNA virus is then produced by transcribing the viral sequence of the plasmid and translation of the viral genes to produce the coat protein(s) which encapsidate the viral RNA.

[0070] Construction of plant RNA viruses for the introduction and expression in plants of non-viral exogenous nucleic acid sequences such as those included in the construct of the present disclosure is demonstrated by the above references as well as in U.S. Pat. No. 5,316,931.

[0071] In one aspect, a plant viral nucleic acid is provided in which the native coat protein coding sequence has been deleted from a viral nucleic acid, a non-native plant viral coat protein coding sequence and a non-native promoter, preferably the subgenomic promoter of the non-native coat protein coding sequence, capable of expression in the plant host, packaging of the recombinant plant viral nucleic acid, and ensuring a systemic infection of the host by the recombinant plant viral nucleic acid, has been inserted. Alternatively, the coat protein gene may be inactivated by insertion of the non-native nucleic acid sequence within it, such that a protein is produced. The recombinant plant viral nucleic acid may contain one or more additional non-native subgenomic promoters. Each non-native subgenomic promoter is capable of transcribing or expressing adjacent genes or nucleic acid sequences in the plant host and incapable of recombination with each other and with native subgenomic promoters. Non-native (foreign) nucleic acid sequences may be inserted adjacent the native plant viral subgenomic promoter or the native and a non-native plant viral subgenomic promoters if more than one nucleic acid sequence is included. The non-native nucleic acid sequences are transcribed or expressed in the host plant under control of the subgenomic promoter to produce the desired products.

[0072] In a second aspect, a recombinant plant viral nucleic acid is provided as in the first aspect except that the native coat protein coding sequence is placed adjacent one of the non-native coat protein subgenomic promoters instead of a non-native coat protein coding sequence.

[0073] In a third aspect, a recombinant plant viral nucleic acid is provided in which the native coat protein gene is adjacent its subgenomic promoter and one or more non-native subgenomic promoters have been inserted into the viral nucleic acid. The inserted non-native subgenomic promoters are capable of transcribing or expressing adjacent genes in a plant host and are incapable of recombination with each other and with native subgenomic promoters. Non-native nucleic acid sequences may be inserted adjacent the non-native subgenomic plant viral promoters such that said sequences are transcribed or expressed in the host plant under control of the subgenomic promoters to produce the desired product.

[0074] In a fourth aspect, a recombinant plant viral nucleic acid is provided as in the third aspect except that the native coat protein coding sequence is replaced by a non-native coat protein coding sequence.

[0075] The viral vectors are encapsidated by the coat proteins encoded by the recombinant plant viral nucleic acid to produce a recombinant plant virus. The recombinant plant viral nucleic acid or recombinant plant virus is used to infect appropriate host plants. The recombinant plant viral nucleic acid is capable of replication in the host, systemic spread in the host, and transcription or expression of foreign gene(s) (isolated nucleic acid) in the host to produce the desired protein.

[0076] A technique for introducing exogenous nucleic acid sequences to the genome of the chloroplasts is known. This technique involves the following procedures. First, plant cells are chemically treated so as to reduce the number of chloroplasts per cell to about one. Then, the exogenous nucleic acid is introduced via particle bombardment into the cells with the aim of introducing at least one exogenous nucleic acid molecule into the chloroplasts. The exogenous nucleic acid is selected such that it is integratable into the chloroplast's genome via homologous recombination which is readily effected by enzymes inherent to the chloroplast. To this end, the exogenous nucleic acid includes, in addition to a gene of interest, at least one nucleic acid stretch which is derived from the chloroplast's genome. In addition, the exogenous nucleic acid includes a selectable marker, which serves by sequential selection procedures to ascertain that all or substantially all of the copies of the chloroplast genomes following such selection will include the exogenous nucleic acid. Further details relating to this technique are found in U.S. Pat. Nos. 4,945,050; and 5,693,507. A polypeptide can thus be produced by the protein expression system of the chloroplast and become integrated into the chloroplast's inner membrane.

[0077] The above described transformation approaches can be used to produce collagen chains and/or modifying enzymes as well as assembled collagen (with or without propeptides) in any species of plant, or plant tissue or isolated plants cell derived therefrom.

[0078] Preferred plants are those which are capable of accumulating large amounts of collagen chains, collagen and/or the processing enzymes described herein. Such plants may also be selected according to their resistance to stress conditions and the ease at which expressed components or assembled collagen can be extracted. Examples of preferred plants include Tobacco, Maize, Alfalfa, Rice, Potato, Soybean, Tomato, Wheat, Barley, Canola and Cotton.

[0079] Collagen fibers are extensively used in the food and cosmetics industry. Thus, although collagen fiber components (alpha chains) and modifying enzymes expressed by plants find utility in industrial synthesis of collagen, complete collagen production in plants is preferred for its simplicity and cost effectiveness.

[0080] Several approaches can be used to generate type I collagen in plants. For example, collagen alpha 1 chain

can be isolated from a plant expressing collagen alpha 1 and P4H (and optionally LH3) and mixed with a collagen alpha 2 chain which is isolated from a plant expressing collagen alpha 2 and P4H (and optionally LH3 and protease C and/or N). Since collagen alpha 1 chain self assembles into a triple helix by itself, it may be necessary to denature such a homotrimer prior to mixing and renaturation with the collagen alpha 2 chain.

[0081] Preferably, a first plant expressing collagen alpha 1 and P4H (and optionally LH3 and protease C and/or N) can be crossed with a second (and preferably isogenic) plant which expresses collagen alpha 2 or alternatively, a first plant expressing both alpha chains can be crossed with a second plant expressing P4H and optionally LH3 and protease C and/or N.

[0082] It should be noted that although the above described plant breeding approaches utilize two individually transformed plants, approaches which utilize three or more individually transformed plants, each expressing one or two components can also be utilized.

[0083] One of ordinary skill in the art would be well aware of various plant breeding techniques and as such no further description of such techniques is provided herein.

[0084] Although plant breeding approaches are preferred, it should be noted that a single plant expressing collagen alpha 1 and 2, P4H and LH3 (and optionally protease C and/or N) can be generated via several transformation events each designed for introducing one more expressible components into the cell. In such cases, stability of each transformation event can be verified using specific selection markers.

[0085] In any case, transformation and plant breeding approaches can be used to generate any plant, expressing any number of components. Presently preferred are plants which express collagen alpha 1 and 2 chains, P4H, LH3 and at least one protease (e.g. protease C and/or N). As is further described in the Examples section which follows, such plants accumulate collagen which exhibits stability at temperatures of up to 42 °C.

[0086] Progeny resulting from breeding or alternatively multiple-transformed plants can be selected, by verifying presence of exogenous mRNA and/or polypeptides by using nucleic acid or protein probes (e.g. antibodies). The latter approach is preferred since it enables localization of the expressed polypeptide components (by for example, probing fractionated plants extracts) and thus also verifies a potential for correct processing and assembly. Examples of suitable probes are provided in the Examples section which follows

[0087] Once collagen-expressing progeny is identified, such plants are further cultivated under conditions which maximize expression of the collagen chains as well as the modifying enzymes.

[0088] Since free proline accumulation may facilitate over production of different proline-rich proteins including the collagen chains expressed by the genetically modified plants of the present disclosure, preferred cultivating conditions are those which increase free proline accumulation in the cultivated plant.

[0089] Free proline accumulates in a variety of plants in response to a wide range of environmental stresses including water deprivation, salinization, low temperature, high temperature, pathogen infection, heavy metal toxicity, anaerobiosis, nutrient deficiency, atmospheric pollution and UV - irradiation (Hare and Cress, 1997).

[0090] Free proline may also accumulate in response to treatment of the plant or soil with compounds such as ABA or stress inducing compounds such as copper salt, paraquat, salicylic acid and the like.

[0091] Thus, collagen-expressing progeny can be grown under different stress conditions (e.g. different concentrations of NaCl ranging from 50mM up to 250mM). In order to further enhance collagen production, the effect of various stress conditions on collagen expression will be examined and optimized with respect to plant viability, biomass and collagen accumulation.

[0092] Plant tissues/cells are preferably harvested at maturity, and the collagen fibers are isolated using well known prior art extraction approaches, one such approach is detailed below.

[0093] Leaves of transgenic plants are ground to a powder under liquid nitrogen and the homogenate is extracted in 0.5 M acetic acid containing 0.2 M NaCl for 60 h at 4 °C. Insoluble material is removed by centrifugation. The supernatant containing the recombinant collagen is salt-fractionated at 0.4 M and 0.7 M NaCl. The 0.7 M NaCl precipitate, containing the recombinant heterotrimeric collagen, is dissolved in and dialyzed against 0.1 M acetic acid and stored at -20 °C (following Ruggiero et al., 2000).

[0094] Additional objects, advantages, and novel features of the present disclosure will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various aspects and aspects of the present disclosure as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

EXAMPLES

[0095] Reference is now made to the following examples, which together with the above descriptions, illustrate the disclosure in a non limiting fashion.

[0096] Generally, the nomenclature used herein and the laboratory procedures utilized in the present disclosure include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained

in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., Eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996). Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader.

EXAMPLE 1

Constructs and Transformation Schemes

[0097] Constructions of expression cassettes and vectors used in this work are illustrated in Figure 1a-d. All of the coding sequences in this work were optimized for expression in tobacco and chemically synthesized with desired flanking regions (SEQ ID NOs: 1, 4, 7, 12, 14, 16, 18, 20, 22). Figure 1a - the synthetic genes coding for Coll and Col2 (SEQ ID's 1, 4) fused either to the vacuolar signal or to the apoplast signal (encoded by SEQ ID NO: 7) or without signals were cloned in expression cassettes composed of a Chrysanthemum rbcS1 promoter and 5' UTR (SEQ ID NO: 10) and a Chrysanthemum rbcS1 3'UTR and terminator (SEQ ID NO: 11). The complete expression cassettes were cloned in the multiple cloning site of the pBINPLUS plant transformation vector (van Engelen et al., 1995, Transgenic Res 4: 288-290). Figure 1b - The synthetic genes coding for P4H beta-human, P4H alpha-human and P4H-plant (SEQ ID NOs: 12, 14 and 16) fused either to the vacuolar signal or to the apoplast signal (encoded by SEQ ID NO: 7) or without signals were cloned in expression cassettes composed of the CaMV 35S promoter and TMV omega sequence and Agrobacterium Nopaline synthetase (NOS) terminator carried by the vector pJD330 (Galili et al., 1987, Nucleic Acids Res 15: 3257-3273). The complete expression cassettes were cloned in the multiple cloning site of the pBINPLUS vectors carrying the expression cassettes of Coll or Col2. Figure 1c - The synthetic genes coding for Proteinase C and Proteinase N (SEQ ID NOs: 18, 20) fused either to the vacuolar signal or to the apoplast signal (encoded by SEQ ID NO: 7) were cloned in expression cassettes composed of a Chrysanthemum rbcS1 promoter and 5' UTR (SEQ ID NO: 10) and a Chrysanthemum rbcS1 3'UTR and terminator (SEQ ID NO: 11). The complete expression cassettes were cloned in the multiple cloning site of the pBINPLUS plant transformation vector. Figure 1d - The synthetic gene coding for LH3 (SEQ ID NO: 22) with flanking Strawberry vein banding virus (SVBV) promoter (NCBI accession AF331666 REGION: 623..950 version AF331666.1 GI:13345788) and terminated by Agrobacterium octopin synthase (OCS) terminator (NCBI accession Z37515 REGION: 1344..1538 version Z37515.1 GI:886843) fused either to the vacuolar signal or to the apoplast signal (encoded by SEQ ID NO: 7) or without signals was cloned in the multiple cloning site of the pBINPLUS vector carrying the expression cassettes of Coll and P4H beta.

[0098] Co-transformations schemes utilizing the expression cassettes described in Figure 1 into a host plant are illustrated in Figure 2. Each expression cassette insert is represented by a short name of the coding sequence. The coding sequences and related SEQ ID NOs. are described in Table 1. Each co-transformation is preformed by two pBINPLUS binary vectors. Each rectangle represents a single pBINPLUS vector carrying one, two or three expression cassettes. Promoters and terminators are specified in Figure 1.

EXAMPLE 2

Plant Collagen expression

[0099] Synthetic polynucleotide sequences encoding the proteins listed in Table 1 below were designed and optimized for expression in tobacco plants.

Table 1 - List of expressed proteins

Name:	SwissProt accession	Amino acids	Splicing isoform	Deletions	name	Included in SEQ ID NO.	Encoded by SEQ ID NO.
Collagen alpha 1(I) chain [Precursor]	p02452	1442	One version	ER signal	Coll	3	1
Collagen alpha 2(I) chain [Precursor]	p08123 Two changes done in p08123: D549A and N249I	1342	One version	ER signal	Col2	6	4
Prolyl 4-hydroxylase beta subunit	p07237	487	One version	ER signal, KDEL	P4H betaHuman	13	12
Prolyl 4-hydroxylase alpha-1 subunit	p13674	517	P13674-1	ER signal	P4H alphaHuman	15	14
Prolyl 4-hydroxylase Plant	No entry in Swissprot. NCBI accession: gi: 15227885	252	One version	Mitochondrial signal predicted as: aa1-39	P4Hplant	17	16
Procollagen C-proteinase	p13497	866	P13497-1 BMP1-3	ER signal, propeptide	Proteinase C	19	18
Procollagen IN-proteinase	o95450	958	095450-1 LpNPI	ER signal, propeptide	Proteinase N	21	20
Lysyl hydroxylase 3	o60568	714	One version	ER signal	LH3	23	22

Signal peptides**[0100]**

(i) Vacuole signal sequence of barley gene for Thiol protease aleurain precursor (NCBI accession P05167 GI:113603) MAHARVLLLALAVLATAAAVAVASSSFADSNPIRPVTDRAASTLA (SEQ ID NO: 24).

(ii) Apoplast signal of Arabidopsis thaliana endo-1,4-beta-glucanase (Cell, NCBI accession CAA67156.1 GI:2440033); SEQ ID NO. 9, encoded by SEQ ID NO. 7.

Construction of plasmids

[0101] Plant expression vectors were constructed as taught in Example 1, the composition of each constructed expression vector was confirmed via restriction analysis and sequencing.

[0102] Expression vectors including the following expression cassettes were constructed:

1. Collagen alpha 1
2. Collagen alpha 1 + human P4H beta subunit
3. Collagen alpha 1 + human P4H beta subunit + human LH3

4. Collagen alpha 2
5. Collagen alpha 2 + with human P4H alpha subunit
6. Collagen alpha 2 + with Arabidopsis P4H
7. Human P4H beta subunit + human LH3
8. Human P4H alpha subunit

Each of the above described coding sequences was either translationally fused to a vacuole transit peptide or to an apoplasm transit peptide or was devoid of any transit peptide sequences, in which case cytoplasmic accumulation is expected.

Plant transformation and PCR screening

[0103] Tobacco plants (*Nicotiana tabacum*, Samsun NN) were transformed with the above described expression vectors according to the transformation scheme taught in Figure 2.

[0104] Resultant transgenic plants were screened via multiplex PCR using four primers which were designed capable of amplifying a 324bp fragment of Collagen alpha 1 and a 537bp fragment of Collagen alpha 2 (Table 2). Figure 3 illustrates the results of one multiplex PCR screen.

Table 2 - List of primers for multiplex PCR for amplification of a 324bp fragment of Collagen alpha 1 and a 537bp fragment of Collagen alpha 2

Col1 forward primer (24-mer):	5' ATCACCAGGAGAACAGGGACCATC 3'	SEQ ID 25
Coll reverse primer (29-mer):	5' TCCACTTCCAAATCTCTATCCCTAACAAC 3'	SEQ ID 26
Col2 forward primer (23-mer):	5' AGGCATTAGAGGCGATAAGGGAG 3'	SEQ ID 27
Col2 reverse primer (27-mer):	5' TCAATCCAATAATAGCCACTTGACCAC 3'	SEQ ID 28

EXAMPLE 3

Detection of human collagen in transgenic tobacco plants

[0105] Total soluble proteins were extracted from tobacco transformants 2, 3 and 4 by grinding 500 mg of leaves in 0.5 ml 50 mM Tris-HCl pH=7.5 with a "Complete" protease inhibitor cocktail (product #1836145 from Roche Diagnostics GmbH, 1 tablet per 50 ml buffer). The crude extract was mixed with 250µl 4X Sample application buffer containing 10% beta-mercapto-ethanol and 8% SDS, the samples were boiled for 7 minutes and centrifuged for 8 minutes in 13000 rpm. 20µl of the supernatant were loaded in a 10% polyacrylamide gel and tested with anti-Collagen I (denatured) antibody ((#AB745 from Chemicon Inc.) in a standard Western blot procedure (Figure 4). W.T. is a wild type tobacco. Positive collagen bands are visible in plants that are PCR positive for collagen type I alpha 1 or alpha 2 or both. Positive control band of 500ng collagen type I from human placenta (#CC050 from Chemicon Inc.) represents about 0.3% of the total soluble proteins (about 150µg) in the samples from the transgenic plants.

[0106] Plants expressing collagen at the expected molecular weight up to ~1% of the total soluble proteins were detected when collagen was targeted to the vacuole (Figure 4). Subcellular targeting of full length collagen to the apoplast was successfully achieved (Figure 5). Plants expressing collagen in the cytoplasm (i.e. no targeting peptide) did not accumulate collagen to detectable levels showing that subcellular targeting of collagen in plants is critical for success.

[0107] In addition in contrast to the studies of Ruggiero et al. 2000 and Merle et al. 2002 which showed that collagen lacking the N-propeptide was subjected to significant proteolysis, using the present approach full length collagen proteins with C-propeptide and N-propeptide accumulated in subcellular compartments at high levels.

[0108] The present data also clearly shows that crossing two plants each expressing a different collagen chain type is advantageous in that it enables selection of plants expressing optimal levels of each chain type and subsequent plant crossing to achieve the desired collagen producing plant.

[0109] Collagen produced by the plants of the present disclosure includes the native propeptides and therefore is expected to form a larger protein than the human control that was purified by proteolysis. The calculated molecular weight of Collagen alpha 1 and alpha 2 chains without hydroxylations or glycosylations are the following: Coll with propeptides - 136kDa, Coll without propeptides - 95kDa, Col2 with propeptides - 127kDa, Col2 without propeptides - 92kDa.

[0110] As can be seen in Figures 4, the Coll bands in transformants 3-5 and 3-49 appears larger than Coll bands in other plants. This indicates prolines hydroxylation in collagen chains by human proline-4-hydroxylase holoenzyme com-

posed of alpha and beta subunits that were coexpressed in these plants and targeted to the same subcellular compartment as the human collagen chains (e.g. vacuole).

EXAMPLE 4

Collagen triple helix assembly and thermal stability in transgenic plants

[0111] Assembly of collagen triple helix and the helix thermal stability in transgenic plants were tested by thermal denaturation followed by trypsin or pepsin digestion of the total crude protein extract of transgenic plants (Figures 6a-b). In a first experiment, total soluble proteins from tobacco 2-9 (expressing only col alfa1 and no P4H) and 3-5 (expressing both col alfa1+2 and P4H) were extracted by grinding 500 mg leaves in 0.5 ml of 50 mM Tris-HCl pH=7.5, centrifuging for 10 minutes in 13000 rpm and collecting the supernatant. 50µl of the supernatant were subjected to heat treatment (15 minutes in 33 °C or 43 °C) and then immediately placed on ice. Trypsin digestion was initiated by adding to each sample 6µl of 1 mg/ml Trypsin in 50 mM Tris-HCl pH=7.5. The samples were incubated for 20 minutes at room temperature (about 22 °C). The digestion was terminated by addition of 20µl 4X sample application buffer containing 10% betamer-captoethanol and 8% SDS, the samples were boiled for 7 minutes and centrifuged for 7 minutes at 13000 rpm. 50µl of the supernatant were loaded onto a 10% polyacrylamide gel and tested with anti-Collagen I antibody ((#AB745 from Chemicon Inc.) using a standard Western blot procedure. Positive controls were samples of ~500 ng human collagen I (#CC050 from Chemicon Inc., extracted from human placenta by pepsin digestion) which was added to 50µl total soluble proteins extracted from w.t. tobacco.

[0112] As shown in Figure 6a, collagen triple helix that formed in plants #3-5 as well as control human collagen was resistant to denaturation at 33 °C. In contrast, collagen formed by plants #2-9 denatured at 33 °C. This difference in thermal stability indicates a successful triple helix assembly and post translational proline hydroxylation in transformants #3-5 which express both collagen alpha 1 and collagen alpha 2 as well as P4H beta and alpha subunits.

[0113] Two bands in transformants #2-9 may represent dimers or trimers, which are stable following 7 minutes of boiling with SDS and mercaptoethanol. Similar bands are visible in human collagen (upper panel) and in transformants #3-5. A possible explanation is a covalent bond between two peptides in different triple helixes (cross link), formed following oxidative deamination of two lysines by Lysine oxidase.

In a second experiment, total soluble proteins from transgenic tobacco 13-6 (expressing collagen I alpha 1 and alpha 2 chains - pointed by arrows, human P4H alpha and beta subunits and human LH3) were extracted by grinding 500 mg of leaves in 0.5 ml of 100 mM Tris-HCl pH=7.5 and 300 mM NaCl, centrifuging for 7 minutes at 10000 rpm and collecting the supernatant. 50µl of the supernatant was subjected to heat treatment (20 minutes in 33 °C, 38 °C or 42 °C) and then immediately placed on ice. Pepsin digestion was initiated by adding to each sample 4.5µl of 0.1M HCl and 4µl of 2.5 mg/ml Pepsin in 10 mM acetic acid. The samples were incubated for 30 minutes at room temperature (about 22 °C). The digestion was terminated by adding 5µl of unbuffered 1 M Tris. Each sample was mixed with 22µl 4X Sample application buffer containing 10% beta-mercapto-ethanol and 8% SDS, boiled for 7 minutes and centrifuged for 7 minutes in 13000 rpm. 40µl of the supernatant were loaded in a 10% polyacrylamide gel and tested with anti-Collagen I antibody ((#AB745 from Chemicon Inc.) in a standard Western blot procedure. Positive control was sample of ~50 ng human collagen I (#CC050 from Chemicon Inc., extracted from human placenta by pepsin digestion) added to total soluble proteins from w.t. tobacco.

[0114] As is illustrated in Figure 6b, collagen triple helix that formed in plant #13-6 was resistant to denaturation at 42 °C. Cleavage of the propeptides is first visible at 33 °C and gradually increases in efficiency when the temperature is raised to 38 °C and again to 42 °C. The cleaved collagen triple helix domain shows a similar migration on the gel to the migration of the pepsin treated human collagen. The human collagen that was used in this experiment was extracted from human placenta by pepsin proteolysis and therefore lacks the propeptides and some of the telopeptides.

EXAMPLE 5

Plant P4H expression

Induction of native plant P4H

[0115] Tobacco P4H cDNA was cloned and used as a probe to determine conditions and treatments that would induce endogenous P4H expression. Northern blot analysis (Figure 7) clearly shows that P4H is expressed at relatively high levels in the shoot apex and at low levels in leaves. P4H level was induced significantly in leaves 4 hours following abrasion treatment ("wounded" in the lower panel). Similar results were achieved using other stress conditions (not shown).

Detection of human P4H alpha and beta subunits and collagen alpha 1 and alpha 2 chains in transgenic tobacco plants

[0116] Detection of human P4H alpha and beta subunits and collagen type I alpha 1 and alpha 2 chains in transgenic tobacco plants was effected using anti-human P4H alpha subunit antibody (#63-163 from ICN Biomedicals Inc.), anti-human P4H beta subunit antibody (#MAB2701 from Chemicon Inc.) and anti-Collagen I antibody (#AB745 from Chemicon Inc.). The results of a western blot probed with these antibodies are shown in Figure 8.

[0117] Expression of P4H alpha, P4H beta and collagen I alpha 1 and alpha 2 bands was confirmed in plant 13-6 (also transformed also with human LH3). The calculated molecular weights of P4H alpha and beta including the vacuolar signal peptide are 65.5 kDa and 53.4 kDa respectively. The calculated molecular weights of Collagen alpha 1 and alpha 2 chains with propeptides, without hydroxylations or glycosylations are 136 kDa and 127 kDa respectively.

[0118] It is appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate aspects, may also be provided in combination in a single aspect. Conversely, various features of the disclosure, which are, for brevity, described in the context of a single aspect, may also be provided separately or in any suitable subcombination.

REFERENCES

[0119] (other references are cited in the document)

1. Bulleid NJ, John DC, Kadler KE. Recombinant expression systems for the production of collagen. *Biochem Soc Trans.* 2000;28(4):350-3. Review. PMID: 10961917 [PubMed - indexed for MEDLINE]

2. Hare PD, Cress WA. Metabolic implications of stress-induced proline accumulation in plants. *Plant Growth Regulation* 1997; 21: 79-102.

3. Hieta R, Myllyharju J. Cloning and characterization of a low molecular weight prolyl 4-hydroxylase from *Arabidopsis thaliana*. Effective hydroxylation of proline-rich, collagen-like, and hypoxia-inducible transcription factor alpha-like peptides. *J Biol Chem.* 2002 Jun 28;277(26):23965-71. Epub 2002 Apr 25. PMID: 11976332 [PubMed - indexed for MEDLINE]

4. Hulmes DJ. Building collagen molecules, fibrils, and suprafibrillar structures. *J Struct Biol.* 2002 Jan-Feb;137(1-2):2-10. Review. PMID: 12064927 [PubMed - indexed for MEDLINE]

5. Inkinen K. Connective tissue formation in wound healing. An experimental study. Academic Dissertation, September 2003. University of Helsinki, Faculty of Science, Department of Biosciences, Division of Biochemistry (ISBN 952-10-1313-3) <http://ethesis.helsinki.fi/julkaisut/mat/bioti/vk/inkinen/>

6. Merle C, Perret S, Lacour T, Jonval V, Hudaverdian S, Garrone R, Ruggiero F, Theisen M. Hydroxylated human homotrimeric collagen I in *Agrobacterium tumefaciens*-mediated transient expression and in transgenic tobacco plant. *FEBS Lett.* 2002 Mar 27;515(1-3):114-8. PMID: 11943205 [PubMed - indexed for MEDLINE]

7. Olsen D, Yang C, Bodo M, Chang R, Leigh S, Baez J, Carmichael D, Perala M, Hamalainen ER, Jarvinen M, Polarek J. Recombinant collagen and gelatin for drug delivery. *Adv Drug Deliv Rev.* 2003 Nov 28;55(12):1547-67. PMID: 14623401 [PubMed - in process]

8. Ruggiero F, Exposito JY, Bournat P, Gruber V, Perret S, Comte J, Olgarnier B, Garrone R, Theisen M. Triple helix assembly and processing of human collagen produced in transgenic tobacco plants. *FEBS Lett.* 2000 Mar 3;469(1):132-6. PMID: 10708770 [PubMed - indexed for MEDLINE]

9. Tanaka M, Sato K, Uchida T. Plant prolyl hydroxylase recognizes poly(L-proline) II helix. *J Biol Chem.* 1981 Nov 25;256(22):11397-400. PMID: 6271746 [PubMed - indexed for MEDLINE]

10. Wang C, Luosujarvi H, Heikkinen J, Risteli M, Uitto L, Myllyla R. The third activity for lysyl hydroxylase 3: galactosylation of hydroxyllysyl residues in collagens in vitro. *Matrix Biol.* 2002 Nov;21(7):559-66. PMID: 12475640 [PubMed - indexed for MEDLINE]

SEQUENCE LISTING

[0120]

5 <110> CollPlant Ltd.

 <120> COLLAGEN PRODUCING PLANTS AND METHODS OF GENERATING AND USING
 SAME

10 <130> F-13500-EP-SS

 <140> 05789469.3
 <141> 28-September-2005

15 <150> US 60/613,719
 <151> 29-September-2004

 <160> 28

20 <170> PatentIn version 3.3

 <210> 1
 <211> 4662
 <212> DNA

25 <213> Artificial sequence

 <220>
 <223> Synthetic sequence containing the coding regions of the vascular signal sequence of barley gene for Thiol
 protease aleurain precursor fused to the human Collagen alpha 1(I) chain and flanking regions

30 <400> 1

35

40

45

50

55

EP 3 312 282 B1

	gcgatgcatg taatgtcatg agccacatga tccaatggcc acaggaacgt aagaatgtag	60
	atagatttga ttttgtccgt tagatagcaa acaacattat aaaaggtgtg tatcaatacg	120
5	aactaattca ctcatgggat tcatagaagt ccattcctcc taagtatcta aaccatggct	180
	cacgctcgtg ttctcctcct cgctctcgtg gttttggcaa cagctgctgt ggctgtggct	240
10	tctagttctt cttttgctga ttcaaaccct attagacctg ttactgatag agcagcttcc	300
	actttggctc aattgcaaga ggagggccag gttgagggcc aagatgagga tatccctcca	360
	attacatgcg tgcaaaatgg cttgcgttac cacgataggg atgtgtggaa acctgaacct	420
15	tgtcgtatct gtgtgtgtga taacggcaag gtgctctcgc atgatgttat ctgcgatgag	480
	acaaaaaatt gccctggcgc tgaagttcct gagggcgagt gttgccctgt gtgccctgat	540
	ggttccgagt ccccaactga tcaggaaact actggcgtgg agggcccaaa aggagatact	600
20	gggccacgtg gtcctagggg tccagcaggt cctccaggta gagatggtat tccaggccag	660
	cctggattgc caggaccacc agggccacct ggcccaccag gacctcctgg tcttggtgga	720
	aatttcgctc cacaactctc ttatggctat gatgagaagt caacagggtg tatttccgtt	780
25	ccaggtccta tgggaccatc cggaccaaga ggtctcccag gtcctccagg tgctcctgga	840
	cctcaaggct ttcaaggacc tccaggcgaa ccaggagaac caggcgcttc tggaccaatg	900
30	ggcccaaggg gaccacctgg cccaccagga aaaaatggcg atgatggcga agctggaaag	960
35		
40		
45		
50		
55		

EP 3 312 282 B1

	cctggtcgctc	ctggagagag	aggtcctcct	ggcccacagg	gtgcaagagg	cttgccagga	1020
	actgctggct	tgcctggaat	gaagggacat	aggggcttct	ccggcctcga	tggcgctaag	1080
5	ggtgatgctg	gccctgctgg	accaaagggc	gagccagggt	cccctggaga	aaacgggtgct	1140
	cctggacaaa	tgggtcctcg	tggacttcca	ggagaaaggg	gtcgtccagg	cgctccagga	1200
	ccagcagggtg	ctaggggaaa	cgatgggtgca	acaggcgctg	ctggccctcc	tggcccaact	1260
10	ggtcctgctg	gccctccagg	attcccaggc	gcagttggag	ctaaaggaga	agcaggacca	1320
	cagggcccta	ggggttctga	aggacctcag	ggtgttagag	gtgaaccagg	tcctccaggc	1380
	ccagctggag	cagctgggtcc	agcaggaaat	ccagggtgctg	atggtcaacc	tggagctaag	1440
15	ggcgctaata	gcgaccagg	tatcgaggc	gcaccagggt	ttcctggcgc	tagaggccca	1500
	agtggtcctc	aaggaccagg	tggaccacca	ggtccaaaag	gcaattctg	cgaacctggc	1560
20	gctccagggt	ctaaaggaga	tactgggtgct	aaaggcgaac	caggacctgt	tgggtgttcag	1620
	ggtcctcctg	gtcctgctgg	agaagaagga	aaaagagggt	ctcgtggaga	accaggacca	1680
	actggacttc	ctggacctcc	tgggtgaacgt	ggcggacctg	gctcaagggg	tttccctgga	1740
25	gctgatggag	tggcagggtcc	aaaaggccct	gctggagaga	gagggttcacc	aggtccagct	1800
	ggtcctaagg	gctcccctgg	tgaagcagggt	agaccaggcg	aagcaggatt	gccaggcgca	1860
	aagggttgga	caggctctcc	tggtagtcct	ggcccagatg	gaaaaacagg	cccaccagggt	1920
30	ccagcaggac	aagatggacg	tccaggccca	ccaggtcctc	ctggagcaag	gggacaagct	1980
	ggcgttatgg	gttttccagg	acctaaagggt	gctgctggag	agccaggaaa	ggcagggtgaa	2040
35	agaggagttc	ctgggtccacc	aggagcagtg	ggtcctgctg	gcaaagatgg	tgaagctgga	2100
	gcacagggcc	ctccaggccc	tgctggccca	gctggcgaac	gtggagaaca	aggcccagct	2160
	ggtagtcag	gatttcaagg	attgcctggc	cctgctggcc	ctccaggaga	agcaggaaaa	2220
40	cctggagaac	aaggagtcc	tgggtgattg	ggagcacctg	gaccttcagg	agcacgtggt	2280
	gaaagaggct	tccctggcga	gaggggtgtt	caagggtccac	cagggtccagc	aggacctaga	2340
	ggtgctaata	gcgctcctgg	caacgatgga	gcaaaagggt	atgctggtgc	tcctggcgca	2400
45	cctggaagtc	aggggtgctcc	tggattgcaa	ggaatgcctg	gagagagggg	tgtgctggc	2460
	ttgccaggcc	caaagggcga	taggggtgat	gctggaccaa	aagggtgctga	tggatcccca	2520
	ggaaaagatg	gagttcgtgg	tcttactggc	ccaatcggac	ctccaggccc	tgtggtcgct	2580
50	ccagggtgata	agggcgaaag	tggcccaagt	ggacctgctg	gacctactgg	tgttagaggt	2640
	gcacctgggtg	ataggggtga	acctggacca	cctgggtccag	ctggttttgc	tggtcctcct	2700
55	ggagctgatg	gacaacctgg	cgcaaaggggt	gaaccagggtg	atgctggcgc	aaagggagat	2760
	gctgggtccac	ctggacctgc	tgggtccagca	ggccccctg	ggccaatcgg	taatgttgga	2820

EP 3 312 282 B1

	gcaccaggtg	ctaagggagc	taggggttcc	gctggtccac	ctggagcaac	aggattttcca	2880
	ggcgctgctg	gtagagttgg	cccaccaggc	ccatccggaa	acgcaggccc	tcctggtcct	2940
5	ccaggtcctg	ctggcaagga	gggtggcaaa	ggaccaaggg	gcgaaactgg	ccctgctggt	3000
	agacctggcg	aagttggccc	tcctggacca	ccaggtccag	caggagaaaa	aggttcccca	3060
	ggagctgatg	gcccagctgg	tgctccagga	actccaggcc	ctcaaggtat	tgctggacag	3120
10	agaggcgttg	tgggactccc	tggtcaaagg	ggagagagag	gattttccagg	cttgccagga	3180
	cctagtggag	aacctggaaa	acaaggccca	tcaggcgcta	gtggagagcg	tggacctcct	3240
	ggccctatgg	gacctcctgg	attggctggc	ccacctggcg	aatcaggtcg	tgaaggcgca	3300
15	ccaggcgag	aaggatcacc	tggaagagat	ggatcccctg	gtgctaaagg	cgatcgtgga	3360
	gaaactggtc	cagcaggccc	accaggcgca	ccaggtgcac	ctggcgctcc	aggacctgtg	3420
20	ggaccagctg	gaaaatccgg	agataggggc	gagacaggcc	cagcaggacc	agctggacct	3480
	gttggccctg	ctggcgctcg	tggaccagca	ggacctcaag	gaccaagggg	agataagggga	3540
	gaaacaggcg	aacaaggcga	taggggcatt	aagggtcata	ggggttttag	tggcctccag	3600
25	ggtcctcctg	gcccacctgg	atcaccagga	gaacagggac	catctggtgc	ttccggccca	3660
	gctggtccaa	gaggacctcc	aggatcagct	ggtgcacctg	gaaaagatgg	tcttaacggt	3720
	ctcccaggac	caatcgccc	tccaggacct	agaggaagaa	caggagatgc	tggccctgtt	3780
30	ggccctccag	gacctcctgg	tccaccaggt	ccacctggtc	ctccatcagc	tggattcgat	3840
	ttttcatttc	ttccacagcc	accacaagag	aaagctcacg	atggcggcag	atattaccgt	3900
35	gctgatgatg	ctaacgttgt	tagggataga	gatttggaag	tggatacaac	tttgaaatcc	3960
	ctctcccagc	aaattgaaaa	cattagatct	ccagaagggt	cacgtaaaaa	cccagctaga	4020
	acatgtcgtg	atttgaaaat	gtgtcactcc	gattggaaaa	gtggtgaata	ctggattgat	4080
40	ccaaatcagg	gctgtaatct	cgatgctatc	aaagttttct	gtaacatgga	aacaggcgaa	4140
	acatgcgttt	atcctactca	accttccgtg	gctcagaaaa	attggtacat	ctcaaaaaat	4200
	cctaaagata	agaggcacgt	ttggttcggt	gaaagtatga	ctgatggatt	tcaatttgag	4260
45	tacggcggtc	aaggtagtga	tccagctgat	gtggctattc	aactcacatt	tttgcgctctt	4320
	atgtccacag	aggcatcaca	aaacatcact	taccactgca	aaaacagtgt	ggcttatatg	4380
	gatcaacaaa	caggaaacct	taagaaggct	cttcttttga	agggtctaaa	cgagattgag	4440
50	attagagcag	agggcaactc	aaggtttact	tattcagtta	ctgttgatgg	ctgcacttca	4500
	catactggcg	cttggggtaa	aacagttatc	gagtataaga	ctacaaaaac	atcaagactc	4560
55	ccaatcattg	atgttgctcc	tctcgatgtt	ggcgctcctg	atcaagagtt	cggttttgat	4620
	gtgggcccag	tttgtttcct	ctaatgagct	cgcggccgca	tc		4662

EP 3 312 282 B1

<210> 2
<211> 4662
<212> DNA
<213> Artificial sequence

5

<220>
<223> Synthetic sequence of the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the human Collagen alpha 1(I) chain and flanking regions

10
<220>
<221> CDS
<222> (175)..(4644)

15

<400> 2

20

25

30

35

40

45

50

55

EP 3 312 282 B1

	gcgatgcatg taatgtcatg agccacatga tccaatggcc acaggaacgt aagaatgtag	60
	atagatttga ttttgtccgt tagatagcaa acaacattat aaaaggtgtg tatcaatacg	120
5	aactaattca ctcatgggat tcatagaagt ccattcctcc taagtatcta aacc atg Met 1	177
10	gct cac gct cgt gtt ctc ctc ctc gct ctc gct gtt ttg gca aca gct Ala His Ala Arg Val Leu Leu Leu Ala Leu Ala Val Leu Ala Thr Ala 5 10 15	225
15	gct gtg gct gtg gct tct agt tct tct ttt gct gat tca aac cct att Ala Val Ala Val Ala Ser Ser Ser Ser Phe Ala Asp Ser Asn Pro Ile 20 25 30	273
20	aga cct gtt act gat aga gca gct tcc act ttg gct caa ttg caa gag Arg Pro Val Thr Asp Arg Ala Ala Ser Thr Leu Ala Gln Leu Gln Glu 35 40 45	321
25	gag ggc cag gtt gag ggc caa gat gag gat atc cct cca att aca tgc Glu Gly Gln Val Glu Gly Gln Asp Glu Asp Ile Pro Pro Ile Thr Cys 50 55 60 65	369
30	gtg caa aat ggc ttg cgt tac cac gat agg gat gtg tgg aaa cct gaa Val Gln Asn Gly Leu Arg Tyr His Asp Arg Asp Val Trp Lys Pro Glu 70 75 80	417
35	cct tgt cgt atc tgt gtg tgt gat aac ggc aag gtg ctc tgc gat gat Pro Cys Arg Ile Cys Val Cys Asp Asn Gly Lys Val Leu Cys Asp Asp 85 90 95	465
40	gtt atc tgc gat gag aca aaa aat tgc cct ggc gct gaa gtt cct gag Val Ile Cys Asp Glu Thr Lys Asn Cys Pro Gly Ala Glu Val Pro Glu 100 105 110	513
45	ggc gag tgt tgc cct gtg tgc cct gat ggt tcc gag tcc cca act gat Gly Glu Cys Cys Pro Val Cys Pro Asp Gly Ser Glu Ser Pro Thr Asp 115 120 125	561
50	cag gaa act act ggc gtg gag ggc cca aaa gga gat act ggt cca cgt Gln Glu Thr Thr Gly Val Glu Gly Pro Lys Gly Asp Thr Gly Pro Arg 130 135 140 145	609
55	ggt cct agg ggt cca gca ggt cct cca ggt aga gat ggt att cca ggc Gly Pro Arg Gly Pro Ala Gly Pro Pro Gly Arg Asp Gly Ile Pro Gly 150 155 160	657

EP 3 312 282 B1

	cag cct gga ttg cca gga cca cca ggc cca cct ggc cca cca gga cct	705
	Gln Pro Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro	
	165 170 175	
5	cct ggt ctt ggt gga aat ttc gct cca caa ctc tct tat ggc tat gat	753
	Pro Gly Leu Gly Gly Asn Phe Ala Pro Gln Leu Ser Tyr Gly Tyr Asp	
	180 185 190	
10	gag aag tca aca ggt ggt att tcc gtt cca ggt cct atg gga cca tcc	801
	Glu Lys Ser Thr Gly Gly Ile Ser Val Pro Gly Pro Met Gly Pro Ser	
	195 200 205	
15	gga cca aga ggt ctc cca ggt cct cca ggt gct cct gga cct caa ggc	849
	Gly Pro Arg Gly Leu Pro Gly Pro Pro Gly Ala Pro Gly Pro Gln Gly	
	210 215 220 225	
20	ttt caa gga cct cca ggc gaa cca gga gaa cca ggc gct tct gga cca	897
	Phe Gln Gly Pro Pro Gly Glu Pro Gly Glu Pro Gly Ala Ser Gly Pro	
	230 235 240	
25	atg ggc cca agg gga cca cct ggc cca cca gga aaa aat ggc gat gat	945
	Met Gly Pro Arg Gly Pro Pro Gly Pro Pro Gly Lys Asn Gly Asp Asp	
	245 250 255	
30	ggc gaa gct gga aag cct ggt cgt cct gga gag aga ggt cct cct ggc	993
	Gly Glu Ala Gly Lys Pro Gly Arg Pro Gly Glu Arg Gly Pro Pro Gly	
	260 265 270	
35	cca cag ggt gca aga ggc ttg cca gga act gct ggc ttg cct gga atg	1041
	Pro Gln Gly Ala Arg Gly Leu Pro Gly Thr Ala Gly Leu Pro Gly Met	
	275 280 285	
40	aag gga cat agg ggc ttc tcc ggc ctc gat ggc gct aag ggt gat gct	1089
	Lys Gly His Arg Gly Phe Ser Gly Leu Asp Gly Ala Lys Gly Asp Ala	
	290 295 300 305	
45	ggc cct gct gga cca aag ggc gag cca ggt tcc cct gga gaa aac ggt	1137
	Gly Pro Ala Gly Pro Lys Gly Glu Pro Gly Ser Pro Gly Glu Asn Gly	
	310 315 320	
50	gct cct gga caa atg ggt cct cgt gga ctt cca gga gaa agg ggt cgt	1185
	Ala Pro Gly Gln Met Gly Pro Arg Gly Leu Pro Gly Glu Arg Gly Arg	
	325 330 335	
55	cca ggc gct cca gga cca gca ggt gct agg gga aac gat ggt gca aca	1233
	Pro Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly Asn Asp Gly Ala Thr	
	340 345 350	
60	ggc gct gct ggc cct cct ggc cca act ggt cct gct ggc cct cca gga	1281
	Gly Ala Ala Gly Pro Pro Gly Pro Thr Gly Pro Ala Gly Pro Pro Gly	
	355 360 365	
65	ttc cca ggc gca gtt gga gct aaa gga gaa gca gga cca cag ggc cct	1329
	Phe Pro Gly Ala Val Gly Ala Lys Gly Glu Ala Gly Pro Gln Gly Pro	
	370 375 380 385	
70	agg ggt tct gaa gga cct cag ggt gtt aga ggt gaa cca ggt cct cca	1377
	Arg Gly Ser Glu Gly Pro Gln Gly Val Arg Gly Glu Pro Gly Pro Pro	
	390 395 400	
75	ggc cca gct gga gca gct ggt cca gca gga aat cca ggt gct gat ggt	1425
	Gly Pro Ala Gly Ala Ala Gly Pro Ala Gly Asn Pro Gly Ala Asp Gly	

EP 3 312 282 B1

	405							410					415					
5	caa	cct	gga	gct	aag	ggc	gct	aat	ggc	gca	cca	ggt	atc	gca	ggc	gca	1473	
	Gln	Pro	Gly	Ala	Lys	Gly	Ala	Asn	Gly	Ala	Pro	Gly	Ile	Ala	Gly	Ala		
			420					425					430					
	cca	ggt	ttt	cct	ggc	gct	aga	ggc	cca	agt	ggt	cct	caa	gga	cca	ggt	1521	
	Pro	Gly	Phe	Pro	Gly	Ala	Arg	Gly	Pro	Ser	Gly	Pro	Gln	Gly	Pro	Gly		
			435				440					445						
10	gga	cca	cca	ggt	cca	aaa	ggc	aat	tct	ggc	gaa	cct	ggc	gct	cca	ggt	1569	
	Gly	Pro	Pro	Gly	Pro	Lys	Gly	Asn	Ser	Gly	Glu	Pro	Gly	Ala	Pro	Gly		
	450					455					460					465		
15	tct	aaa	gga	gat	act	ggt	gct	aaa	ggc	gaa	cca	gga	cct	gtt	ggt	gtt	1617	
	Ser	Lys	Gly	Asp	Thr	Gly	Ala	Lys	Gly	Glu	Pro	Gly	Pro	Val	Gly	Val		
					470					475					480			
	cag	ggt	cct	cct	ggt	cct	gct	gga	gaa	gaa	gga	aaa	aga	ggt	gct	cgt	1665	
	Gln	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Glu	Glu	Gly	Lys	Arg	Gly	Ala	Arg		
				485					490					495				
20	gga	gaa	cca	gga	cca	act	gga	ctt	cct	gga	cct	cct	ggt	gaa	cgt	ggc	1713	
	Gly	Glu	Pro	Gly	Pro	Thr	Gly	Leu	Pro	Gly	Pro	Pro	Gly	Glu	Arg	Gly		
			500					505					510					
25	gga	cct	ggc	tca	agg	ggt	ttc	cct	gga	gct	gat	gga	gtg	gca	ggt	cca	1761	
	Gly	Pro	Gly	Ser	Arg	Gly	Phe	Pro	Gly	Ala	Asp	Gly	Val	Ala	Gly	Pro		
		515					520					525						
30	aaa	ggc	cct	gct	gga	gag	aga	ggt	tca	cca	ggt	cca	gct	ggt	cct	aag	1809	
	Lys	Gly	Pro	Ala	Gly	Glu	Arg	Gly	Ser	Pro	Gly	Pro	Ala	Gly	Pro	Lys		
	530					535					540					545		
	ggc	tcc	cct	ggt	gaa	gca	ggt	aga	cca	ggc	gaa	gca	gga	ttg	cca	ggc	1857	
	Gly	Ser	Pro	Gly	Glu	Ala	Gly	Arg	Pro	Gly	Glu	Ala	Gly	Leu	Pro	Gly		
					550					555					560			
35	gca	aag	gga	ttg	aca	ggc	tct	cct	ggt	agt	cct	ggc	cca	gat	gga	aaa	1905	
	Ala	Lys	Gly	Leu	Thr	Gly	Ser	Pro	Gly	Ser	Pro	Gly	Pro	Asp	Gly	Lys		
				565				570						575				
40	aca	ggc	cca	cca	ggt	cca	gca	gga	caa	gat	gga	cgt	cca	ggc	cca	cca	1953	
	Thr	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Gln	Asp	Gly	Arg	Pro	Gly	Pro	Pro		
			580					585					590					
	ggt	cct	cct	gga	gca	agg	gga	caa	gct	ggc	gtt	atg	ggt	ttt	cca	gga	2001	
	Gly	Pro	Pro	Gly	Ala	Arg	Gly	Gln	Ala	Gly	Val	Met	Gly	Phe	Pro	Gly		
		595					600					605						
45	cct	aaa	ggt	gct	gct	gga	gag	cca	gga	aag	gca	ggt	gaa	aga	gga	gtt	2049	
	Pro	Lys	Gly	Ala	Ala	Gly	Glu	Pro	Gly	Lys	Ala	Gly	Glu	Arg	Gly	Val		
	610					615					620					625		
50	cct	ggt	cca	cca	gga	gca	gtg	ggt	cct	gct	ggc	aaa	gat	ggt	gaa	gct	2097	
	Pro	Gly	Pro	Pro	Gly	Ala	Val	Gly	Pro	Ala	Gly	Lys	Asp	Gly	Glu	Ala		
					630				635						640			
55	gga	gca	cag	ggc	cct	cca	ggc	cct	gct	ggc	cca	gct	ggc	gaa	cgt	gga	2145	
	Gly	Ala	Gln	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Pro	Ala	Gly	Glu	Arg	Gly		
			645					650					655					
	gaa	caa	ggc	cca	gct	ggt	agt	cca	gga	ttt	caa	gga	ttg	cct	ggc	cct	2193	

EP 3 312 282 B1

	Glu	Gln	Gly	Pro	Ala	Gly	Ser	Pro	Gly	Phe	Gln	Gly	Leu	Pro	Gly	Pro	
			660					665					670				
5	gct	ggc	cct	cca	gga	gaa	gca	gga	aaa	cct	gga	gaa	caa	gga	gtt	cct	2241
	Ala	Gly	Pro	Pro	Gly	Glu	Ala	Gly	Lys	Pro	Gly	Glu	Gln	Gly	Val	Pro	
			675				680					685					
10	ggt	gat	ttg	gga	gca	cct	gga	cct	tca	gga	gca	cgt	ggt	gaa	aga	ggc	2289
	Gly	Asp	Leu	Gly	Ala	Pro	Gly	Pro	Ser	Gly	Ala	Arg	Gly	Glu	Arg	Gly	
						695					700					705	
	ttc	cct	ggc	gag	agg	ggt	gtt	caa	ggt	cca	cca	ggt	cca	gca	gga	cct	2337
	Phe	Pro	Gly	Glu	Arg	Gly	Val	Gln	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Pro	
					710				715						720		
15	aga	ggt	gct	aat	ggc	gct	cct	ggc	aac	gat	gga	gca	aaa	ggt	gat	gct	2385
	Arg	Gly	Ala	Asn	Gly	Ala	Pro	Gly	Asn	Asp	Gly	Ala	Lys	Gly	Asp	Ala	
				725					730					735			
20	ggt	gct	cct	ggc	gca	cct	gga	agt	cag	ggt	gct	cct	gga	ttg	caa	gga	2433
	Gly	Ala	Pro	Gly	Ala	Pro	Gly	Ser	Gln	Gly	Ala	Pro	Gly	Leu	Gln	Gly	
			740					745					750				
25	atg	cct	gga	gag	agg	ggt	gct	gct	ggc	ttg	cca	ggc	cca	aag	ggc	gat	2481
	Met	Pro	Gly	Glu	Arg	Gly	Ala	Ala	Gly	Leu	Pro	Gly	Pro	Lys	Gly	Asp	
		755					760					765					
30	agg	ggt	gat	gct	gga	cca	aaa	ggt	gct	gat	gga	tcc	cca	gga	aaa	gat	2529
	Arg	Gly	Asp	Ala	Gly	Pro	Lys	Gly	Ala	Asp	Gly	Ser	Pro	Gly	Lys	Asp	
		770				775				780						785	
35	gga	gtt	cgt	ggt	ctt	act	ggc	cca	atc	gga	cct	cca	ggc	cct	gct	ggc	2577
	Gly	Val	Arg	Gly	Leu	Thr	Gly	Pro	Ile	Gly	Pro	Pro	Gly	Pro	Ala	Gly	
					790				795						800		
40	gct	cca	ggt	gat	aag	ggc	gaa	agt	ggc	cca	agt	gga	cct	gct	gga	cct	2625
	Ala	Pro	Gly	Asp	Lys	Gly	Glu	Ser	Gly	Pro	Ser	Gly	Pro	Ala	Gly	Pro	
				805					810					815			
45	act	ggt	gct	aga	ggt	gca	cct	ggt	gat	agg	ggt	gaa	cct	gga	cca	cct	2673
	Thr	Gly	Ala	Arg	Gly	Ala	Pro	Gly	Asp	Arg	Gly	Glu	Pro	Gly	Pro	Pro	
			820					825					830				
50	ggt	cca	gct	ggt	ttt	gct	ggt	cct	cct	gga	gct	gat	gga	caa	cct	ggc	2721
	Gly	Pro	Ala	Gly	Phe	Ala	Gly	Pro	Pro	Gly	Ala	Asp	Gly	Gln	Pro	Gly	
			835				840					845					
55	gca	aag	ggt	gaa	cca	ggt	gat	gct	ggc	gca	aag	gga	gat	gct	ggt	cca	2769
	Ala	Lys	Gly	Glu	Pro	Gly	Asp	Ala	Gly	Ala	Lys	Gly	Asp	Ala	Gly	Pro	
						855					860					865	
60	cct	gga	cct	gct	ggt	cca	gca	ggc	ccc	cct	ggg	cca	atc	ggt	aat	gtt	2817
	Pro	Gly	Pro	Ala	Gly	Pro	Ala	Gly	Pro	Pro	Gly	Pro	Ile	Gly	Asn	Val	
					870					875					880		
65	gga	gca	cca	ggt	gct	aag	gga	gct	agg	ggt	tcc	gct	ggt	cca	cct	gga	2865
	Gly	Ala	Pro	Gly	Ala	Lys	Gly	Ala	Arg	Gly	Ser	Ala	Gly	Pro	Pro	Gly	
					885				890					895			
70	gca	aca	gga	ttt	cca	ggc	gct	gct	ggt	aga	gtt	ggc	cca	cca	ggc	cca	2913
	Ala	Thr	Gly	Phe	Pro	Gly	Ala	Ala	Gly	Arg	Val	Gly	Pro	Pro	Gly	Pro	
			900					905					910				

EP 3 312 282 B1

	tcc gga aac gca ggc cct cct ggt cct cca ggt cct gct ggc aag gag	2961
	Ser Gly Asn Ala Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Lys Glu	
	915 920 925	
5	ggt ggc aaa gga cca agg ggc gaa act ggc cct gct ggt aga cct ggc	3009
	Gly Gly Lys Gly Pro Arg Gly Glu Thr Gly Pro Ala Gly Arg Pro Gly	
	930 935 940 945	
10	gaa gtt ggc cct cct gga cca cca ggt cca gca gga gaa aaa ggt tcc	3057
	Glu Val Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Glu Lys Gly Ser	
	950 955 960	
15	cca gga gct gat ggc cca gct ggt gct cca gga act cca ggc cct caa	3105
	Pro Gly Ala Asp Gly Pro Ala Gly Ala Pro Gly Thr Pro Gly Pro Gln	
	965 970 975	
20	ggt att gct gga cag aga ggc gtt gtg gga ctc cct ggt caa agg gga	3153
	Gly Ile Ala Gly Gln Arg Gly Val Val Gly Leu Pro Gly Gln Arg Gly	
	980 985 990	
25	gag aga gga ttt cca ggc ttg cca gga cct agt gga gaa cct gga aaa	3201
	Glu Arg Gly Phe Pro Gly Leu Pro Gly Pro Ser Gly Glu Pro Gly Lys	
	995 1000 1005	
30	caa ggc cca tca ggc gct agt gga gag cgt gga cct cct ggc cct	3246
	Gln Gly Pro Ser Gly Ala Ser Gly Glu Arg Gly Pro Pro Gly Pro	
	1010 1015 1020	
35	atg gga cct cct gga ttg gct ggc cca cct ggc gaa tca ggt cgt	3291
	Met Gly Pro Pro Gly Leu Ala Gly Pro Pro Gly Glu Ser Gly Arg	
	1025 1030 1035	
40	gaa ggc gca cca ggc gca gaa gga tca cct gga aga gat gga tcc	3336
	Glu Gly Ala Pro Gly Ala Glu Gly Ser Pro Gly Arg Asp Gly Ser	
	1040 1045 1050	
45	cct ggt gct aaa ggc gat cgt gga gaa act ggt cca gca ggc cca	3381
	Pro Gly Ala Lys Gly Asp Arg Gly Glu Thr Gly Pro Ala Gly Pro	
	1055 1060 1065	
50	cca ggc gca cca ggt gca cct ggc gct cca gga cct gtg gga cca	3426
	Pro Gly Ala Pro Gly Ala Pro Gly Ala Pro Gly Pro Val Gly Pro	
	1070 1075 1080	
55	gct gga aaa tcc gga gat agg ggc gag aca ggc cca gca gga cca	3471
	Ala Gly Lys Ser Gly Asp Arg Gly Glu Thr Gly Pro Ala Gly Pro	
	1085 1090 1095	
60	gct gga cct gtt ggc cct gct ggc gct cgt gga cca gca gga cct	3516
	Ala Gly Pro Val Gly Pro Ala Gly Ala Arg Gly Pro Ala Gly Pro	
	1100 1105 1110	
65	caa gga cca agg gga gat aag gga gaa aca ggc gaa caa ggc gat	3561
	Gln Gly Pro Arg Gly Asp Lys Gly Glu Thr Gly Glu Gln Gly Asp	
	1115 1120 1125	
70	agg ggc att aag ggt cat agg ggt ttt agt ggc ctc cag ggt cct	3606
	Arg Gly Ile Lys Gly His Arg Gly Phe Ser Gly Leu Gln Gly Pro	
	1130 1135 1140	
75	cct ggc cca cct gga tca cca gga gaa cag gga cca tct ggt gct	3651
	Pro Gly Pro Pro Gly Ser Pro Gly Glu Gln Gly Pro Ser Gly Ala	
	1145 1150 1155	

EP 3 312 282 B1

	tcc Ser 1160	ggc Gly	cca Pro	gct Ala	ggt Gly	cca Pro 1165	aga Arg	gga Gly	cct Pro	cca Pro	gga Gly 1170	tca Ser	gct Ala	ggt Gly	gca Ala	3696
5	cct Pro 1175	gga Gly	aaa Lys	gat Asp	ggt Gly	ctt Leu 1180	aac Asn	ggt Gly	ctc Leu	cca Pro	gga Gly 1185	cca Pro	atc Ile	ggc Gly	cct Pro	3741
10	cca Pro 1190	gga Gly	cct Pro	aga Arg	gga Gly	aga Arg 1195	aca Thr	gga Gly	gat Asp	gct Ala	ggc Gly 1200	cct Pro	gtt Val	ggc Gly	cct Pro	3786
15	cca Pro 1205	gga Gly	cct Pro	cct Pro	ggt Gly	cca Pro 1210	cca Pro	ggt Gly	cca Pro	cct Pro	ggt Gly 1215	cct Pro	cca Pro	tca Ser	gct Ala	3831
	gga Gly 1220	ttc Phe	gat Asp	ttt Phe	tca Ser	ttt Phe 1225	ctt Leu	cca Pro	cag Gln	cca Pro	cca Pro 1230	caa Gln	gag Glu	aaa Lys	gct Ala	3876
20	cac His 1235	gat Asp	ggc Gly	ggc Gly	aga Arg	tat Tyr 1240	tac Tyr	cgt Arg	gct Ala	gat Asp	gat Asp 1245	gct Ala	aac Asn	gtt Val	gtt Val	3921
25	agg Arg 1250	gat Asp	aga Arg	gat Asp	ttg Leu	gaa Glu 1255	gtg Val	gat Asp	aca Thr	act Thr	ttg Leu 1260	aaa Lys	tcc Ser	ctc Leu	tcc Ser	3966
	cag Gln 1265	caa Gln	att Ile	gaa Glu	aac Asn	att Ile 1270	aga Arg	tct Ser	cca Pro	gaa Glu	ggt Gly 1275	tca Ser	cgt Arg	aaa Lys	aac Asn	4011
30	cca Pro 1280	gct Ala	aga Arg	aca Thr	tgt Cys	cgt Arg 1285	gat Asp	ttg Leu	aaa Lys	atg Met	tgt Cys 1290	cac His	tcc Ser	gat Asp	tgg Trp	4056
35	aaa Lys 1295	agt Ser	ggt Gly	gaa Glu	tac Tyr	tgg Trp 1300	att Ile	gat Asp	cca Pro	aat Asn	cag Gln 1305	ggc Gly	tgt Cys	aat Asn	ctc Leu	4101
40	gat Asp 1310	gct Ala	atc Ile	aaa Lys	gtt Val	ttc Phe 1315	tgt Cys	aac Asn	atg Met	gaa Glu	aca Thr 1320	ggc Gly	gaa Glu	aca Thr	tgc Cys	4146
	gtt Val 1325	tat Tyr	cct Pro	act Thr	caa Gln	cct Pro 1330	tcc Ser	gtg Val	gct Ala	cag Gln	aaa Lys 1335	aat Asn	tgg Trp	tac Tyr	atc Ile	4191
45	tca Ser 1340	aaa Lys	aat Asn	cct Pro	aaa Lys	gat Asp 1345	aag Lys	agg Arg	cac His	gtt Val	tgg Trp 1350	ttc Phe	ggt Gly	gaa Glu	agt Ser	4236
50	atg Met 1355	act Thr	gat Asp	gga Gly	ttt Phe	caa Gln 1360	ttt Phe	gag Glu	tac Tyr	ggc Gly	ggt Gly 1365	caa Gln	ggt Gly	agt Ser	gat Asp	4281
	cca Pro 1370	gct Ala	gat Asp	gtg Val	gct Ala	att Ile 1375	caa Gln	ctc Leu	aca Thr	ttt Phe	ttg Leu 1380	cgt Arg	ctt Leu	atg Met	tcc Ser	4326
55	aca Thr	gag Glu	gca Ala	tca Ser	caa Gln	aac Asn	atc Ile	act Thr	tac Tyr	cac His	tgc Cys	aaa Lys	aac Asn	agt Ser	gtg Val	4371

EP 3 312 282 B1

	1385		1390		1395														
	gct	tat	atg	gat	caa	caa	aca	gga	aac	ctt	aag	aag	gct	ctt	ctt				4416
5	Ala	Tyr	Met	Asp	Gln	Gln	Thr	Gly	Asn	Leu	Lys	Lys	Ala	Leu	Leu				
	1400					1405					1410								
	ttg	aag	ggc	tca	aac	gag	att	gag	att	aga	gca	gag	ggc	aac	tca				4461
	Leu	Lys	Gly	Ser	Asn	Glu	Ile	Glu	Ile	Arg	Ala	Glu	Gly	Asn	Ser				
10	1415					1420					1425								
	agg	ttt	act	tat	tca	gtt	act	gtt	gat	ggc	tgc	act	tca	cat	act				4506
	Arg	Phe	Thr	Tyr	Ser	Val	Thr	Val	Asp	Gly	Cys	Thr	Ser	His	Thr				
	1430					1435					1440								
15	ggc	gct	tgg	ggt	aaa	aca	gtt	atc	gag	tat	aag	act	aca	aaa	aca				4551
	Gly	Ala	Trp	Gly	Lys	Thr	Val	Ile	Glu	Tyr	Lys	Thr	Thr	Lys	Thr				
	1445					1450					1455								
	tca	aga	ctc	cca	atc	att	gat	gtt	gct	cct	ctc	gat	gtt	ggc	gct				4596
20	Ser	Arg	Leu	Pro	Ile	Ile	Asp	Val	Ala	Pro	Leu	Asp	Val	Gly	Ala				
	1460					1465					1470								
	cct	gat	caa	gag	ttc	ggt	ttt	gat	gtg	ggc	cca	gtt	tgt	ttc	ctc				4641
	Pro	Asp	Gln	Glu	Phe	Gly	Phe	Asp	Val	Gly	Pro	Val	Cys	Phe	Leu				
25	1475					1480					1485								
	taa	tgagctcgcg	gccgcac																4662
	<210> 3																		
	<211> 1489																		
30	<212> PRT																		
	<213> Artificial sequence																		
	<220>																		
35	<223> Synthetic sequence of the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the human Collagen alpha 1(I) chain and flanking regions																		
	<400> 3																		
40																			
45																			
50																			
55																			

EP 3 312 282 B1

	Met	Ala	His	Ala	Arg	Val	Leu	Leu	Leu	Ala	Leu	Ala	Val	Leu	Ala	Thr
	1				5					10					15	
5	Ala	Ala	Val	Ala	Val	Ala	Ser	Ser	Ser	Ser	Phe	Ala	Asp	Ser	Asn	Pro
				20					25					30		
10	Ile	Arg	Pro	Val	Thr	Asp	Arg	Ala	Ala	Ser	Thr	Leu	Ala	Gln	Leu	Gln
			35					40					45			
15	Glu	Glu	Gly	Gln	Val	Glu	Gly	Gln	Asp	Glu	Asp	Ile	Pro	Pro	Ile	Thr
		50					55					60				
20	Cys	Val	Gln	Asn	Gly	Leu	Arg	Tyr	His	Asp	Arg	Asp	Val	Trp	Lys	Pro
	65					70					75				80	
25	Glu	Pro	Cys	Arg	Ile	Cys	Val	Cys	Asp	Asn	Gly	Lys	Val	Leu	Cys	Asp
					85					90					95	
30																
35																
40																
45																
50																
55																

EP 3 312 282 B1

	Asp	Val	Ile	Cys	Asp	Glu	Thr	Lys	Asn	Cys	Pro	Gly	Ala	Glu	Val	Pro	
				100					105					110			
5	Glu	Gly	Glu	Cys	Cys	Pro	Val	Cys	Pro	Asp	Gly	Ser	Glu	Ser	Pro	Thr	
				115				120					125				
10	Asp	Gln	Glu	Thr	Thr	Gly	Val	Glu	Gly	Pro	Lys	Gly	Asp	Thr	Gly	Pro	
		130					135					140					
15	Arg	Gly	Pro	Arg	Gly	Pro	Ala	Gly	Pro	Pro	Gly	Arg	Asp	Gly	Ile	Pro	
	145					150					155					160	
20	Gly	Gln	Pro	Gly	Leu	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	
					165					170						175	
25	Pro	Pro	Gly	Leu	Gly	Gly	Asn	Phe	Ala	Pro	Gln	Leu	Ser	Tyr	Gly	Tyr	
				180					185					190			
30	Asp	Glu	Lys	Ser	Thr	Gly	Gly	Ile	Ser	Val	Pro	Gly	Pro	Met	Gly	Pro	
			195					200					205				
35	Ser	Gly	Pro	Arg	Gly	Leu	Pro	Gly	Pro	Pro	Gly	Ala	Pro	Gly	Pro	Gln	
		210					215					220					
40	Gly	Phe	Gln	Gly	Pro	Pro	Gly	Glu	Pro	Gly	Glu	Pro	Gly	Ala	Ser	Gly	
	225					230					235					240	
45	Pro	Met	Gly	Pro	Arg	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Lys	Asn	Gly	Asp	
					245					250					255		
50	Asp	Gly	Glu	Ala	Gly	Lys	Pro	Gly	Arg	Pro	Gly	Glu	Arg	Gly	Pro	Pro	
				260					265					270			
55	Gly	Pro	Gln	Gly	Ala	Arg	Gly	Leu	Pro	Gly	Thr	Ala	Gly	Leu	Pro	Gly	
			275					280					285				
60	Met	Lys	Gly	His	Arg	Gly	Phe	Ser	Gly	Leu	Asp	Gly	Ala	Lys	Gly	Asp	
		290					295					300					
65	Ala	Gly	Pro	Ala	Gly	Pro	Lys	Gly	Glu	Pro	Gly	Ser	Pro	Gly	Glu	Asn	
	305					310					315					320	
70	Gly	Ala	Pro	Gly	Gln	Met	Gly	Pro	Arg	Gly	Leu	Pro	Gly	Glu	Arg	Gly	
					325					330					335		
75	Arg	Pro	Gly	Ala	Pro	Gly	Pro	Ala	Gly	Ala	Arg	Gly	Asn	Asp	Gly	Ala	

EP 3 312 282 B1

	340	345	350
5	Thr Gly Ala Ala Gly Pro Pro Gly Pro Thr Gly Pro Ala Gly Pro Pro 355 360 365		
10	Gly Phe Pro Gly Ala Val Gly Ala Lys Gly Glu Ala Gly Pro Gln Gly 370 375 380		
15	Pro Arg Gly Ser Glu Gly Pro Gln Gly Val Arg Gly Glu Pro Gly Pro 385 390 395 400		
20	Pro Gly Pro Ala Gly Ala Ala Gly Pro Ala Gly Asn Pro Gly Ala Asp 405 410 415		
25	Gly Gln Pro Gly Ala Lys Gly Ala Asn Gly Ala Pro Gly Ile Ala Gly 420 425 430		
30	Ala Pro Gly Phe Pro Gly Ala Arg Gly Pro Ser Gly Pro Gln Gly Pro 435 440 445		
35	Gly Gly Pro Pro Gly Pro Lys Gly Asn Ser Gly Glu Pro Gly Ala Pro 450 455 460		
40	Gly Ser Lys Gly Asp Thr Gly Ala Lys Gly Glu Pro Gly Pro Val Gly 465 470 475 480		
45	Val Gln Gly Pro Pro Gly Pro Ala Gly Glu Glu Gly Lys Arg Gly Ala 485 490 495		
50	Arg Gly Glu Pro Gly Pro Thr Gly Leu Pro Gly Pro Pro Gly Glu Arg 500 505 510		
55	Gly Gly Pro Gly Ser Arg Gly Phe Pro Gly Ala Asp Gly Val Ala Gly 515 520 525		
	Pro Lys Gly Pro Ala Gly Glu Arg Gly Ser Pro Gly Pro Ala Gly Pro 530 535 540		
	Lys Gly Ser Pro Gly Glu Ala Gly Arg Pro Gly Glu Ala Gly Leu Pro 545 550 555 560		
	Gly Ala Lys Gly Leu Thr Gly Ser Pro Gly Ser Pro Gly Pro Asp Gly 565 570 575		
	Lys Thr Gly Pro Pro Gly Pro Ala Gly Gln Asp Gly Arg Pro Gly Pro 580 585 590		

EP 3 312 282 B1

	Pro Gly	Pro	Pro Gly	Ala Arg	Gly	Gln Ala	Gly Val	Met	Gly Phe	Pro					
		595				600		605							
5	Gly Pro	Lys Gly	Ala Ala	Gly	Glu Pro	Gly Lys	Ala	Gly Glu	Arg Gly						
		610			615		620								
10	Val Pro	Gly Pro	Pro Gly	Ala Val	Gly	Pro Ala	Gly Lys	Asp Gly	Glu						
		625			630		635								
	Ala Gly	Ala Gln	Gly Pro	Pro Gly	Pro	Ala Gly	Pro Ala	Gly Glu	Arg						
			645			650		655							
15	Gly Glu	Gln Gly	Pro Ala	Gly Ser	Pro Gly	Phe Gln	Gly Leu	Pro Gly							
			660			665		670							
20	Pro Ala	Gly Pro	Pro Gly	Glu Ala	Gly Lys	Pro Gly	Glu Gln	Gly Val							
		675			680		685								
	Pro Gly	Asp Leu	Gly Ala	Pro Gly	Pro Ser	Gly Ala	Arg Gly	Glu Arg							
		690			695		700								
25															
	Gly Phe	Pro Gly	Glu Arg	Gly Val	Gln Gly	Pro Pro	Gly Pro	Ala Gly							
		705			710		715								
30	Pro Arg	Gly Ala	Asn Gly	Ala Pro	Gly Asn	Asp Gly	Ala Lys	Gly Asp							
			725			730		735							
	Ala Gly	Ala Pro	Gly Ala	Pro Gly	Ser Gln	Gly Ala	Pro Gly	Leu Gln							
35			740			745		750							
	Gly Met	Pro Gly	Glu Arg	Gly Ala	Ala Gly	Leu Pro	Gly Pro	Lys Gly							
		755			760		765								
40															
	Asp Arg	Gly Asp	Ala Gly	Pro Lys	Gly Ala	Asp Gly	Ser Pro	Gly Lys							
		770			775		780								
45	Asp Gly	Val Arg	Gly Leu	Thr Gly	Pro Ile	Gly Pro	Pro Gly	Pro Ala							
		785			790		795								
	Gly Ala	Pro Gly	Asp Lys	Gly Glu	Ser Gly	Pro Ser	Gly Pro	Ala Gly							
			805			810		815							
50															
	Pro Thr	Gly Ala	Arg Gly	Ala Pro	Gly Asp	Arg Gly	Glu Pro	Gly Pro							
			820			825		830							
55	Pro Gly	Pro Ala	Gly Phe	Ala Gly	Pro Pro	Gly Ala	Asp Gly	Gln Pro							
		835				840		845							

EP 3 312 282 B1

	Gly	Ala	Lys	Gly	Glu	Pro	Gly	Asp	Ala	Gly	Ala	Lys	Gly	Asp	Ala	Gly	850	855	860
5	Pro	Pro	Gly	Pro	Ala	Gly	Pro	Ala	Gly	Pro	Pro	Gly	Pro	Ile	Gly	Asn	865	870	875
10	Val	Gly	Ala	Pro	Gly	Ala	Lys	Gly	Ala	Arg	Gly	Ser	Ala	Gly	Pro	Pro	885	890	895
	Gly	Ala	Thr	Gly	Phe	Pro	Gly	Ala	Ala	Gly	Arg	Val	Gly	Pro	Pro	Gly	900	905	910
15	Pro	Ser	Gly	Asn	Ala	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Lys	915	920	925
20	Glu	Gly	Gly	Lys	Gly	Pro	Arg	Gly	Glu	Thr	Gly	Pro	Ala	Gly	Arg	Pro	930	935	940
25	Gly	Glu	Val	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Glu	Lys	Gly	945	950	955
	Ser	Pro	Gly	Ala	Asp	Gly	Pro	Ala	Gly	Ala	Pro	Gly	Thr	Pro	Gly	Pro	965	970	975
30	Gln	Gly	Ile	Ala	Gly	Gln	Arg	Gly	Val	Val	Gly	Leu	Pro	Gly	Gln	Arg	980	985	990
35	Gly	Glu	Arg	Gly	Phe	Pro	Gly	Leu	Pro	Gly	Pro	Ser	Gly	Glu	Pro	Gly	995	1000	1005
40	Lys	Gln	Gly	Pro	Ser	Gly	Ala	Ser	Gly	Glu	Arg	Gly	Pro	Pro	Gly		1010	1015	1020
	Pro	Met	Gly	Pro	Pro	Gly	Leu	Ala	Gly	Pro	Pro	Gly	Glu	Ser	Gly		1025	1030	1035
45	Arg	Glu	Gly	Ala	Pro	Gly	Ala	Glu	Gly	Ser	Pro	Gly	Arg	Asp	Gly		1040	1045	1050
50	Ser	Pro	Gly	Ala	Lys	Gly	Asp	Arg	Gly	Glu	Thr	Gly	Pro	Ala	Gly		1055	1060	1065
	Pro	Pro	Gly	Ala	Pro	Gly	Ala	Pro	Gly	Ala	Pro	Gly	Pro	Val	Gly		1070	1075	1080
55	Pro	Ala	Gly	Lys	Ser	Gly	Asp	Arg	Gly	Glu	Thr	Gly	Pro	Ala	Gly		1085	1090	1095

EP 3 312 282 B1

	Pro	Ala	Gly	Pro	Val	Gly	Pro	Ala	Gly	Ala	Arg	Gly	Pro	Ala	Gly
		1100					1105					1110			
5	Pro	Gln	Gly	Pro	Arg	Gly	Asp	Lys	Gly	Glu	Thr	Gly	Glu	Gln	Gly
		1115					1120					1125			
10	Asp	Arg	Gly	Ile	Lys	Gly	His	Arg	Gly	Phe	Ser	Gly	Leu	Gln	Gly
		1130					1135					1140			
15	Pro	Pro	Gly	Pro	Pro	Gly	Ser	Pro	Gly	Glu	Gln	Gly	Pro	Ser	Gly
		1145					1150					1155			
20	Ala	Ser	Gly	Pro	Ala	Gly	Pro	Arg	Gly	Pro	Pro	Gly	Ser	Ala	Gly
		1160					1165					1170			
25	Ala	Pro	Gly	Lys	Asp	Gly	Leu	Asn	Gly	Leu	Pro	Gly	Pro	Ile	Gly
		1175					1180					1185			
30	Pro	Pro	Gly	Pro	Arg	Gly	Arg	Thr	Gly	Asp	Ala	Gly	Pro	Val	Gly
		1190					1195					1200			
35	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Ser
		1205					1210					1215			
40	Ala	Gly	Phe	Asp	Phe	Ser	Phe	Leu	Pro	Gln	Pro	Pro	Gln	Glu	Lys
		1220					1225					1230			
45	Ala	His	Asp	Gly	Gly	Arg	Tyr	Tyr	Arg	Ala	Asp	Asp	Ala	Asn	Val
		1235					1240					1245			
50	Val	Arg	Asp	Arg	Asp	Leu	Glu	Val	Asp	Thr	Thr	Leu	Lys	Ser	Leu
		1250					1255					1260			
55	Ser	Gln	Gln	Ile	Glu	Asn	Ile	Arg	Ser	Pro	Glu	Gly	Ser	Arg	Lys
		1265					1270					1275			
60	Asn	Pro	Ala	Arg	Thr	Cys	Arg	Asp	Leu	Lys	Met	Cys	His	Ser	Asp
		1280					1285					1290			
65	Trp	Lys	Ser	Gly	Glu	Tyr	Trp	Ile	Asp	Pro	Asn	Gln	Gly	Cys	Asn
		1295					1300					1305			
70	Leu	Asp	Ala	Ile	Lys	Val	Phe	Cys	Asn	Met	Glu	Thr	Gly	Glu	Thr
		1310					1315					1320			
75	Cys	Val	Tyr	Pro	Thr	Gln	Pro	Ser	Val	Ala	Gln	Lys	Asn	Trp	Tyr

EP 3 312 282 B1

	1325		1330		1335
5	Ile Ser Lys Asn Pro Lys Asp Lys Arg His Val Trp Phe Gly Glu 1340 1345 1350				
10	Ser Met Thr Asp Gly Phe Gln Phe Glu Tyr Gly Gly Gln Gly Ser 1355 1360 1365				
15	Asp Pro Ala Asp Val Ala Ile Gln Leu Thr Phe Leu Arg Leu Met 1370 1375 1380				
20	Ser Thr Glu Ala Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser 1385 1390 1395				
25	Val Ala Tyr Met Asp Gln Gln Thr Gly Asn Leu Lys Lys Ala Leu 1400 1405 1410				
30	Leu Leu Lys Gly Ser Asn Glu Ile Glu Ile Arg Ala Glu Gly Asn 1415 1420 1425				
35	Ser Arg Phe Thr Tyr Ser Val Thr Val Asp Gly Cys Thr Ser His 1430 1435 1440				
40	Thr Gly Ala Trp Gly Lys Thr Val Ile Glu Tyr Lys Thr Thr Lys 1445 1450 1455				
	Thr Ser Arg Leu Pro Ile Ile Asp Val Ala Pro Leu Asp Val Gly 1460 1465 1470				
	Ala Pro Asp Gln Glu Phe Gly Phe Asp Val Gly Pro Val Cys Phe 1475 1480 1485				

Leu

<210> 4

<211> 4362

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic sequence containing the coding regions of the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the human Collagen alpha 2(I) chain and flanking regions

<400> 4

gcgatgcatg taatgtcatg agccacatga tccaatggcc acaggaacgt aagaatgtag	60
atagatttga ttttgtccgt tagatagcaa acaacattat aaaaggtgtg tatcaatacg	120

EP 3 312 282 B1

	aactaattca	ctcattggat	tcatagaagt	ccatttcctcc	taagtatcta	aaccatggct	180
	cacgctcgtg	ttctcctcct	cgctctcgct	gttttgcaa	cagctgctgt	ggctgtggct	240
5	tcaagttcta	gttttgctga	ttccaaccca	attcgtccag	ttactgatag	agcagcttcc	300
	actttggctc	aattgcttca	agaagaaact	gtgaggaagg	gccctgctgg	cgataggggc	360
	cctaggggcg	aaaggggtcc	accaggacct	ccaggcaggg	atggcgaga	tggtccaact	420
10	ggccctcctg	gacctcctgg	ccctccaggg	ccacccggct	tggcgga	cttcgcagct	480
	caatacgatg	gcaaggggtg	tggtcttggt	cctggtccta	tgggcttgat	gggacctaga	540
	ggcccacctg	gtgctgctgg	tgctcctgga	ccacagggtt	ttcaggga	agctggcgag	600
15	ccaggagagc	caggccaaac	aggaccagct	ggtgcaaggg	gacctgctgg	acctcctgga	660
	aaagctggtg	aagatggtca	cccaggcaaa	ccaggacgtc	ctggcgaaag	aggtgttgtt	720
	ggaccacaag	gcgctagggg	atttccagg	acacctggat	tgccagggtt	taagggcatt	780
20	cgtggctcata	acggcctcga	tggattgaag	ggacagcctg	gcgcacctgg	cgtaaggggt	840
	gaacctggag	caccagggtga	aaacgggtact	cctggccaga	ctggtgcaag	aggactccca	900
25	ggtgaaagg	gtagagttgg	tgctcctgga	cctgctggag	ctaggggtag	tgatggtagt	960
	gttggctcctg	tgggccctgc	tggtccaatc	ggttccgctg	gccacactgg	attcccaggc	1020
	gctccaggac	ctaaaggaga	aatcggtgct	gtgggtaacg	caggtcctac	tggtccagca	1080
30	ggtcctcgtg	gagaagtggg	attgccagga	ctttctggtc	cagtggggcc	tccaggcaac	1140
	cctggagcta	acggcttgac	aggagctaaa	ggcgagcag	gactccctgg	agtggctggc	1200
	gcaccaggat	tgcttggtcc	aaggggtatc	ccaggccctg	ttggcgagc	tgagctact	1260
35	ggtgcacgtg	gacttggttg	cgaaccaggc	cctgctggat	caaaaggcga	gtctggaaat	1320
	aagggagaac	ctggttctgc	tggacctcaa	ggtcctcctg	gaccttctgg	agaagaagga	1380
	aaaaggggac	caaagggcga	ggctggatca	gcaggtccac	caggaccacc	tgacttcgt	1440
40	ggatcccctg	gtagtagagg	acttccaggc	gctgatggta	gagcaggcgt	tatgggacca	1500
	ccaggaagta	gaggagcatc	cggtccagca	ggagttaggg	gtcctaacgg	agatgctggt	1560
	agaccagggtg	aaccagggtct	tatgggcccc	aggggcctcc	caggtagtcc	aggaaatatc	1620
45	ggccctgctg	gaaaagaagg	ccctgttgga	cttccaggta	ttgatggacg	tcctggccct	1680
	attggcccag	caggtgcaag	aggagaacct	ggcaatattg	gatttccagg	accaaagggt	1740
	ccaacaggcg	atcctggaaa	aaatggagat	aagggtcatg	ctggattggc	aggcgcaagg	1800
50	ggcgctcctg	gtccagatgg	aaacaacggc	gcacagggtc	cacctggccc	tcagggtgtt	1860
	caaggcgga	aaggcgaaca	aggcccagct	ggaccaccag	gctttcaagg	cttgccagga	1920
55	ccaagtggtc	cagcagggtga	agttggcaag	ccaggcgagc	gtggacttca	tggcgagttt	1980
	ggactccctg	gaccagcagg	accaaggggt	gaaagaggcc	ctcctggaga	gagtggcgct	2040

EP 3 312 282 B1

							2100
							2160
5							2220
							2280
							2340
10							2400
							2460
							2520
15							2580
							2640
							2700
							2760
							2820
25							2880
							2940
							3000
30							3060
							3120
							3180
35							3240
							3300
							3360
							3420
							3480
45							3540
							3600
							3660
50							3720
							3780
							3840
55							3900

EP 3 312 282 B1

```

tctaaagata agaaacatgt ttggctcgga gagactatta acgctggttc tcagttcgag 3960
tataatgttg agggcggttac ttctaaagag atggcaactc agctcgcttt tatgagattg 4020
5   ctcgctaact acgcatccca aaacatcact tatcactgca aaaattccat tgcatatatg 4080
gatgaggaga caggaaatth gaagaaagca gttattctcc aaggtagtaa cgatggtgag 4140
cttgtggctg agggaaatag tagattcact tacacagttt tgggtggatgg atgctcaaag 4200
10  aaaactaatg agtggggcaa gacaatcatt gagtacaaga caaataagcc ttctaggctc 4260
ccattttctg atattgcacc tcttgatatc ggaggagctg atcacgagtt ttttgttgat 4320
15  atcggacctg tttgttttaa gtaatgagct cgcggccgca tc 4362

```

<210> 5

<211> 4362

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic sequence of the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the human Collagen alpha 2(I) chain and flanking regions

<220>

<221> CDS

<222> (175)..(4344)

<400> 5

EP 3 312 282 B1

	gcgatgcatg taatgtcatg agccacatga tccaatggcc acaggaacgt aagaatgtag	60
	atagatttga ttttgtccgt tagatagcaa acaacattat aaaaggtgtg tatcaatacg	120
5	aactaattca ctcatgggat tcatagaagt ccattcctcc taagtatcta aacc atg Met 1	177
10	gct cac gct cgt gtt ctc ctc ctc gct ctc gct gtt ttg gca aca gct Ala His Ala Arg Val Leu Leu Leu Ala Leu Ala Val Leu Ala Thr Ala 5 10 15	225
15	gct gtg gct gtg gct tca agt tct agt ttt gct gat tcc aac cca att Ala Val Ala Val Ala Ser Ser Ser Ser Phe Ala Asp Ser Asn Pro Ile 20 25 30	273
20	cgt cca gtt act gat aga gca gct tcc act ttg gct caa ttg ctt caa Arg Pro Val Thr Asp Arg Ala Ala Ser Thr Leu Ala Gln Leu Leu Gln 35 40 45	321
25	gaa gaa act gtg agg aag ggc cct gct ggc gat agg ggc cct agg ggc Glu Glu Thr Val Arg Lys Gly Pro Ala Gly Asp Arg Gly Pro Arg Gly 50 55 60 65	369
30	gaa agg ggt cca cca gga cct cca ggc agg gat ggc gaa gat ggt cca Glu Arg Gly Pro Pro Gly Pro Pro Gly Arg Asp Gly Glu Asp Gly Pro 70 75 80	417
35	act ggc cct cct gga cct cct ggc cct cca ggg cca ccc ggc ttg ggc Thr Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly	465

EP 3 312 282 B1

	85								90								95								
5	gga	aac	ttc	gca	gct	caa	tac	gat	ggc	aag	ggt	gtt	ggt	ctt	ggt	cct									513
	Gly	Asn	Phe	Ala	Ala	Gln	Tyr	Asp	Gly	Lys	Gly	Val	Gly	Leu	Gly	Pro									
			100					105						110											
	ggt	cct	atg	ggc	ttg	atg	gga	cct	aga	ggc	cca	cct	ggt	gct	gct	ggt									561
	Gly	Pro	Met	Gly	Leu	Met	Gly	Pro	Arg	Gly	Pro	Pro	Gly	Ala	Ala	Gly									
			115				120						125												
10	gct	cct	gga	cca	cag	ggt	ttt	cag	gga	cca	gct	ggc	gag	cca	gga	gag									609
	Ala	Pro	Gly	Pro	Gln	Gly	Phe	Gln	Gly	Pro	Ala	Gly	Glu	Pro	Gly	Glu									
						135						140				145									
15	cca	ggc	caa	aca	gga	cca	gct	ggt	gca	agg	gga	cct	gct	gga	cct	cct									657
	Pro	Gly	Gln	Thr	Gly	Pro	Ala	Gly	Ala	Arg	Gly	Pro	Ala	Gly	Pro	Pro									
					150					155					160										
20	gga	aaa	gct	ggt	gaa	gat	ggt	cac	cca	ggc	aaa	cca	gga	cgt	cct	ggc									705
	Gly	Lys	Ala	Gly	Glu	Asp	Gly	His	Pro	Gly	Lys	Pro	Gly	Arg	Pro	Gly									
				165					170					175											
25	gaa	aga	ggt	gtt	gtt	gga	cca	caa	ggc	gct	agg	gga	ttt	cca	ggt	aca									753
	Glu	Arg	Gly	Val	Val	Gly	Pro	Gln	Gly	Ala	Arg	Gly	Phe	Pro	Gly	Thr									
			180					185					190												
30	cct	gga	ttg	cca	ggt	ttt	aag	ggc	att	cgt	ggt	cat	aac	ggc	ctc	gat									801
	Pro	Gly	Leu	Pro	Gly	Phe	Lys	Gly	Ile	Arg	Gly	His	Asn	Gly	Leu	Asp									
			195				200					205													
35	gga	ttg	aag	gga	cag	cct	ggc	gca	cct	ggc	gtt	aag	ggt	gaa	cct	gga									849
	Gly	Leu	Lys	Gly	Gln	Pro	Gly	Ala	Pro	Gly	Val	Lys	Gly	Glu	Pro	Gly									
			210			215					220				225										
40	gca	cca	ggt	gaa	aac	ggt	act	cct	ggc	cag	act	ggt	gca	aga	gga	ctc									897
	Ala	Pro	Gly	Glu	Asn	Gly	Thr	Pro	Gly	Gln	Thr	Gly	Ala	Arg	Gly	Leu									
				230						235					240										
45	cca	ggt	gaa	agg	ggt	aga	gtt	ggt	gct	cct	gga	cct	gct	gga	gct	agg									945
	Pro	Gly	Glu	Arg	Gly	Arg	Val	Gly	Ala	Pro	Gly	Pro	Ala	Gly	Ala	Arg									
				245				250					255												
50	ggt	agt	gat	ggt	agt	gtt	ggt	cct	gtg	ggc	cct	gct	ggt	cca	atc	ggt									993
	Gly	Ser	Asp	Gly	Ser	Val	Gly	Pro	Val	Gly	Pro	Ala	Gly	Pro	Ile	Gly									
			260					265					270												
55	tcc	gct	ggc	cca	cct	gga	ttc	cca	ggc	gct	cca	gga	cct	aaa	gga	gaa									1041
	Ser	Ala	Gly	Pro	Pro	Gly	Phe	Pro	Gly	Ala	Pro	Gly	Pro	Lys	Gly	Glu									
			275				280					285													
60	atc	ggt	gct	gtg	ggt	aac	gca	ggt	cct	act	ggt	cca	gca	ggt	cct	cgt									1089
	Ile	Gly	Ala	Val	Gly	Asn	Ala	Gly	Pro	Thr	Gly	Pro	Ala	Gly	Pro	Arg									
			290			295					300					305									
65	gga	gaa	gtg	gga	ttg	cca	gga	ctt	tct	ggt	cca	gtg	ggc	cct	cca	ggc									1137
	Gly	Glu	Val	Gly	Leu	Pro	Gly	Leu	Ser	Gly	Pro	Val	Gly	Pro	Pro	Gly									
					310				315						320										
70	aac	cct	gga	gct	aac	ggc	ttg	aca	gga	gct	aaa	ggc	gca	gca	gga	ctc									1185
	Asn	Pro	Gly	Ala	Asn	Gly	Leu	Thr	Gly	Ala	Lys	Gly	Ala	Ala	Gly	Leu									
				325					330					335											
75	cct	gga	gtg	gct	ggc	gca	cca	gga	ttg	cct	ggt	cca	agg	ggt	atc	cca									1233

EP 3 312 282 B1

	Pro	Gly	Val	Ala	Gly	Ala	Pro	Gly	Leu	Pro	Gly	Pro	Arg	Gly	Ile	Pro	
			340					345					350				
5	ggc	cct	gtt	ggc	gca	gct	gga	gct	act	ggc	gca	cgt	gga	ctt	gtt	ggc	1281
	Gly	Pro	Val	Gly	Ala	Ala	Gly	Ala	Thr	Gly	Ala	Arg	Gly	Leu	Val	Gly	
		355					360					365					
10	gaa	cca	ggc	cct	gct	gga	tca	aaa	ggc	gag	tct	gga	aat	aag	gga	gaa	1329
	Glu	Pro	Gly	Pro	Ala	Gly	Ser	Lys	Gly	Glu	Ser	Gly	Asn	Lys	Gly	Glu	
	370				375					380						385	
15	cct	ggc	tct	gct	gga	cct	caa	ggc	cct	cct	gga	cct	tct	gga	gaa	gaa	1377
	Pro	Gly	Ser	Ala	Gly	Pro	Gln	Gly	Pro	Pro	Gly	Pro	Ser	Gly	Glu	Glu	
				390					395						400		
20	gga	aaa	agg	gga	cca	aat	ggc	gag	gct	gga	tca	gca	ggc	cca	cca	gga	1425
	Gly	Lys	Arg	Gly	Pro	Asn	Gly	Glu	Ala	Gly	Ser	Ala	Gly	Pro	Pro	Gly	
			405					410					415				
25	cca	cct	gga	ctt	cgt	gga	tcc	cct	ggc	agt	aga	gga	ctt	cca	ggc	gct	1473
	Pro	Pro	Gly	Leu	Arg	Gly	Ser	Pro	Gly	Ser	Arg	Gly	Leu	Pro	Gly	Ala	
			420				425						430				
30	gat	ggc	aga	gca	ggc	gtt	atg	gga	cca	cca	gga	agt	aga	gga	gca	tcc	1521
	Asp	Gly	Arg	Ala	Gly	Val	Met	Gly	Pro	Pro	Gly	Ser	Arg	Gly	Ala	Ser	
		435					440					445					
35	ggc	cca	gca	gga	gtt	agg	ggc	cct	aac	gga	gat	gct	ggc	aga	cca	ggc	1569
	Gly	Pro	Ala	Gly	Val	Arg	Gly	Pro	Asn	Gly	Asp	Ala	Gly	Arg	Pro	Gly	
	450				455					460			465				
40	gaa	cca	ggc	ctt	atg	ggc	cca	agg	ggc	ctc	cca	ggc	agt	cca	gga	aat	1617
	Glu	Pro	Gly	Leu	Met	Gly	Pro	Arg	Gly	Leu	Pro	Gly	Ser	Pro	Gly	Asn	
				470					475						480		
45	atc	ggc	cct	gct	gga	aaa	gaa	ggc	cct	gtt	gga	ctt	cca	ggc	att	gat	1665
	Ile	Gly	Pro	Ala	Gly	Lys	Glu	Gly	Pro	Val	Gly	Leu	Pro	Gly	Ile	Asp	
				485				490					495				
50	gga	cgt	cct	ggc	cct	att	ggc	cca	gca	ggc	gca	aga	gga	gaa	cct	ggc	1713
	Gly	Arg	Pro	Gly	Pro	Ile	Gly	Pro	Ala	Gly	Ala	Arg	Gly	Glu	Pro	Gly	
			500					505					510				
55	aat	att	gga	ttt	cca	gga	cca	aag	ggc	cca	aca	ggc	gat	cct	gga	aaa	1761
	Asn	Ile	Gly	Phe	Pro	Gly	Pro	Lys	Gly	Pro	Thr	Gly	Asp	Pro	Gly	Lys	
		515					520					525					
60	aat	gga	gat	aag	ggc	cat	gct	gga	ttg	gca	ggc	gca	agg	ggc	gct	cct	1809
	Asn	Gly	Asp	Lys	Gly	His	Ala	Gly	Leu	Ala	Gly	Ala	Arg	Gly	Ala	Pro	
	530				535					540						545	
65	ggc	cca	gat	gga	aac	aac	ggc	gca	cag	ggc	cca	cct	ggc	cct	cag	ggc	1857
	Gly	Pro	Asp	Gly	Asn	Asn	Gly	Ala	Gln	Gly	Pro	Pro	Gly	Pro	Gln	Gly	
				550					555						560		
70	gtt	caa	ggc	gga	aaa	ggc	gaa	caa	ggc	cca	gct	gga	cca	cca	ggc	ttt	1905
	Val	Gln	Gly	Gly	Lys	Gly	Glu	Gln	Gly	Pro	Ala	Gly	Pro	Pro	Gly	Phe	
				565				570					575				
75	caa	ggc	ttg	cca	gga	cca	agt	ggc	cca	gca	ggc	gaa	gtt	ggc	aag	cca	1953
	Gln	Gly	Leu	Pro	Gly	Pro	Ser	Gly	Pro	Ala	Gly	Glu	Val	Gly	Lys	Pro	
			580					585					590				

EP 3 312 282 B1

	ggc gag cgt gga ctt cat ggc gag ttt gga ctc cct gga cca gca gga	2001
	Gly Glu Arg Gly Leu His Gly Glu Phe Gly Leu Pro Gly Pro Ala Gly	
	595 600 605	
5	cca agg ggt gaa aga ggc cct cct gga gag agt ggc gct gct gga cca	2049
	Pro Arg Gly Glu Arg Gly Pro Pro Gly Glu Ser Gly Ala Ala Gly Pro	
	610 615 620 625	
10	aca ggc cca atc ggt agt aga ggt cct agt gga cct cca ggc cca gat	2097
	Thr Gly Pro Ile Gly Ser Arg Gly Pro Ser Gly Pro Pro Gly Pro Asp	
	630 635 640	
	gga aat aag ggt gaa cca gga gtt gtg ggc gct gtt gga aca gct ggt	2145
	Gly Asn Lys Gly Glu Pro Gly Val Val Gly Ala Val Gly Thr Ala Gly	
	645 650 655	
15	cct tca gga cca tca gga ctc cca ggc gag aga ggc gct gct ggc att	2193
	Pro Ser Gly Pro Ser Gly Leu Pro Gly Glu Arg Gly Ala Ala Gly Ile	
	660 665 670	
20	cct gga gga aaa ggt gaa aaa ggc gaa cct ggc ctc cgt ggc gaa atc	2241
	Pro Gly Gly Lys Gly Glu Lys Gly Glu Pro Gly Leu Arg Gly Glu Ile	
	675 680 685	
	gga aat cct gga cgt gat ggt gct cgt ggt gca cac ggc gct gtg ggc	2289
	Gly Asn Pro Gly Arg Asp Gly Ala Arg Gly Ala His Gly Ala Val Gly	
	690 695 700 705	
25	gct cca ggc cct gct ggt gct act ggt gat aga gga gag gct ggc gca	2337
	Ala Pro Gly Pro Ala Gly Ala Thr Gly Asp Arg Gly Glu Ala Gly Ala	
	710 715 720	
30	gct ggc cca gca ggt cct gct ggc cca agg ggt agt cct ggt gaa aga	2385
	Ala Gly Pro Ala Gly Pro Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg	
	725 730 735	
35	ggc gaa gtt gga cct gct ggc cct aac ggc ttt gct ggc cct gct gga	2433
	Gly Glu Val Gly Pro Ala Gly Pro Asn Gly Phe Ala Gly Pro Ala Gly	
	740 745 750	
	gca gca ggt caa cct ggc gct aaa ggt gaa agg ggc gga aag ggc cca	2481
	Ala Ala Gly Gln Pro Gly Ala Lys Gly Glu Arg Gly Gly Lys Gly Pro	
	755 760 765	
40	aaa ggt gaa aat ggc gtt gtg gga cca act ggt cca gtg ggc gca gct	2529
	Lys Gly Glu Asn Gly Val Val Gly Pro Thr Gly Pro Val Gly Ala Ala	
	770 775 780 785	
45	gga cct gct ggt cca aat gga cca cca gga cca gca ggt agt aga gga	2577
	Gly Pro Ala Gly Pro Asn Gly Pro Pro Gly Pro Ala Gly Ser Arg Gly	
	790 795 800	
50	gat ggt gga cct cca gga atg aca ggt ttt cca ggt gct gct ggt aga	2625
	Asp Gly Gly Pro Pro Gly Met Thr Gly Phe Pro Gly Ala Ala Gly Arg	
	805 810 815	
	aca gga cct cct ggt cct agt ggt att tct ggt cca cca gga cca cca	2673
	Thr Gly Pro Pro Gly Pro Ser Gly Ile Ser Gly Pro Pro Gly Pro Pro	
	820 825 830	
55	ggt cct gct gga aaa gaa gga ttg agg ggt cca cgt ggt gat caa gga	2721
	Gly Pro Ala Gly Lys Glu Gly Leu Arg Gly Pro Arg Gly Asp Gln Gly	
	835 840 845	

EP 3 312 282 B1

	cca	gtg	ggc	aga	act	ggt	gaa	gtt	ggc	gca	gtg	gga	cca	cct	ggt	ttt	2769
	Pro	Val	Gly	Arg	Thr	Gly	Glu	Val	Gly	Ala	Val	Gly	Pro	Pro	Gly	Phe	
	850					855					860					865	
5	gct	gga	gaa	aag	ggc	cct	tct	gga	gag	gca	gga	aca	gct	ggt	cct	cct	2817
	Ala	Gly	Glu	Lys	Gly	Pro	Ser	Gly	Glu	Ala	Gly	Thr	Ala	Gly	Pro	Pro	
					870					875					880		
10	ggt	aca	cct	gga	cct	caa	gga	ctt	ttg	ggt	gca	cct	ggt	att	ctc	gga	2865
	Gly	Thr	Pro	Gly	Pro	Gln	Gly	Leu	Leu	Gly	Ala	Pro	Gly	Ile	Leu	Gly	
				885					890					895			
15	ttg	cca	gga	agt	agg	ggc	gaa	cgt	gga	ctt	cct	ggc	gtg	gca	gga	gca	2913
	Leu	Pro	Gly	Ser	Arg	Gly	Glu	Arg	Gly	Leu	Pro	Gly	Val	Ala	Gly	Ala	
			900					905					910				
20	ggt	gga	gaa	cct	ggc	cct	ctc	gga	atc	gca	ggc	cca	cca	ggc	gca	aga	2961
	Val	Gly	Glu	Pro	Gly	Pro	Leu	Gly	Ile	Ala	Gly	Pro	Pro	Gly	Ala	Arg	
			915				920					925					
25	gga	cca	cca	gga	gct	ggt	gga	tca	cca	ggc	gtg	aat	ggt	gca	cct	ggc	3009
	Gly	Pro	Pro	Gly	Ala	Val	Gly	Ser	Pro	Gly	Val	Asn	Gly	Ala	Pro	Gly	
						935					940					945	
30	gag	gct	ggt	cgt	gat	gga	aac	cca	gga	aat	gat	ggc	cca	cca	gga	aga	3057
	Glu	Ala	Gly	Arg	Asp	Gly	Asn	Pro	Gly	Asn	Asp	Gly	Pro	Pro	Gly	Arg	
				950						955					960		
35	gat	ggt	caa	cct	gga	cac	aaa	ggc	gag	agg	ggc	tac	cca	gga	aat	att	3105
	Asp	Gly	Gln	Pro	Gly	His	Lys	Gly	Glu	Arg	Gly	Tyr	Pro	Gly	Asn	Ile	
				965					970					975			
40	ggc	cca	gtt	ggt	gct	gct	ggc	gca	cca	ggc	cca	cac	ggt	cca	gtt	gga	3153
	Gly	Pro	Val	Gly	Ala	Ala	Gly	Ala	Pro	Gly	Pro	His	Gly	Pro	Val	Gly	
			980					985					990				
45	cca	gca	gga	aaa	cac	ggt	aat	cgt	ggc	gaa	aca	ggc	cct	tca	ggc	cca	3201
	Pro	Ala	Gly	Lys	His	Gly	Asn	Arg	Gly	Glu	Thr	Gly	Pro	Ser	Gly	Pro	
			995				1000					1005					
50	gtg	gga	cct	gct	ggt	gct	gtt	ggc	cca	aga	gga	cca	tct	gga	cct		3246
	Val	Gly	Pro	Ala	Gly	Ala	Val	Gly	Pro	Arg	Gly	Pro	Ser	Gly	Pro		
	1010					1015					1020						
55	caa	ggc	att	aga	ggc	gat	aag	gga	gag	cct	ggc	gaa	aaa	gga	cct		3291
	Gln	Gly	Ile	Arg	Gly	Asp	Lys	Gly	Glu	Pro	Gly	Glu	Lys	Gly	Pro		
	1025					1030					1035						
60	aga	ggc	ttg	cct	ggt	ttt	aaa	gga	cac	aac	ggt	ctc	caa	gga	ctt		3336
	Arg	Gly	Leu	Pro	Gly	Phe	Lys	Gly	His	Asn	Gly	Leu	Gln	Gly	Leu		
	1040					1045					1050						
65	cca	ggt	atc	gct	ggt	cat	cat	gga	gat	cag	ggt	gct	cct	gga	tca		3381
	Pro	Gly	Ile	Ala	Gly	His	His	Gly	Asp	Gln	Gly	Ala	Pro	Gly	Ser		
	1055					1060					1065						
70	gtg	ggt	cca	gca	ggt	cct	aga	ggc	cca	gca	ggc	cct	tcc	ggt	cca		3426
	Val	Gly	Pro	Ala	Gly	Pro	Arg	Gly	Pro	Ala	Gly	Pro	Ser	Gly	Pro		
	1070					1075					1080						
75	gca	gga	aag	gat	gga	cgt	act	ggc	cac	cct	gga	act	gtg	ggc	cct		3471
	Ala	Gly	Lys	Asp	Gly	Arg	Thr	Gly	His	Pro	Gly	Thr	Val	Gly	Pro		

EP 3 312 282 B1

	1085		1090		1095		
5	gct gga att aga ggt cct caa ggt cat cag ggc cct gct ggc cct Ala Gly Ile Arg Gly Pro Gln Gly His Gln Gly Pro Ala Gly Pro 1100 1105 1110					3516	
	cca ggt cca cca ggt cct cca ggc cca cca gga gtt tca ggt ggt Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Val Ser Gly Gly 1115 1120 1125					3561	
10	ggt tac gat ttt ggt tac gat ggt gat ttt tac cgt gct gat caa Gly Tyr Asp Phe Gly Tyr Asp Gly Asp Phe Tyr Arg Ala Asp Gln 1130 1135 1140					3606	
15	cct aga agt gct cct tct ctc cgt cct aaa gat tat gaa gtt gat Pro Arg Ser Ala Pro Ser Leu Arg Pro Lys Asp Tyr Glu Val Asp 1145 1150 1155					3651	
20	gct act ttg aaa tca ctt aac aac cag att gag act ctt ctc aca Ala Thr Leu Lys Ser Leu Asn Asn Gln Ile Glu Thr Leu Leu Thr 1160 1165 1170					3696	
	cct gag gga tca aga aag aat cca gca cgt aca tgc cgt gat ctc Pro Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr Cys Arg Asp Leu 1175 1180 1185					3741	
25	aga ctt agt cac cca gag tgg tca agt ggc tat tat tgg att gat Arg Leu Ser His Pro Glu Trp Ser Ser Gly Tyr Tyr Trp Ile Asp 1190 1195 1200					3786	
30	cct aat cag ggt tgt aca atg gag gct atc aaa gtt tac tgt gat Pro Asn Gln Gly Cys Thr Met Glu Ala Ile Lys Val Tyr Cys Asp 1205 1210 1215					3831	
	ttt cca act gga gag aca tgt att agg gca caa cct gag aac att Phe Pro Thr Gly Glu Thr Cys Ile Arg Ala Gln Pro Glu Asn Ile 1220 1225 1230					3876	
35	cca gct aaa aat tgg tat cgt tcc tct aaa gat aag aaa cat gtt Pro Ala Lys Asn Trp Tyr Arg Ser Ser Lys Asp Lys Lys His Val 1235 1240 1245					3921	
40	tgg ctc gga gag act att aac gct ggt tct cag ttc gag tat aat Trp Leu Gly Glu Thr Ile Asn Ala Gly Ser Gln Phe Glu Tyr Asn 1250 1255 1260					3966	
45	gtt gag ggc gtt act tct aaa gag atg gca act cag ctc gct ttt Val Glu Gly Val Thr Ser Lys Glu Met Ala Thr Gln Leu Ala Phe 1265 1270 1275					4011	
	atg aga ttg ctc gct aac tac gca tcc caa aac atc act tat cac Met Arg Leu Leu Ala Asn Tyr Ala Ser Gln Asn Ile Thr Tyr His 1280 1285 1290					4056	
50	tgc aaa aat tcc att gca tat atg gat gag gag aca gga aat ttg Cys Lys Asn Ser Ile Ala Tyr Met Asp Glu Glu Thr Gly Asn Leu 1295 1300 1305					4101	
55	aag aaa gca gtt att ctc caa ggt agt aac gat gtt gag ctt gtg Lys Lys Ala Val Ile Leu Gln Gly Ser Asn Asp Val Glu Leu Val 1310 1315 1320					4146	
	gct gag gga aat agt aga ttc act tac aca gtt ttg gtg gat gga					4191	

EP 3 312 282 B1

	Ala	Glu	Gly	Asn	Ser	Arg	Phe	Thr	Tyr	Thr	Val	Leu	Val	Asp	Gly	
	1325					1330					1335					
5	tgc	tca	aag	aaa	act	aat	gag	tgg	ggc	aag	aca	atc	att	gag	tac	4236
	Cys	Ser	Lys	Lys	Thr	Asn	Glu	Trp	Gly	Lys	Thr	Ile	Ile	Glu	Tyr	
	1340					1345					1350					
	aag	aca	aat	aag	cct	tct	agg	ctc	cca	ttt	ctc	gat	att	gca	cct	4281
10	Lys	Thr	Asn	Lys	Pro	Ser	Arg	Leu	Pro	Phe	Leu	Asp	Ile	Ala	Pro	
	1355					1360					1365					
	ctt	gat	atc	gga	gga	gct	gat	cac	gag	ttt	ttt	gtt	gat	atc	gga	4326
	Leu	Asp	Ile	Gly	Gly	Ala	Asp	His	Glu	Phe	Phe	Val	Asp	Ile	Gly	
	1370					1375					1380					
15	cct	gtt	tgt	ttt	aag	taa	tgagctcgcg	gccgcac								4362
	Pro	Val	Cys	Phe	Lys											
	1385															
	<210> 6															
20	<211> 1389															
	<212> PRT															
	<213> Artificial sequence															
	<220>															
25	<223> Synthetic sequence containing the coding regions of the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the human Collagen alpha 2(I) chain and flanking regions															
	<400> 6															
30	Met	Ala	His	Ala	Arg	Val	Leu	Leu	Leu	Ala	Leu	Ala	Val	Leu	Ala	Thr
	1				5					10				15		
35	Ala	Ala	Val	Ala	Val	Ala	Ser	Ser	Ser	Ser	Phe	Ala	Asp	Ser	Asn	Pro
				20					25					30		
	Ile	Arg	Pro	Val	Thr	Asp	Arg	Ala	Ala	Ser	Thr	Leu	Ala	Gln	Leu	Leu
40			35				40					45				
	Gln	Glu	Glu	Thr	Val	Arg	Lys	Gly	Pro	Ala	Gly	Asp	Arg	Gly	Pro	Arg
	50						55					60				
45																
	Gly	Glu	Arg	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Arg	Asp	Gly	Glu	Asp	Gly
	65				70					75				80		
	Pro	Thr	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Leu
50				85					90					95		
	Gly	Gly	Asn	Phe	Ala	Ala	Gln	Tyr	Asp	Gly	Lys	Gly	Val	Gly	Leu	Gly
55				100					105				110			
	Pro	Gly	Pro	Met	Gly	Leu	Met	Gly	Pro	Arg	Gly	Pro	Pro	Gly	Ala	Ala
				115				120					125			

EP 3 312 282 B1

	Gly	Ala	Pro	Gly	Pro	Gln	Gly	Phe	Gln	Gly	Pro	Ala	Gly	Glu	Pro	Gly	
	130						135					140					
5	Glu	Pro	Gly	Gln	Thr	Gly	Pro	Ala	Gly	Ala	Arg	Gly	Pro	Ala	Gly	Pro	
	145					150					155					160	
	Pro	Gly	Lys	Ala	Gly	Glu	Asp	Gly	His	Pro	Gly	Lys	Pro	Gly	Arg	Pro	
10					165					170					175		
	Gly	Glu	Arg	Gly	Val	Val	Gly	Pro	Gln	Gly	Ala	Arg	Gly	Phe	Pro	Gly	
				180					185					190			
15	Thr	Pro	Gly	Leu	Pro	Gly	Phe	Lys	Gly	Ile	Arg	Gly	His	Asn	Gly	Leu	
			195					200					205				
	Asp	Gly	Leu	Lys	Gly	Gln	Pro	Gly	Ala	Pro	Gly	Val	Lys	Gly	Glu	Pro	
20		210					215					220					
	Gly	Ala	Pro	Gly	Glu	Asn	Gly	Thr	Pro	Gly	Gln	Thr	Gly	Ala	Arg	Gly	
25		225				230					235					240	
	Leu	Pro	Gly	Glu	Arg	Gly	Arg	Val	Gly	Ala	Pro	Gly	Pro	Ala	Gly	Ala	
					245					250					255		
30	Arg	Gly	Ser	Asp	Gly	Ser	Val	Gly	Pro	Val	Gly	Pro	Ala	Gly	Pro	Ile	
				260					265					270			
	Gly	Ser	Ala	Gly	Pro	Pro	Gly	Phe	Pro	Gly	Ala	Pro	Gly	Pro	Lys	Gly	
35			275					280					285				
	Glu	Ile	Gly	Ala	Val	Gly	Asn	Ala	Gly	Pro	Thr	Gly	Pro	Ala	Gly	Pro	
40		290					295					300					
	Arg	Gly	Glu	Val	Gly	Leu	Pro	Gly	Leu	Ser	Gly	Pro	Val	Gly	Pro	Pro	
	305					310					315					320	
45	Gly	Asn	Pro	Gly	Ala	Asn	Gly	Leu	Thr	Gly	Ala	Lys	Gly	Ala	Ala	Gly	
					325					330					335		
	Leu	Pro	Gly	Val	Ala	Gly	Ala	Pro	Gly	Leu	Pro	Gly	Pro	Arg	Gly	Ile	
50				340					345					350			
	Pro	Gly	Pro	Val	Gly	Ala	Ala	Gly	Ala	Thr	Gly	Ala	Arg	Gly	Leu	Val	
			355					360					365				
55	Gly	Glu	Pro	Gly	Pro	Ala	Gly	Ser	Lys	Gly	Glu	Ser	Gly	Asn	Lys	Gly	

EP 3 312 282 B1

	370		375		380	
5	Glu Pro Gly Ser Ala Gly	Pro Gln Gly Pro	Pro Gly Pro Ser Gly	Glu		
	385	390	395	400		
10	Glu Gly Lys Arg Gly	Pro Asn Gly Glu Ala Gly	Ser Ala Gly	Pro Pro		
		405	410	415		
15	Gly Pro Pro Gly Leu Arg Gly	Ser Pro Gly Ser Arg Gly	Leu Pro Gly			
		420	425	430		
20	Ala Asp Gly Arg Ala Gly	Val Met Gly Pro Pro Gly	Ser Arg Gly	Ala		
		435	440	445		
25	Ser Gly Pro Ala Gly	Val Arg Gly Pro Asn Gly	Asp Ala Gly Arg	Pro		
		450	455	460		
30	Gly Glu Pro Gly Leu Met	Gly Pro Arg Gly Leu Pro Gly	Ser Pro Gly			
		465	470	475	480	
35	Asn Ile Gly Pro Ala Gly	Lys Glu Gly Pro Val Gly	Leu Pro Gly	Ile		
		485	490	495		
40	Asp Gly Arg Pro Gly	Pro Ile Gly Pro Ala Gly	Ala Arg Gly	Glu Pro		
		500	505	510		
45	Gly Asn Ile Gly Phe Pro	Gly Pro Lys Gly Pro Thr Gly	Asp Pro Gly			
		515	520	525		
50	Lys Asn Gly Asp Lys Gly	His Ala Gly Leu Ala Gly	Ala Arg Gly	Ala		
		530	535	540		
55	Pro Gly Pro Asp Gly	Asn Asn Gly Ala Gln Gly	Pro Pro Gly	Pro Gln		
		545	550	555	560	
60	Gly Val Gln Gly Gly	Lys Gly Glu Gln Gly	Pro Ala Gly	Pro Gly		
		565	570	575		
65	Phe Gln Gly Leu Pro Gly	Pro Ser Gly Pro Ala Gly	Glu Val Gly	Lys		
		580	585	590		
70	Pro Gly Glu Arg Gly	Leu His Gly Glu Phe Gly	Leu Pro Gly	Pro Ala		
		595	600	605		
75	Gly Pro Arg Gly Glu	Arg Gly Pro Pro Gly	Glu Ser Gly	Ala Ala Gly		
		610	615	620		

EP 3 312 282 B1

	Pro	Thr	Gly	Pro	Ile	Gly	Ser	Arg	Gly	Pro	Ser	Gly	Pro	Pro	Gly	Pro	625	630	635	640
5	Asp	Gly	Asn	Lys	Gly	Glu	Pro	Gly	Val	Val	Gly	Ala	Val	Gly	Thr	Ala	645	650	655	
10	Gly	Pro	Ser	Gly	Pro	Ser	Gly	Leu	Pro	Gly	Glu	Arg	Gly	Ala	Ala	Gly	660	665	670	
	Ile	Pro	Gly	Gly	Lys	Gly	Glu	Lys	Gly	Glu	Pro	Gly	Leu	Arg	Gly	Glu	675	680	685	
15	Ile	Gly	Asn	Pro	Gly	Arg	Asp	Gly	Ala	Arg	Gly	Ala	His	Gly	Ala	Val	690	695	700	
20	Gly	Ala	Pro	Gly	Pro	Ala	Gly	Ala	Thr	Gly	Asp	Arg	Gly	Glu	Ala	Gly	705	710	715	720
25	Ala	Ala	Gly	Pro	Ala	Gly	Pro	Ala	Gly	Pro	Arg	Gly	Ser	Pro	Gly	Glu	725	730	735	
	Arg	Gly	Glu	Val	Gly	Pro	Ala	Gly	Pro	Asn	Gly	Phe	Ala	Gly	Pro	Ala	740	745	750	
30	Gly	Ala	Ala	Gly	Gln	Pro	Gly	Ala	Lys	Gly	Glu	Arg	Gly	Gly	Lys	Gly	755	760	765	
35	Pro	Lys	Gly	Glu	Asn	Gly	Val	Val	Gly	Pro	Thr	Gly	Pro	Val	Gly	Ala	770	775	780	
40	Ala	Gly	Pro	Ala	Gly	Pro	Asn	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Ser	Arg	785	790	795	800
	Gly	Asp	Gly	Gly	Pro	Pro	Gly	Met	Thr	Gly	Phe	Pro	Gly	Ala	Ala	Gly	805	810	815	
45	Arg	Thr	Gly	Pro	Pro	Gly	Pro	Ser	Gly	Ile	Ser	Gly	Pro	Pro	Gly	Pro	820	825	830	
50	Pro	Gly	Pro	Ala	Gly	Lys	Glu	Gly	Leu	Arg	Gly	Pro	Arg	Gly	Asp	Gln	835	840	845	
	Gly	Pro	Val	Gly	Arg	Thr	Gly	Glu	Val	Gly	Ala	Val	Gly	Pro	Pro	Gly	850	855	860	
55	Phe	Ala	Gly	Glu	Lys	Gly	Pro	Ser	Gly	Glu	Ala	Gly	Thr	Ala	Gly	Pro	865	870	875	880

EP 3 312 282 B1

	Pro Gly Thr Pro Gly Pro Gln Gly Leu Leu Gly Ala Pro Gly Ile Leu	885	890	895
5	Gly Leu Pro Gly Ser Arg Gly Glu Arg Gly Leu Pro Gly Val Ala Gly	900	905	910
10	Ala Val Gly Glu Pro Gly Pro Leu Gly Ile Ala Gly Pro Pro Gly Ala	915	920	925
	Arg Gly Pro Pro Gly Ala Val Gly Ser Pro Gly Val Asn Gly Ala Pro	930	935	940
15	Gly Glu Ala Gly Arg Asp Gly Asn Pro Gly Asn Asp Gly Pro Pro Gly	945	950	955
				960
20	Arg Asp Gly Gln Pro Gly His Lys Gly Glu Arg Gly Tyr Pro Gly Asn	965	970	975
	Ile Gly Pro Val Gly Ala Ala Gly Ala Pro Gly Pro His Gly Pro Val	980	985	990
25	Gly Pro Ala Gly Lys His Gly Asn Arg Gly Glu Thr Gly Pro Ser Gly	995	1000	1005
30	Pro Val Gly Pro Ala Gly Ala Val Gly Pro Arg Gly Pro Ser Gly	1010	1015	1020
35	Pro Gln Gly Ile Arg Gly Asp Lys Gly Glu Pro Gly Glu Lys Gly	1025	1030	1035
	Pro Arg Gly Leu Pro Gly Phe Lys Gly His Asn Gly Leu Gln Gly	1040	1045	1050
40	Leu Pro Gly Ile Ala Gly His His Gly Asp Gln Gly Ala Pro Gly	1055	1060	1065
45	Ser Val Gly Pro Ala Gly Pro Arg Gly Pro Ala Gly Pro Ser Gly	1070	1075	1080
	Pro Ala Gly Lys Asp Gly Arg Thr Gly His Pro Gly Thr Val Gly	1085	1090	1095
50	Pro Ala Gly Ile Arg Gly Pro Gln Gly His Gln Gly Pro Ala Gly	1100	1105	1110
55	Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Val Ser Gly	1115	1120	1125

EP 3 312 282 B1

	Gly	Gly	Tyr	Asp	Phe	Gly	Tyr	Asp	Gly	Asp	Phe	Tyr	Arg	Ala	Asp
	1130						1135					1140			
5	Gln	Pro	Arg	Ser	Ala	Pro	Ser	Leu	Arg	Pro	Lys	Asp	Tyr	Glu	Val
	1145						1150					1155			
10	Asp	Ala	Thr	Leu	Lys	Ser	Leu	Asn	Asn	Gln	Ile	Glu	Thr	Leu	Leu
	1160						1165					1170			
15	Thr	Pro	Glu	Gly	Ser	Arg	Lys	Asn	Pro	Ala	Arg	Thr	Cys	Arg	Asp
	1175						1180					1185			
20	Leu	Arg	Leu	Ser	His	Pro	Glu	Trp	Ser	Ser	Gly	Tyr	Tyr	Trp	Ile
	1190						1195					1200			
25	Asp	Pro	Asn	Gln	Gly	Cys	Thr	Met	Glu	Ala	Ile	Lys	Val	Tyr	Cys
	1205						1210					1215			
30	Asp	Phe	Pro	Thr	Gly	Glu	Thr	Cys	Ile	Arg	Ala	Gln	Pro	Glu	Asn
	1220						1225					1230			
35	Ile	Pro	Ala	Lys	Asn	Trp	Tyr	Arg	Ser	Ser	Lys	Asp	Lys	Lys	His
	1235						1240					1245			
40	Val	Trp	Leu	Gly	Glu	Thr	Ile	Asn	Ala	Gly	Ser	Gln	Phe	Glu	Tyr
	1250						1255					1260			
45	Asn	Val	Glu	Gly	Val	Thr	Ser	Lys	Glu	Met	Ala	Thr	Gln	Leu	Ala
	1265						1270					1275			
50	Phe	Met	Arg	Leu	Leu	Ala	Asn	Tyr	Ala	Ser	Gln	Asn	Ile	Thr	Tyr
	1280						1285					1290			
55	His	Cys	Lys	Asn	Ser	Ile	Ala	Tyr	Met	Asp	Glu	Glu	Thr	Gly	Asn
	1295						1300					1305			
60	Leu	Lys	Lys	Ala	Val	Ile	Leu	Gln	Gly	Ser	Asn	Asp	Val	Glu	Leu
	1310						1315					1320			
65	Val	Ala	Glu	Gly	Asn	Ser	Arg	Phe	Thr	Tyr	Thr	Val	Leu	Val	Asp
	1325						1330					1335			
70	Gly	Cys	Ser	Lys	Lys	Thr	Asn	Glu	Trp	Gly	Lys	Thr	Ile	Ile	Glu
	1340						1345					1350			
75	Tyr	Lys	Thr	Asn	Lys	Pro	Ser	Arg	Leu	Pro	Phe	Leu	Asp	Ile	Ala

EP 3 312 282 B1

	1355	1360	1365	
5	Pro Leu Asp Ile Gly Gly Ala Asp His Glu Phe Phe Val Asp Ile			
	1370	1375	1380	
10	Gly Pro Val Cys Phe Lys			
	1385			
15	<210> 7			
	<211> 127			
	<212> DNA			
	<213> Artificial sequence			
20	<220>			
	<223> Synthetic sequence containing the coding region of the appoplast signal of Arabidopsis thaliana endo-1,4-beta-glucanase and flanking regions			
25	<400> 7			
	gccatggcta ggaagtcttt gattttccca gtgattcttc ttgctgtgct tcttttctct			60
	ccacctatatt actctgctgg acacgattat agggatgctc ttaggaagtc atctatggct			120
	caattgc			127
30	<210> 8			
	<211> 127			
	<212> DNA			
	<213> Artificial sequence			
35	<220>			
	<223> Synthetic sequence of the appoplast signal of Arabidopsis thaliana endo-1,4-beta-glucanase and flanking regions			
40	<220>			
	<221> CDS			
	<222> (10)..(120)			
	<400> 8			
45	gccatggct agg aag tct ttg att ttc cca gtg att ctt ctt gct gtg ctt			51
	Arg Lys Ser Leu Ile Phe Pro Val Ile Leu Leu Ala Val Leu			
	1	5	10	
50	ctt ttc tct cca cct att tac tct gct gga cac gat tat agg gat gct			99
	Leu Phe Ser Pro Pro Ile Tyr Ser Ala Gly His Asp Tyr Arg Asp Ala			
	15	20	25	30
	ctt agg aag tca tct atg gct caattgc			127
	Leu Arg Lys Ser Ser Met Ala			
	35			
55	<210> 9			
	<211> 37			
	<212> PRT			
	<213> Artificial sequence			

EP 3 312 282 B1

<220>

<223> Synthetic sequence of the appoplast signal of Arabidopsis thaliana endo-1,4-beta-glucanase and flanking regions

5 <400> 9

Arg Lys Ser Leu Ile Phe Pro Val Ile Leu Leu Ala Val Leu Leu Phe
1 5 10 15

10 Ser Pro Pro Ile Tyr Ser Ala Gly His Asp Tyr Arg Asp Ala Leu Arg
20 25 30

15 Lys Ser Ser Met Ala
35

<210> 10

<211> 1037

20 <212> DNA

<213> Artificial sequence

<220>

<223> Chrysanthemum rbcS1 promoter and 5' UTR

25 <400> 10

30

35

40

45

50

55

EP 3 312 282 B1

	aaatggcgcg ccaagcttag acaaacaccc cttgttatac aaagaatttc gctttacaaa	60
	atcaaattcg agaaaataat atatgcacta aataagatca ttcggatcca atctaaccaa	120
5	ttacgatacg ctttgggtac acttgatttt tgtttcagta gttacatata tcttgtttta	180
	tatgctatct ttaaggatct tcaactcaaag actattttgtt gatgttcttg atggggctcg	240
	gaagatttga tatgatacac tctaattcttt aggagatacc agccaggatt atattcagta	300
10	agacaatcaa atttttacgtg ttcaaactcg ttatcttttc atttaatgga tgagccagaa	360
	tctctataga atgattgcaa tcgagaatat gttcggccga tatccctttg ttggcttcaa	420
	tattctacat atcacacaag aatcgaccgt attgtaccct ctttccataa aggaacacac	480
15	agtatgcaga tgcttttttc ccacatgcag taacataggt attcaaaaat ggctaaaaga	540
	agttggataa caaattgaca actattttcca tttctgttat ataaatttca caacacaaa	600
20	aagcccgtaa tcaagagtct gcccatgtac gaaataactt ctattatttg gtattgggcc	660
	taagcccagc tcagagtacg tgggggtacc acatatagga aggtaacaaa atactgcaag	720
	atagccccat aacgtaccag cctctcctta ccacgaagag ataagatata agaccacccc	780
25	tgccacgtgt cacatcgtca tgggtggttaa tgataaggga ttacatcctt ctatgtttgt	840
	ggacatgatg catgtaatgt catgagccac atgatccaat ggccacagga acgtaagaat	900
30	gtagatagat ttgattttgt ccgttagata gcaaacaaca ttataaaagg tgtgtatcaa	960
	tacgaactaa ttcactcatt ggattcatag aagtccattc ctcctaagta tctaaacata	1020
	tgcaattgtc gactaaa	1037
35	<210> 11 <211> 975 <212> DNA <213> Artificial sequence	
40	<220> <223> Chrysanthemum rbcS1 3'UTR and terminator <400> 11	
45		
50		
55		

EP 3 312 282 B1

5
 10
 15
 20
 25
 30

aaaaggatcc	gcggccgcat	aagttttact	atttaccaag	acttttgaat	attaaccttc	60
ttgtaacgag	tcgggttaa	attgattgtt	aggggtttgt	attatttttt	tttgggtctt	120
taattcatca	ctttaattcc	ctaattgtct	gttcatttcg	ttgtttgttt	ccggatcgat	180
aatgaaatgt	aagagatatc	atatataaat	aataaattgt	cgtttcatat	ttgcaatctt	240
tttttacaaa	cctttaatta	attgtatgta	tgacattttc	ttcttgttat	attaggggga	300
aataatgtta	aataaaaagta	caaaataaac	tacagtacat	cgtactgaat	aaattaccta	360
gccaaaaagt	acacctttcc	atatacttcc	tacatgaagg	cattttcaac	attttcaa	420
aaggaatgct	acaaccgcat	aataacatcc	acaaattttt	ttataaaata	acatgtcaga	480
cagtgtattga	aagattttat	tatagtttcg	ttatcttctt	ttctcattaa	gcgaatcact	540
acctaacacg	tcattttgtg	aaatattttt	tgaatgtttt	tatatagttg	tagcattcct	600
cttttcaa	tagggtttgt	ttgagatagc	atttcagccg	gttcatacaa	cttaaaagca	660
tactcta	ctggaaaaaa	gactaaaaaa	tcttgtaagt	tagcgcagaa	tattgaccca	720
aattatatac	acacatgacc	ccatatagag	actaattaca	cttttaacca	ctaataatta	780
ttactgtatt	ataacatcta	ctaattaaac	ttgtgagttt	ttgctagaat	tattatcata	840
tatactaaaa	ggcaggaacg	caaacattgc	cccgggtactg	tagcaactac	ggtagacgca	900
ttaattgtct	atagtggacg	cattaattaa	ccaaaaccgc	ctctttcccc	ttcttcttga	960
agcttgagct	ctttt					975

<210> 12

<211> 1633

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic sequence containing the coding regions of the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the human Prolyl 4-hydroxylase beta subunit and flanking regions

<400> 12

45
 50

ctcgagtaaa	ccatgggtca	tgctaggggt	ttgcttttgg	ctcttgctgt	tcttgctact	60
gctgctgttg	ctgtgggttc	ttcttcatct	ttcgctgatt	ctaacccta	taggccagt	120
actgatagag	ctgcttctac	tcttgctcaa	ttggtcgaca	tgatgctcc	agaagaggag	180
gatcacgttc	ttgtgcttag	gaagtcta	ttcgctgaag	ctcttgctgc	tcacaagtac	240

EP 3 312 282 B1

5 cttcttgtgg agttttatgc tccttggtgc ggacattgca aagctcttgc tccagagtat 300
 gctaaggctg ctggaaaagt gaaggctgag ggatctgaaa ttaggcttgc taaagtggat 360
 10 gctactgagg agtctgatct tgctcaacag tacggagtta ggggataccc aactattaag 420
 ttcttcagga acggagatac tgcttctcca aaggagtata ctgctggaag ggaggctgat 480
 gatattgtga actggcttaa gaagagaact ggaccagctg ctactactct tccagatgga 540
 15 gctgctgctg aatctcttgt ggagtcactt gaggtggcag tgattggatt cttcaaggat 600
 gtggagtctg attctgctaa gcagttcctt caagctgctg aggctattga tgatattcca 660
 ttcggaatta cttctaactc tgatgtgttc tctaagtacc agcttgataa ggatggagtg 720
 gtgcttttca agaaattcga tgaggggaag aacaatttcg agggagaggt gacaaaggag 780
 aaccttcttg atttcattaa gcacaaccag cttccacttg tgattgagtt cactgagcag 840
 20 actgctccaa agattttcgg aggagagatt aagactcaca ttcttctttt ccttccaaag 900
 tctgtgtctg attacgatgg aaagttgtct aacttcaaga ctgctgctga gtctttcaag 960
 ggaaagattc ttttcatttt cattgattct gatcacactg ataaccagag gattcttgag 1020
 25 ttcttcggac ttaagaagga agagtgccca gctgttaggc ttattactct tgaggaggag 1080
 atgactaagt acaagccaga gtctgaagaa cttactgctg agaggattac tgagttctgc 1140
 30 cacagattcc ttgagggaaa gattaagcca caccttatgt ctcaagagct tccagaggat 1200
 tgggataagc agccagttaa ggtgttggtg ggtaaaaact tcgaggatgt ggctttcgat 1260
 gagaagaaga acgtgttcgt ggagttctac gcaccttggt gtggtcactg taagcagctt 1320
 35 gctccaattt gggataagtt gggagagact tacaaggatc acgagaacat tgtgattgct 1380
 aagatggatt ctactgctaa cgaggtggag gctgttaagg ttactctttt cccaactttg 1440
 aagttcttcc cagcttctgc tgataggact gtgattgatt acaacggaga aaggactctt 1500
 40 gatggattca agaagttcct tgagtctgga ggacaagatg gagctggaga tgatgatgat 1560
 cttgaggatt tggaagaagc tgaggagcca gatatggagg aggatgatga tcagaaggct 1620
 45 gtgtgatgag ctc 1633

<210> 13

<211> 537

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic sequence containing the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the human Prolyl 4-hydroxylase beta subunit and flanking regions

<400> 13

EP 3 312 282 B1

Met Ala His Ala Arg Val Leu Leu Leu Ala Leu Ala Val Leu Ala Thr

5

10

15

20

25

30

35

40

45

50

55

EP 3 312 282 B1

	1			5					10				15			
5	Ala	Ala	Val	Ala	Val	Ala	Ser	Ser	Ser	Ser	Phe	Ala	Asp	Ser	Asn	Pro
				20					25					30		
	Ile	Arg	Pro	Val	Thr	Asp	Arg	Ala	Ala	Ser	Thr	Leu	Ala	Gln	Leu	Val
10			35					40					45			
	Asp	Met	Asp	Ala	Pro	Glu	Glu	Glu	Asp	His	Val	Leu	Val	Leu	Arg	Lys
		50					55					60				
15	Ser	Asn	Phe	Ala	Glu	Ala	Leu	Ala	Ala	His	Lys	Tyr	Leu	Leu	Val	Glu
	65					70					75					80
	Phe	Tyr	Ala	Pro	Trp	Cys	Gly	His	Cys	Lys	Ala	Leu	Ala	Pro	Glu	Tyr
20					85					90					95	
	Ala	Lys	Ala	Ala	Gly	Lys	Leu	Lys	Ala	Glu	Gly	Ser	Glu	Ile	Arg	Leu
25				100					105					110		
	Ala	Lys	Val	Asp	Ala	Thr	Glu	Glu	Ser	Asp	Leu	Ala	Gln	Gln	Tyr	Gly
			115					120					125			
30	Val	Arg	Gly	Tyr	Pro	Thr	Ile	Lys	Phe	Phe	Arg	Asn	Gly	Asp	Thr	Ala
		130					135					140				
	Ser	Pro	Lys	Glu	Tyr	Thr	Ala	Gly	Arg	Glu	Ala	Asp	Asp	Ile	Val	Asn
35		145				150					155					160
	Trp	Leu	Lys	Lys	Arg	Thr	Gly	Pro	Ala	Ala	Thr	Thr	Leu	Pro	Asp	Gly
					165					170					175	
40	Ala	Ala	Ala	Glu	Ser	Leu	Val	Glu	Ser	Ser	Glu	Val	Ala	Val	Ile	Gly
				180					185					190		
	Phe	Phe	Lys	Asp	Val	Glu	Ser	Asp	Ser	Ala	Lys	Gln	Phe	Leu	Gln	Ala
45			195					200					205			
	Ala	Glu	Ala	Ile	Asp	Asp	Ile	Pro	Phe	Gly	Ile	Thr	Ser	Asn	Ser	Asp
50		210					215					220				
	Val	Phe	Ser	Lys	Tyr	Gln	Leu	Asp	Lys	Asp	Gly	Val	Val	Leu	Phe	Lys
		225				230					235					240
55	Lys	Phe	Asp	Glu	Gly	Arg	Asn	Asn	Phe	Glu	Gly	Glu	Val	Thr	Lys	Glu
					245					250					255	

EP 3 312 282 B1

	Asn	Leu	Leu	Asp	Phe	Ile	Lys	His	Asn	Gln	Leu	Pro	Leu	Val	Ile	Glu	
				260					265					270			
5	Phe	Thr	Glu	Gln	Thr	Ala	Pro	Lys	Ile	Phe	Gly	Gly	Glu	Ile	Lys	Thr	
			275					280					285				
10	His	Ile	Leu	Leu	Phe	Leu	Pro	Lys	Ser	Val	Ser	Asp	Tyr	Asp	Gly	Lys	
		290					295					300					
15	Leu	Ser	Asn	Phe	Lys	Thr	Ala	Ala	Glu	Ser	Phe	Lys	Gly	Lys	Ile	Leu	
	305					310					315					320	
20	Phe	Ile	Phe	Ile	Asp	Ser	Asp	His	Thr	Asp	Asn	Gln	Arg	Ile	Leu	Glu	
					325					330					335		
25	Phe	Phe	Gly	Leu	Lys	Lys	Glu	Glu	Cys	Pro	Ala	Val	Arg	Leu	Ile	Thr	
				340					345					350			
30	Leu	Glu	Glu	Glu	Met	Thr	Lys	Tyr	Lys	Pro	Glu	Ser	Glu	Glu	Leu	Thr	
			355					360					365				
35	Ala	Glu	Arg	Ile	Thr	Glu	Phe	Cys	His	Arg	Phe	Leu	Glu	Gly	Lys	Ile	
		370					375					380					
40	Lys	Pro	His	Leu	Met	Ser	Gln	Glu	Leu	Pro	Glu	Asp	Trp	Asp	Lys	Gln	
	385					390					395					400	
45	Pro	Val	Lys	Val	Leu	Val	Gly	Lys	Asn	Phe	Glu	Asp	Val	Ala	Phe	Asp	
					405					410					415		
50	Glu	Lys	Lys	Asn	Val	Phe	Val	Glu	Phe	Tyr	Ala	Pro	Trp	Cys	Gly	His	
				420					425					430			
55	Cys	Lys	Gln	Leu	Ala	Pro	Ile	Trp	Asp	Lys	Leu	Gly	Glu	Thr	Tyr	Lys	
			435					440					445				
60	Asp	His	Glu	Asn	Ile	Val	Ile	Ala	Lys	Met	Asp	Ser	Thr	Ala	Asn	Glu	
		450					455					460					
65	Val	Glu	Ala	Val	Lys	Val	His	Ser	Phe	Pro	Thr	Leu	Lys	Phe	Phe	Pro	
	465					470					475					480	
70	Ala	Ser	Ala	Asp	Arg	Thr	Val	Ile	Asp	Tyr	Asn	Gly	Glu	Arg	Thr	Leu	
					485					490					495		
75	Asp	Gly	Phe	Lys	Lys	Phe	Leu	Glu	Ser	Gly	Gly	Gln	Asp	Gly	Ala	Gly	
				500					505					510			

EP 3 312 282 B1

Asp Asp Asp Asp Leu Glu Asp Leu Glu Glu Ala Glu Glu Pro Asp Met
515 520 525

5 Glu Glu Asp Asp Asp Gln Lys Ala Val
530 535

<210> 14

<211> 1723

10 <212> DNA

<213> Artificial sequence

<220>

15 <223> Synthetic sequence containing the coding regions of the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the human Prolyl 4-hydroxylase alpha-1 subunit and flanking regions

<400> 14

20	ctcgagtaaa ccatggctca tgctagggtt ttgcttttgg ctcttgctgt tcttgctact	60
	gctgctggtt ctgtggcttc ttcttcatct ttcgctgatt ctaacccaat taggccagtg	120
	actgatagag ctgcttctac tcttgctcaa ttggtcgaca tgcacccagg attcttcact	180
25	tctattggac agatgactga tcttattcac actgagaagg atcttgtgac ttctcttaag	240
	gattacatta aggctgagga ggataagttg gagcagatta agaagtgggc tgagaagttg	300
	gataggctta cttctactgc taaaaagat ccagagggat tcgttgggtca tccagtgaac	360
30	gctttcaagt tgatgaagag gcttaacact gagtggagtg agcttgagaa ccttgtgctt	420
	aaggatatgt ctgatggatt catttctaac cttactattc agaggcagta cttcccaa	480
35	gatgaggatc aagtgggagc tgctaaggct cttcttaggc ttcaggatac ttacaacctt	540
	gatactgata caatttctaa gggaacctt ccaggagtta agcacaagtc tttccttact	600
	gctgaggatt gcttcgagct tggaaaggtt gcatacactg aggctgatta ctaccacact	660
40	gagctttgga tggacaagc tcttaggcaa cttgatgagg gagagatttc tactattgat	720
	aaggtgtcag tgcttgatta cctttcttac gctgtgtacc agcagggtga tcttgataag	780
	gctcttttgc ttactaagaa gttgcttgag cttgatccag aacatcagag ggctaacgga	840
45	aaccttaagt acttcgagta cattatggct aaggaaaagg atgtgaacaa gtctgcttct	900
	gatgatcagt ctgatcaaaa gactactcca aagaagaagg gagtggctgt tgattatctt	960
50	cctgagaggc agaagtatga gatgttgtgt aggggagagg gtattaagat gactccaagg	1020
	aggcagaaga agttgttctg caggtatcac gatggaaaca ggaacccaaa gttcattctt	1080
	gctccagcta agcaagaaga tgagtgggat aagccaagga ttattagggt ccacgatatt	1140
55	atttctgatg ctgagattga gattgtgaag gatcttgcta agccaagact taggagggct	1200
	actatttcta accctattac tggatgatctt gagactgtgc actacaggat ttctaagtct	1260

EP 3 312 282 B1

```

gcttggcttt ctggatacga gaacccagtg gtgtctagga ttaacatgag gattcaggat 1320
cttactggac ttgatgtgtc tactgctgag gagcttcaag ttgctaacta cggagttgga 1380
5 ggacaatatg agccacactt cgatttcgct aggaaggatg agccagatgc ttttaaggag 1440
cttggaaactg gaaacaggat tgctacttgg cttttctaca tgtctgatgt ttctgctgga 1500
ggagctactg ttttcccaga agtgggagct tctgtttggc caaagaaggg aactgctgtg 1560
10 ttctggtaca accttttcgc ttctggagag ggagattact ctactaggca tgctgcttgc 1620
ccagttcttg ttggaaacaa gtgggtgtca aacaagtggc ttcattgagag gggacaagag 1680
15 tttagaaggc catgcactct ttctgagctt gagtgatgag ctc 1723

```

<210> 15

<211> 567

<212> PRT

20 <213> Artificial sequence

<220>

<223> Synthetic sequence containing the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the human Prolyl 4-hydroxylase alpha-1 subunit and flanking regions

25

<400> 15

30

35

40

45

50

55

EP 3 312 282 B1

	Met	Ala	His	Ala	Arg	Val	Leu	Leu	Leu	Ala	Leu	Ala	Val	Leu	Ala	Thr
	1				5					10					15	
5	Ala	Ala	Val	Ala	Val	Ala	Ser	Ser	Ser	Ser	Phe	Ala	Asp	Ser	Asn	Pro
				20					25					30		
	Ile	Arg	Pro	Val	Thr	Asp	Arg	Ala	Ala	Ser	Thr	Leu	Ala	Gln	Leu	Val
10			35					40					45			
	Asp	Met	His	Pro	Gly	Phe	Phe	Thr	Ser	Ile	Gly	Gln	Met	Thr	Asp	Leu
	50						55					60				
15	Ile	His	Thr	Glu	Lys	Asp	Leu	Val	Thr	Ser	Leu	Lys	Asp	Tyr	Ile	Lys
	65					70					75					80
	Ala	Glu	Glu	Asp	Lys	Leu	Glu	Gln	Ile	Lys	Lys	Trp	Ala	Glu	Lys	Leu
20					85					90					95	
	Asp	Arg	Leu	Thr	Ser	Thr	Ala	Thr	Lys	Asp	Pro	Glu	Gly	Phe	Val	Gly
25				100					105					110		
	His	Pro	Val	Asn	Ala	Phe	Lys	Leu	Met	Lys	Arg	Leu	Asn	Thr	Glu	Trp
			115					120					125			
30	Ser	Glu	Leu	Glu	Asn	Leu	Val	Leu	Lys	Asp	Met	Ser	Asp	Gly	Phe	Ile
	130						135					140				

35

40

45

50

55

EP 3 312 282 B1

	Ser	Asn	Leu	Thr	Ile	Gln	Arg	Gln	Tyr	Phe	Pro	Asn	Asp	Glu	Asp	Gln	
	145					150					155					160	
5	Val	Gly	Ala	Ala	Lys	Ala	Leu	Leu	Arg	Leu	Gln	Asp	Thr	Tyr	Asn	Leu	
					165					170					175		
10	Asp	Thr	Asp	Thr	Ile	Ser	Lys	Gly	Asn	Leu	Pro	Gly	Val	Lys	His	Lys	
				180					185					190			
15	Ser	Phe	Leu	Thr	Ala	Glu	Asp	Cys	Phe	Glu	Leu	Gly	Lys	Val	Ala	Tyr	
			195					200					205				
20	Thr	Glu	Ala	Asp	Tyr	Tyr	His	Thr	Glu	Leu	Trp	Met	Glu	Gln	Ala	Leu	
	210						215					220					
25	Arg	Gln	Leu	Asp	Glu	Gly	Glu	Ile	Ser	Thr	Ile	Asp	Lys	Val	Ser	Val	
	225					230					235					240	
30	Leu	Asp	Tyr	Leu	Ser	Tyr	Ala	Val	Tyr	Gln	Gln	Gly	Asp	Leu	Asp	Lys	
					245					250					255		
35	Ala	Leu	Leu	Leu	Thr	Lys	Lys	Leu	Leu	Glu	Leu	Asp	Pro	Glu	His	Gln	
				260					265					270			
40	Arg	Ala	Asn	Gly	Asn	Leu	Lys	Tyr	Phe	Glu	Tyr	Ile	Met	Ala	Lys	Glu	
			275					280					285				
45	Lys	Asp	Val	Asn	Lys	Ser	Ala	Ser	Asp	Asp	Gln	Ser	Asp	Gln	Lys	Thr	
	290						295					300					
50	Thr	Pro	Lys	Lys	Lys	Gly	Val	Ala	Val	Asp	Tyr	Leu	Pro	Glu	Arg	Gln	
	305					310					315					320	
55	Lys	Tyr	Glu	Met	Leu	Cys	Arg	Gly	Glu	Gly	Ile	Lys	Met	Thr	Pro	Arg	
				325						330					335		
60	Arg	Gln	Lys	Lys	Leu	Phe	Cys	Arg	Tyr	His	Asp	Gly	Asn	Arg	Asn	Pro	
				340					345					350			
65	Lys	Phe	Ile	Leu	Ala	Pro	Ala	Lys	Gln	Glu	Asp	Glu	Trp	Asp	Lys	Pro	
			355					360					365				
70	Arg	Ile	Ile	Arg	Phe	His	Asp	Ile	Ile	Ser	Asp	Ala	Glu	Ile	Glu	Ile	
	370						375					380					
75	Val	Lys	Asp	Leu	Ala	Lys	Pro	Arg	Leu	Arg	Arg	Ala	Thr	Ile	Ser	Asn	

EP 3 312 282 B1

	385		390		395		400									
5	Pro	Ile	Thr	Gly	Asp	Leu	Glu	Thr	Val	His	Tyr	Arg	Ile	Ser	Lys	Ser
				405						410					415	
10	Ala	Trp	Leu	Ser	Gly	Tyr	Glu	Asn	Pro	Val	Val	Ser	Arg	Ile	Asn	Met
				420					425					430		
15	Arg	Ile	Gln	Asp	Leu	Thr	Gly	Leu	Asp	Val	Ser	Thr	Ala	Glu	Glu	Leu
			435					440					445			
20	Gln	Val	Ala	Asn	Tyr	Gly	Val	Gly	Gly	Gln	Tyr	Glu	Pro	His	Phe	Asp
		450					455					460				
25	Phe	Ala	Arg	Lys	Asp	Glu	Pro	Asp	Ala	Phe	Lys	Glu	Leu	Gly	Thr	Gly
	465					470					475					480
30	Asn	Arg	Ile	Ala	Thr	Trp	Leu	Phe	Tyr	Met	Ser	Asp	Val	Ser	Ala	Gly
					485					490					495	
35	Gly	Ala	Thr	Val	Phe	Pro	Glu	Val	Gly	Ala	Ser	Val	Trp	Pro	Lys	Lys
				500					505					510		
40	Gly	Thr	Ala	Val	Phe	Trp	Tyr	Asn	Leu	Phe	Ala	Ser	Gly	Glu	Gly	Asp
			515					520					525			
45	Tyr	Ser	Thr	Arg	His	Ala	Ala	Cys	Pro	Val	Leu	Val	Gly	Asn	Lys	Trp
		530					535					540				
50	Val	Ser	Asn	Lys	Trp	Leu	His	Glu	Arg	Gly	Gln	Glu	Phe	Arg	Arg	Pro
	545					550					555					560
55	Cys	Thr	Leu	Ser	Glu	Leu	Glu									
					565											
55	<210> 16															
	<211> 928															
	<212> DNA															
	<213> Artificial sequence															
50	<220>															
	<223> Synthetic sequence containing the coding regions of the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the plant Prolyl 4-hydroxylase Plant and flanking regions															
55	<400> 16															

EP 3 312 282 B1

ctcgagtaaa ccatggctca tgctagggtt ttgcttttgg ctcttgctgt tcttgctact 60
gctgctgttg ctgtggcttc ttcttcatct ttcgctgatt ctaacccaat taggccagtg 120
5 actgatagag ctgcttctac tcttgctcaa ttggctcgaca tgcttggtat tctttctctt 180
ccaaacgcta acaggaactc ttctaagact aacgatctta ctaacattgt gaggaagtct 240
10 gagacttctt ctggagatga ggagggaaat ggagaaagat gggtggaagt gatttcttgg 300
gagccaaggg ctgttggtta ccacaacttc cttactaatg aggagtgcga gcaccttatt 360
tctcttgcta agccatctat ggtgaagtct actgtggtgg atgagaaaac tggaggatct 420
15 aaggattcaa gagtgaggac ttcatctggt actttcctta ggaggggaca tgatgaagtt 480
gtggaagtta ttgagaagag gatttctgat ttcactttca ttccagtga gaacggagaa 540
ggacttcaag ttcttacta ccaagtggga caaaagtacg agccacacta cgattacttc 600
20 cttgatgagt tcaacactaa gaacggagga cagaggattg ctactgtgct tatgtacctt 660
tctgatgtgg atgatggagg agagactgtt tttccagctg ctaggggaaa catttctgct 720
25 gttccttggt ggaacgagct ttctaagtgt ggaaaggagg gactttctgt gcttccaaag 780
aaaagggatg ctcttctttt ctggaacatg aggccagatg cttctcttga tccatcttct 840
cttcatggag gatgcccgat tgtaaggga aacaagtggc catctactaa gtggttccac 900
30 gtgcacgagt tcaaggtgta atgagctc 928

<210> 17

<211> 302

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic sequence containing the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the plant Prolyl 4-hydroxylase Plant and flanking regions

<400> 17

EP 3 312 282 B1

	Met	Ala	His	Ala	Arg	Val	Leu	Leu	Leu	Ala	Leu	Ala	Val	Leu	Ala	Thr
	1				5					10					15	
5	Ala	Ala	Val	Ala	Val	Ala	Ser	Ser	Ser	Ser	Phe	Ala	Asp	Ser	Asn	Pro
				20					25					30		
10	Ile	Arg	Pro	Val	Thr	Asp	Arg	Ala	Ala	Ser	Thr	Leu	Ala	Gln	Leu	Val
			35					40					45			
15	Asp	Met	Leu	Gly	Ile	Leu	Ser	Leu	Pro	Asn	Ala	Asn	Arg	Asn	Ser	Ser
	50						55					60				
20	Lys	Thr	Asn	Asp	Leu	Thr	Asn	Ile	Val	Arg	Lys	Ser	Glu	Thr	Ser	Ser
	65					70					75				80	
25	Gly	Asp	Glu	Glu	Gly	Asn	Gly	Glu	Arg	Trp	Val	Glu	Val	Ile	Ser	Trp
					85					90					95	

EP 3 312 282 B1

	Glu	Pro	Arg	Ala	Val	Val	Tyr	His	Asn	Phe	Leu	Thr	Asn	Glu	Glu	Cys	
				100					105					110			
5	Glu	His	Leu	Ile	Ser	Leu	Ala	Lys	Pro	Ser	Met	Val	Lys	Ser	Thr	Val	
			115					120					125				
10	Val	Asp	Glu	Lys	Thr	Gly	Gly	Ser	Lys	Asp	Ser	Arg	Val	Arg	Thr	Ser	
		130					135					140					
15	Ser	Gly	Thr	Phe	Leu	Arg	Arg	Gly	His	Asp	Glu	Val	Val	Glu	Val	Ile	
	145					150					155					160	
20	Glu	Lys	Arg	Ile	Ser	Asp	Phe	Thr	Phe	Ile	Pro	Val	Glu	Asn	Gly	Glu	
				165						170					175		
25	Gly	Leu	Gln	Val	Leu	His	Tyr	Gln	Val	Gly	Gln	Lys	Tyr	Glu	Pro	His	
			180						185					190			
30	Tyr	Asp	Tyr	Phe	Leu	Asp	Glu	Phe	Asn	Thr	Lys	Asn	Gly	Gly	Gln	Arg	
		195						200					205				
35	Ile	Ala	Thr	Val	Leu	Met	Tyr	Leu	Ser	Asp	Val	Asp	Asp	Gly	Gly	Glu	
	210						215					220					
40	Thr	Val	Phe	Pro	Ala	Ala	Arg	Gly	Asn	Ile	Ser	Ala	Val	Pro	Trp	Trp	
	225					230					235					240	
45	Asn	Glu	Leu	Ser	Lys	Cys	Gly	Lys	Glu	Gly	Leu	Ser	Val	Leu	Pro	Lys	
					245					250					255		
50	Lys	Arg	Asp	Ala	Leu	Leu	Phe	Trp	Asn	Met	Arg	Pro	Asp	Ala	Ser	Leu	
			260						265					270			
55	Asp	Pro	Ser	Ser	Leu	His	Gly	Gly	Cys	Pro	Val	Val	Lys	Gly	Asn	Lys	
		275						280					285				
60	Trp	Ser	Ser	Thr	Lys	Trp	Phe	His	Val	His	Glu	Phe	Lys	Val			
	290						295					300					
65	<210> 18																
	<211> 2689																
	<212> DNA																
	<213> Artificial sequence																
	<220>																
	<223> Synthetic sequence containing the coding regions of the human Procollagen C-proteinase and flanking regions																
	<400> 18																

EP 3 312 282 B1

	agatctatcg atgcatgccca tggtagccgc ccatggctca attggctgca acatcaaggc	60
	ctgaaagagt ttggccagat ggtgttattc ctttcgttat tggtagaaac tttactggat	120
5	ctcagagagc agtttttaga caagctatga gacattggga aaagcacact tgtgtgacat	180
	tccttgaaag gactgatgaa gattcttata ttgtgttcac ataccgtcca tgtggatgct	240
	gctcatatgt tggtagaagg ggaggaggtc cacaagcaat ttctattgga aaaaactgcg	300
10	ataagttcgg aattgtggtg catgaattgg gacatgttgt tggtttctgg cacgaacaca	360
	caaggccaga tagggatagg cacgtgtcta ttgtgaggga aaacattcag ccagggtcaag	420
15	agtacaattt tcttaagatg gaacctcaag aggtggaatc tctcggagag acttacgact	480
	tcgactccat catgcactac gcaaggaata ctttcagcag gggcatcttc ttggatacca	540
	ttgtgcctaa gtacgaggtg aacggcgta agccacctat tggtagaaag actaggctct	600
20	ctaagggtga tattgcacag gctaggaagc tctacaaatg tccagcatgc ggagaaactc	660
	ttcaggattc cactggcaac ttctcatctc cagagtacc aaacggatac tctgctcata	720
	tgcactgtgt ttggaggatc tcagtactc ctggagagaa gatcatcctc aacttcactt	780
25	ccctcgatct ctatcgttct aggctctgtt ggtacgacta tgtggaagtg agagatggct	840
	tctggagaaa ggctccactt agaggaaggt tctgcggatc taaacttcct gagccaatcg	900
	tgtctactga ttccagattg tgggtggagt tcaggtcctc ttctaattgg gttggcaagg	960
30	gcttttttgc tgtgtacgag gctatttgtg gcggcgacgt gaaaaaggac tacggacata	1020
	ttcaaagtcc aaattaccca gatgattacc gtccttcaaa agtgtgtatt tggaggattc	1080
35	aagtgagtga gggtttccat gttggattga cattccaatc tttcgaaatt gagagacacg	1140
	attcatgcgc atacgattat ttggaagtga gagatggaca ctctgaatct tctacactta	1200
	ttggaaggta ctgcggttat gagaaacctg atgatattaa gtctacttct agtaggttgt	1260
40	ggcttaaatt tgtgtcagat ggttctatta acaaggctgg tttcgcagtg aacttcttca	1320
	aggaagtgga tgaatgctca agacctaa ca gagaggatg tgagcaaaga tgccttaaca	1380
45	ctttgggaag ttacaagtgt tcttgcgatc ctggatacga gttggctcct gataagagaa	1440
	gatgcgaagc tgcttgcggt ggttttttga caaaattgaa cggatctatt acttctcctg	1500
	gatggccaaa agagtaccca cctaataaga attgcatttg gcagcttgtt gcacctactc	1560
50	agtaccgtat ttcattgcaa ttcgattttt tcgagactga gggtaatgat gtgtgcaagt	1620
	acgatttcgt ggaagtgaga tcaggcttta ctgctgatag taaattgcac ggaaagttct	1680
	gcggatctga aaaaccagaa gtgattacat cacagtacaa caatatgagg gtggagttca	1740
55	aatctgataa tactgtttct aaaaaaggtt ttaaggcaca tttcttttct gataaggacg	1800
	agtgctctaa agataatggg ggttgccagc aggattgcgt gaacacattc ggttcatatg	1860

EP 3 312 282 B1

```

    agtgccaatg ccgtagtgga tttgttcttc acgataacaa acatgattgc aaagaggcag 1920
    gttgcgatca caaggtgaca tctacttcag gtactatcac atctccaaac tggcctgata 1980
5    agtatccttc aaaaaaagaa tgtacatggg caatttcttc tacaccaggt cataggggta 2040
    agttgacatt catggagatg gatattgaga gtcaaccaga gtgcgcttat gatcatcttg 2100
    aggtgttcga tggaagggat gctaaggctc ctgttcttgg tagattctgt ggtagtaaaa 2160
10   agccagaacc agtgcttgca acaggatcta ggatgttcct tagattctac tctgataact 2220
    cagttcagag gaaaggattc caagctagtc acgcaactga atgcggtgga caagttagag 2280
    cagatgttaa gactaaggat ctttactcac acgcacagtt cggagataac aactaccctg 2340
15   gaggagttga ttgcgagtgg gttattgtgg ctgaagaggg atacggagtt gagcttggtt 2400
    tccagacatt cgaggtggag gaggaaactg attgcggtta cgattatatg gaactttttg 2460
20   atggatacga tagtactgct ccaagacttg gaaggtattg tggtagtggg ccaccagaag 2520
    aggtgtactc agctggagat agtgttcttg ttaagttcca cagtgatgat acaattacta 2580
    agaagggatt ccatcttaga tatacttcaa ctaagtttca ggatactctt cattctagga 2640
25   agtaatgagc tcgcggccgc atccaagctt ctgcagacgc gtcgacgc 2689

```

<210> 19

<211> 870

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic sequence containing the human Procollagen C-proteinase and flanking regions

<400> 19

```

    Met Ala Gln Leu Ala Ala Thr Ser Arg Pro Glu Arg Val Trp Pro Asp
    1          5          10          15
40   Gly Val Ile Pro Phe Val Ile Gly Gly Asn Phe Thr Gly Ser Gln Arg
    20          25          30
45   Ala Val Phe Arg Gln Ala Met Arg His Trp Glu Lys His Thr Cys Val
    35          40          45
50   Thr Phe Leu Glu Arg Thr Asp Glu Asp Ser Tyr Ile Val Phe Thr Tyr
    50          55          60
55   Arg Pro Cys Gly Cys Cys Ser Tyr Val Gly Arg Arg Gly Gly Gly Pro
    65          70          75          80
    Gln Ala Ile Ser Ile Gly Lys Asn Cys Asp Lys Phe Gly Ile Val Val
    85          90          95

```

EP 3 312 282 B1

	His	Glu	Leu	Gly	His	Val	Val	Gly	Phe	Trp	His	Glu	His	Thr	Arg	Pro	
				100					105					110			
5	Asp	Arg	Asp	Arg	His	Val	Ser	Ile	Val	Arg	Glu	Asn	Ile	Gln	Pro	Gly	
			115					120					125				
10	Gln	Glu	Tyr	Asn	Phe	Leu	Lys	Met	Glu	Pro	Gln	Glu	Val	Glu	Ser	Leu	
		130					135					140					
15	Gly	Glu	Thr	Tyr	Asp	Phe	Asp	Ser	Ile	Met	His	Tyr	Ala	Arg	Asn	Thr	
	145					150					155					160	
20	Phe	Ser	Arg	Gly	Ile	Phe	Leu	Asp	Thr	Ile	Val	Pro	Lys	Tyr	Glu	Val	
					165					170					175		
25	Asn	Gly	Val	Lys	Pro	Pro	Ile	Gly	Gln	Arg	Thr	Arg	Leu	Ser	Lys	Gly	
				180					185					190			
30	Asp	Ile	Ala	Gln	Ala	Arg	Lys	Leu	Tyr	Lys	Cys	Pro	Ala	Cys	Gly	Glu	
			195					200					205				
35	Thr	Leu	Gln	Asp	Ser	Thr	Gly	Asn	Phe	Ser	Ser	Pro	Glu	Tyr	Pro	Asn	
	210						215					220					
40	Gly	Tyr	Ser	Ala	His	Met	His	Cys	Val	Trp	Arg	Ile	Ser	Val	Thr	Pro	
	225					230					235					240	
45	Gly	Glu	Lys	Ile	Ile	Leu	Asn	Phe	Thr	Ser	Leu	Asp	Leu	Tyr	Arg	Ser	
				245						250					255		
50	Arg	Leu	Cys	Trp	Tyr	Asp	Tyr	Val	Glu	Val	Arg	Asp	Gly	Phe	Trp	Arg	
				260					265					270			
55	Lys	Ala	Pro	Leu	Arg	Gly	Arg	Phe	Cys	Gly	Ser	Lys	Leu	Pro	Glu	Pro	
		275						280					285				
60	Ile	Val	Ser	Thr	Asp	Ser	Arg	Leu	Trp	Val	Glu	Phe	Arg	Ser	Ser	Ser	
	290						295					300					
65	Asn	Trp	Val	Gly	Lys	Gly	Phe	Phe	Ala	Val	Tyr	Glu	Ala	Ile	Cys	Gly	
	305					310					315					320	
70	Gly	Asp	Val	Lys	Lys	Asp	Tyr	Gly	His	Ile	Gln	Ser	Pro	Asn	Tyr	Pro	
				325						330					335		
75	Asp	Asp	Tyr	Arg	Pro	Ser	Lys	Val	Cys	Ile	Trp	Arg	Ile	Gln	Val	Ser	
				340					345					350			

EP 3 312 282 B1

	Glu	Gly	Phe	His	Val	Gly	Leu	Thr	Phe	Gln	Ser	Phe	Glu	Ile	Glu	Arg	
			355					360					365				
5	His	Asp	Ser	Cys	Ala	Tyr	Asp	Tyr	Leu	Glu	Val	Arg	Asp	Gly	His	Ser	
		370					375					380					
10	Glu	Ser	Ser	Thr	Leu	Ile	Gly	Arg	Tyr	Cys	Gly	Tyr	Glu	Lys	Pro	Asp	
	385					390					395					400	
15	Asp	Ile	Lys	Ser	Thr	Ser	Ser	Arg	Leu	Trp	Leu	Lys	Phe	Val	Ser	Asp	
				405						410					415		
20	Gly	Ser	Ile	Asn	Lys	Ala	Gly	Phe	Ala	Val	Asn	Phe	Phe	Lys	Glu	Val	
				420					425					430			
25	Asp	Glu	Cys	Ser	Arg	Pro	Asn	Arg	Gly	Gly	Cys	Glu	Gln	Arg	Cys	Leu	
			435					440					445				
30	Asn	Thr	Leu	Gly	Ser	Tyr	Lys	Cys	Ser	Cys	Asp	Pro	Gly	Tyr	Glu	Leu	
	450						455					460					
35	Ala	Pro	Asp	Lys	Arg	Arg	Cys	Glu	Ala	Ala	Cys	Gly	Gly	Phe	Leu	Thr	
	465					470					475					480	
40	Lys	Leu	Asn	Gly	Ser	Ile	Thr	Ser	Pro	Gly	Trp	Pro	Lys	Glu	Tyr	Pro	
				485						490					495		
45	Pro	Asn	Lys	Asn	Cys	Ile	Trp	Gln	Leu	Val	Ala	Pro	Thr	Gln	Tyr	Arg	
			500					505						510			
50	Ile	Ser	Leu	Gln	Phe	Asp	Phe	Phe	Glu	Thr	Glu	Gly	Asn	Asp	Val	Cys	
			515					520					525				
55	Lys	Tyr	Asp	Phe	Val	Glu	Val	Arg	Ser	Gly	Leu	Thr	Ala	Asp	Ser	Lys	
	530						535					540					
60	Leu	His	Gly	Lys	Phe	Cys	Gly	Ser	Glu	Lys	Pro	Glu	Val	Ile	Thr	Ser	
	545					550					555					560	
65	Gln	Tyr	Asn	Asn	Met	Arg	Val	Glu	Phe	Lys	Ser	Asp	Asn	Thr	Val	Ser	
					565					570					575		
70	Lys	Lys	Gly	Phe	Lys	Ala	His	Phe	Phe	Ser	Asp	Lys	Asp	Glu	Cys	Ser	
				580					585					590			
75	Lys	Asp	Asn	Gly	Gly	Cys	Gln	Gln	Asp	Cys	Val	Asn	Thr	Phe	Gly	Ser	

EP 3 312 282 B1

	595	600	605
5	Tyr Glu Cys Gln Cys Arg Ser Gly Phe Val Leu His Asp Asn Lys His 610 615 620		
10	Asp Cys Lys Glu Ala Gly Cys Asp His Lys Val Thr Ser Thr Ser Gly 625 630 635 640		
15	Thr Ile Thr Ser Pro Asn Trp Pro Asp Lys Tyr Pro Ser Lys Lys Glu 645 650 655		
20	Cys Thr Trp Ala Ile Ser Ser Thr Pro Gly His Arg Val Lys Leu Thr 660 665 670		
25	Phe Met Glu Met Asp Ile Glu Ser Gln Pro Glu Cys Ala Tyr Asp His 675 680 685		
30	Leu Glu Val Phe Asp Gly Arg Asp Ala Lys Ala Pro Val Leu Gly Arg 690 695 700		
35	Phe Cys Gly Ser Lys Lys Pro Glu Pro Val Leu Ala Thr Gly Ser Arg 705 710 715 720		
40	Met Phe Leu Arg Phe Tyr Ser Asp Asn Ser Val Gln Arg Lys Gly Phe 725 730 735		
45	Gln Ala Ser His Ala Thr Glu Cys Gly Gly Gln Val Arg Ala Asp Val 740 745 750		
50	Lys Thr Lys Asp Leu Tyr Ser His Ala Gln Phe Gly Asp Asn Asn Tyr 755 760 765		
55	Pro Gly Gly Val Asp Cys Glu Trp Val Ile Val Ala Glu Glu Gly Tyr 770 775 780		
	Gly Val Glu Leu Val Phe Gln Thr Phe Glu Val Glu Glu Thr Asp 785 790 795 800		
	Cys Gly Tyr Asp Tyr Met Glu Leu Phe Asp Gly Tyr Asp Ser Thr Ala 805 810 815		
	Pro Arg Leu Gly Arg Tyr Cys Gly Ser Gly Pro Pro Glu Glu Val Tyr 820 825 830		
	Ser Ala Gly Asp Ser Val Leu Val Lys Phe His Ser Asp Asp Thr Ile 835 840 845		

EP 3 312 282 B1

Thr Lys Lys Gly Phe His Leu Arg Tyr Thr Ser Thr Lys Phe Gln Asp
850 855 860

5

Thr Leu His Ser Arg Lys
865 870

10

<210> 20

<211> 2912

<212> DNA

<213> Artificial sequence

15

<220>

<223> Synthetic sequence containing the coding regions of the human Procollagen I N-proteinase and flanking regions

<400> 20

20

25

30

35

40

45

50

55

EP 3 312 282 B1

	gcgccatggc tcaattgagg agaagggcta ggagacacgc agctgatgat gattacaaca	60
	ttgaagtttt gcttggtggt gatgatagtg tgggtgcaatt ccacggaaaa gagcatgttc	120
5	agaaatatct tttgacactt atgaatattg tgaacgaaat ctaccatgat gagtctttgg	180
	gagcacacat taacgtggtt cttgtgagga ttattcttct ttcatacggg aaatctatgt	240
10	cacttattga gattggaaac ccttctcagt ctcttgagaa tgtgtgcaga tgggcatacc	300
	ttcaacagaa gcctgatact ggacacgatg agtatcacga tcacgctatt ttccttacia	360
	ggcaggatth cggtccaagt ggaatgcaag gatatgctcc tgttactggg atgtgccacc	420
15	ctgttaggtc ttgtacactt aaccacgagg atgggtttttc atctgctttc gtgggtggctc	480
	atgagacagg tcatgttttg ggaatggaac atgatggaca gggtaataga tgtggagatg	540
	aagtgagact tgggttcaatt atggctcctc ttgttcaagc tgcttttcat aggttccact	600
20	ggagtaggtg ttcacagcaa gaggttgagta gataccttca ttcttacgat tgcttgcttg	660
	atgatccatt tgctcatgat tggccagctt tgcctcaact tcctggattg cactactcta	720
25	tgaacgagca gtgcagatth gatttcgggtc ttggttacat gatgtgcaca gctttcagga	780
	ctttcgatcc atgcaaacag ttgtggtggt cacacccaga taaccatata ttctgtaaaa	840
	caaaaaaagg tccaccactt gatggtacta tgtgcgcacc tggaagcac tgcttcaagg	900
30	gacactgcat ttggcttact cctgatattc ttaaaaggga tggatcatgg ggagcttggg	960
	ctccattcgg aagttgctca agaacttgcg gaacaggtgt taagtttaga actaggcagt	1020
	gcgataatcc acaccctgct aatggtggtg gaacttgctc tggacttgct tacgattttc	1080
35	agtttgtgtc taggcaagat tggcctgata gtcttgctga ttttagagaa gagcaatgta	1140
	gacagtggga tctttacttt gagcacggcg acgctcagca ccactggctt ccacacgagc	1200
40	atagagatgc aaaagaaagg tgtcaccttt attgcgagag tagagagact ggagaggtgg	1260
	tgtcaatgaa gagaatggtg cacgatggta caagggtgtc ttataaggat gcattctctt	1320
	tgtgtgtgag gggagattgc aggaaagtgg gttgtgatgg agtgattgga tctagtaagc	1380

45

50

55

EP 3 312 282 B1

	aagaagataa gtgcggagtg tgcggaggag ataactctca ttgcaagggt gtgaaaggaa	1440
	cttttacaag atcaccaaaa aaacacgggt acattaagat gttcgaaatt cctgctggag	1500
5	caaggcattt gcttattcag gaagtggatg caacatctca ccacttggca gtgaaaaacc	1560
	ttgagactgg aaaattcatt ttgaacgagg agaacgatgt tgatgcatct agtaagactt	1620
	tcattgcaat ggggtgttgaa tgggagtata gggatgagga tgggaaggga acacttcaaa	1680
10	caatgggtcc tcttcatgga acaattactg tgttgggtgat tccagtggga gatacaaggg	1740
	tgtcattgac atacaagtat atgattcacg aggatagtct taacgttgat gataacaacg	1800
	ttttggaaga agattctgtg gtttacgagt gggctcttaa gaaatggtca ccttgctcta	1860
15	agccatgtgg tggaggaagt cagttcacta agtatggttg taggaggagg cttgatcata	1920
	agatggttca taggggattt tgcgcagcac ttagtaagcc aaaggcaatt aggagggctt	1980
20	gtaaccctca agaatgctca caaccagttt ggggtgacagg agagtgggag ccatgttcac	2040
	aaacatgcgg aagaactgga atgcaagtta gatcagttag atgcattcaa cctcttcatg	2100
	ataacactac aagaagtgtg cacgcaaaac actgtaacga tgctaggcca gagagtagaa	2160
25	gagcttgctc tagggaactt tgccctggta gatggagggc aggaccttg agtcagtgct	2220
	ctgtgacatg tggaaacggt actcaggaaa gacctgttcc atgtagaact gctgatgata	2280
	gtttcggaat ttgtcaggag gaaaggccag aaacagctag gacttgtaga cttggacctt	2340
30	gtcctaggaa tatttctgat cctagtaaaa aatcatacgt ggtgcaatgg ttgagtaggc	2400
	cagatccaga ttcaccaatt aggaagattt cttcaaaagg aactgccag ggtgataaga	2460
35	gtattttctg cagaatggaa gttcttagta ggtactgttc tattccaggt tataacaaac	2520
	tttcttgtaa gagttgcaac ttgtataaca atcttactaa cgtggaggggt agaattgaac	2580
	ctccaccagg aaagcacaac gatattgatg tgtttatgcc tactcttcct gtgccaacag	2640
40	ttgcaatgga agttagacct tctccatcta ctccacttga ggtgccactt aatgcatcaa	2700
	gtactaacgc tactgaggat caccagaga ctaacgcagt tgatgagcct tataagattc	2760
	acggacttga ggatgaggtt cagccaccaa accttattcc taggaggcca agtccttacg	2820
45	aaaaaactag aaatcagagg attcaggagc ttattgatga gatgaggaaa aaggagatgc	2880
	ttggaaagtt ctaatgagct cgcggccgca tc	2912
50	<210> 21 <211> 962 <212> PRT <213> Artificial sequence	
55	<220> <223> Synthetic sequence containing the human Procollagen I N-proteinase and flanking regions <400> 21	

EP 3 312 282 B1

	Met	Ala	Gln	Leu	Arg	Arg	Arg	Ala	Arg	Arg	His	Ala	Ala	Asp	Asp	Asp	
	1				5					10					15		
5	Tyr	Asn	Ile	Glu	Val	Leu	Leu	Gly	Val	Asp	Asp	Ser	Val	Val	Gln	Phe	
				20					25					30			
	His	Gly	Lys	Glu	His	Val	Gln	Lys	Tyr	Leu	Leu	Thr	Leu	Met	Asn	Ile	
10			35					40					45				
	Val	Asn	Glu	Ile	Tyr	His	Asp	Glu	Ser	Leu	Gly	Ala	His	Ile	Asn	Val	
		50					55					60					
15	Val	Leu	Val	Arg	Ile	Ile	Leu	Leu	Ser	Tyr	Gly	Lys	Ser	Met	Ser	Leu	
	65					70					75					80	
	Ile	Glu	Ile	Gly	Asn	Pro	Ser	Gln	Ser	Leu	Glu	Asn	Val	Cys	Arg	Trp	
20					85					90					95		
	Ala	Tyr	Leu	Gln	Gln	Lys	Pro	Asp	Thr	Gly	His	Asp	Glu	Tyr	His	Asp	
				100					105					110			
25	His	Ala	Ile	Phe	Leu	Thr	Arg	Gln	Asp	Phe	Gly	Pro	Ser	Gly	Met	Gln	
			115					120					125				
30	Gly	Tyr	Ala	Pro	Val	Thr	Gly	Met	Cys	His	Pro	Val	Arg	Ser	Cys	Thr	
		130					135					140					
	Leu	Asn	His	Glu	Asp	Gly	Phe	Ser	Ser	Ala	Phe	Val	Val	Ala	His	Glu	
35	145					150					155					160	
	Thr	Gly	His	Val	Leu	Gly	Met	Glu	His	Asp	Gly	Gln	Gly	Asn	Arg	Cys	
					165					170					175		
40	Gly	Asp	Glu	Val	Arg	Leu	Gly	Ser	Ile	Met	Ala	Pro	Leu	Val	Gln	Ala	
					180				185					190			
45	Ala	Phe	His	Arg	Phe	His	Trp	Ser	Arg	Cys	Ser	Gln	Gln	Glu	Leu	Ser	
			195					200					205				
	Arg	Tyr	Leu	His	Ser	Tyr	Asp	Cys	Leu	Leu	Asp	Asp	Pro	Phe	Ala	His	
50		210					215					220					
	Asp	Trp	Pro	Ala	Leu	Pro	Gln	Leu	Pro	Gly	Leu	His	Tyr	Ser	Met	Asn	
	225					230					235					240	
55	Glu	Gln	Cys	Arg	Phe	Asp	Phe	Gly	Leu	Gly	Tyr	Met	Met	Cys	Thr	Ala	

EP 3 312 282 B1

	245	250	255
5	Phe Arg Thr Phe Asp Pro Cys Lys Gln Leu Trp Cys Ser His Pro Asp 260 265 270		
10	Asn Pro Tyr Phe Cys Lys Thr Lys Lys Gly Pro Pro Leu Asp Gly Thr 275 280 285		
15	Met Cys Ala Pro Gly Lys His Cys Phe Lys Gly His Cys Ile Trp Leu 290 295 300		
20	Thr Pro Asp Ile Leu Lys Arg Asp Gly Ser Trp Gly Ala Trp Ser Pro 305 310 315 320		
25	Phe Gly Ser Cys Ser Arg Thr Cys Gly Thr Gly Val Lys Phe Arg Thr 325 330 335		
30	Arg Gln Cys Asp Asn Pro His Pro Ala Asn Gly Gly Arg Thr Cys Ser 340 345 350		
35	Gly Leu Ala Tyr Asp Phe Gln Leu Cys Ser Arg Gln Asp Cys Pro Asp 355 360 365		
40	Ser Leu Ala Asp Phe Arg Glu Glu Gln Cys Arg Gln Trp Asp Leu Tyr 370 375 380		
45	Phe Glu His Gly Asp Ala Gln His His Trp Leu Pro His Glu His Arg 385 390 395 400		
50	Asp Ala Lys Glu Arg Cys His Leu Tyr Cys Glu Ser Arg Glu Thr Gly 405 410 415		
55	Glu Val Val Ser Met Lys Arg Met Val His Asp Gly Thr Arg Cys Ser 420 425 430		
	Tyr Lys Asp Ala Phe Ser Leu Cys Val Arg Gly Asp Cys Arg Lys Val 435 440 445		
	Gly Cys Asp Gly Val Ile Gly Ser Ser Lys Gln Glu Asp Lys Cys Gly 450 455 460		
	Val Cys Gly Gly Asp Asn Ser His Cys Lys Val Val Lys Gly Thr Phe 465 470 475 480		
	Thr Arg Ser Pro Lys Lys His Gly Tyr Ile Lys Met Phe Glu Ile Pro 485 490 495		

EP 3 312 282 B1

	Ala	Gly	Ala	Arg	His	Leu	Leu	Ile	Gln	Glu	Val	Asp	Ala	Thr	Ser	His	
				500					505					510			
5	His	Leu	Ala	Val	Lys	Asn	Leu	Glu	Thr	Gly	Lys	Phe	Ile	Leu	Asn	Glu	
			515					520					525				
	Glu	Asn	Asp	Val	Asp	Ala	Ser	Ser	Lys	Thr	Phe	Ile	Ala	Met	Gly	Val	
10		530					535					540					
	Glu	Trp	Glu	Tyr	Arg	Asp	Glu	Asp	Gly	Arg	Glu	Thr	Leu	Gln	Thr	Met	
	545					550					555					560	
15	Gly	Pro	Leu	His	Gly	Thr	Ile	Thr	Val	Leu	Val	Ile	Pro	Val	Gly	Asp	
					565					570					575		
	Thr	Arg	Val	Ser	Leu	Thr	Tyr	Lys	Tyr	Met	Ile	His	Glu	Asp	Ser	Leu	
20				580					585					590			
	Asn	Val	Asp	Asp	Asn	Asn	Val	Leu	Glu	Glu	Asp	Ser	Val	Val	Tyr	Glu	
25			595					600					605				
	Trp	Ala	Leu	Lys	Lys	Trp	Ser	Pro	Cys	Ser	Lys	Pro	Cys	Gly	Gly	Gly	
	610						615					620					
30	Ser	Gln	Phe	Thr	Lys	Tyr	Gly	Cys	Arg	Arg	Arg	Leu	Asp	His	Lys	Met	
	625					630					635					640	
	Val	His	Arg	Gly	Phe	Cys	Ala	Ala	Leu	Ser	Lys	Pro	Lys	Ala	Ile	Arg	
35					645					650					655		
	Arg	Ala	Cys	Asn	Pro	Gln	Glu	Cys	Ser	Gln	Pro	Val	Trp	Val	Thr	Gly	
				660					665					670			
40	Glu	Trp	Glu	Pro	Cys	Ser	Gln	Thr	Cys	Gly	Arg	Thr	Gly	Met	Gln	Val	
			675					680					685				
	Arg	Ser	Val	Arg	Cys	Ile	Gln	Pro	Leu	His	Asp	Asn	Thr	Thr	Arg	Ser	
45			690				695					700					
	Val	His	Ala	Lys	His	Cys	Asn	Asp	Ala	Arg	Pro	Glu	Ser	Arg	Arg	Ala	
50	705					710					715					720	
	Cys	Ser	Arg	Glu	Leu	Cys	Pro	Gly	Arg	Trp	Arg	Ala	Gly	Pro	Trp	Ser	
					725					730					735		
55	Gln	Cys	Ser	Val	Thr	Cys	Gly	Asn	Gly	Thr	Gln	Glu	Arg	Pro	Val	Pro	
				740					745					750			

EP 3 312 282 B1

	Cys	Arg	Thr	Ala	Asp	Asp	Ser	Phe	Gly	Ile	Cys	Gln	Glu	Glu	Arg	Pro
			755					760					765			
5	Glu	Thr	Ala	Arg	Thr	Cys	Arg	Leu	Gly	Pro	Cys	Pro	Arg	Asn	Ile	Ser
		770					775					780				
10	Asp	Pro	Ser	Lys	Lys	Ser	Tyr	Val	Val	Gln	Trp	Leu	Ser	Arg	Pro	Asp
	785					790					795					800
15	Pro	Asp	Ser	Pro	Ile	Arg	Lys	Ile	Ser	Ser	Lys	Gly	His	Cys	Gln	Gly
					805					810					815	
20	Asp	Lys	Ser	Ile	Phe	Cys	Arg	Met	Glu	Val	Leu	Ser	Arg	Tyr	Cys	Ser
				820					825					830		
25	Ile	Pro	Gly	Tyr	Asn	Lys	Leu	Ser	Cys	Lys	Ser	Cys	Asn	Leu	Tyr	Asn
			835					840					845			
30	Asn	Leu	Thr	Asn	Val	Glu	Gly	Arg	Ile	Glu	Pro	Pro	Pro	Gly	Lys	His
	850						855					860				
35	Asn	Asp	Ile	Asp	Val	Phe	Met	Pro	Thr	Leu	Pro	Val	Pro	Thr	Val	Ala
	865					870					875					880
40	Met	Glu	Val	Arg	Pro	Ser	Pro	Ser	Thr	Pro	Leu	Glu	Val	Pro	Leu	Asn
					885					890					895	
45	Ala	Ser	Ser	Thr	Asn	Ala	Thr	Glu	Asp	His	Pro	Glu	Thr	Asn	Ala	Val
				900					905					910		
50	Asp	Glu	Pro	Tyr	Lys	Ile	His	Gly	Leu	Glu	Asp	Glu	Val	Gln	Pro	Pro
			915					920					925			
55	Asn	Leu	Ile	Pro	Arg	Arg	Pro	Ser	Pro	Tyr	Glu	Lys	Thr	Arg	Asn	Gln
	930						935					940				
60	Arg	Ile	Gln	Glu	Leu	Ile	Asp	Glu	Met	Arg	Lys	Lys	Glu	Met	Leu	Gly
	945					950					955					960
65	Lys	Phe														

<210> 22

<211> 2888

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic sequence containing the coding regions of the vascular signal sequence of barley gene for Thiol

EP 3 312 282 B1

protease aleurain precursor fused to the human Lysyl hydroxylase 3 and flanking regions

<400> 22

5	gcgaattcgc tagctatcac tgaaaagaca gcaagacaat ggtgtctcga tgcaccagaa	60
	ccacatcttt gcagcagatg tgaagcagcc agagtgggcc acaagacgca ctgagaaaag	120
10	gcatcttcta ccgacacaga aaaagacaac cacagctcat catccaacat gtagactgtc	180
	gttatgcgtc ggctgaagat aagactgacc ccaggccagc actaaagaag aaataatgca	240
	agtggctcta gctccacttt agctttaata attatgtttc attattattc tctgcttttg	300
15	ctctctatat aaagagcttg tatttttcatt tgaaggcaga ggcgaacaca cacacagaac	360
	ctccctgctt acaaaccaga tcttaaacca tggctcacgc taggggttttg cttcttgctc	420
	ttgctgttct tgctactgct gctgttgctg tggcttcttc aagttctttc gctgattcta	480
20	acccaattag gccagtgact gatagagctg cttctactct tgctcaattg agatctatgt	540
	ctgatagacc aaggggaagg gatccagtta atccagagaa gttgcttggtg attactgtgg	600
25	ctactgctga gactgaagga taccttagat tccttaggag tgctgagttc ttcaactaca	660
	ctgtgaggac tcttggactt ggagaagaat ggaggggagg agatgttgct agaactgttg	720
	gaggaggaca gaaagtgaga tggcttaaga aagagatgga gaagtacgct gatagggagg	780
30	atatgattat tatgttcgtg gattcttacg atgtgattct tgctggatct ccaactgagc	840
	ttttgaagaa attcgttcag tctggatcta ggcttctttt ctctgctgag tctttttgtt	900
	ggccagaatg gggacttgct gagcaatatc cagaagtggg aactggaaag agattcctta	960
35	actctggagg attcattgga ttcgctacta ctattcacca gattgtgagg cagtggaaagt	1020
	acaaggatga cgatgatgat cagcttttct acactaggct ttaccttgat ccaggactta	1080
40	gggagaagtt gtctcttaac cttgatcaca agtctaggat tttccagaac cttaacggtg	1140
	ctcttgatga ggttggtgctt aagttcgata ggaacagagt gaggattagg aacgtggctt	1200
	acgatactct tcctattgtg gtgcatggaa acggaccaac aaaactccag ctttaactacc	1260
45	ttggaaacta cgttccaaac ggatggactc cagaaggagg atgtggattc tgcaatcagg	1320
	ataggagaac tcttccagga ggacaaccac caccaagagt tttccttgct gtgttcggtg	1380
	aacagccaac tccattcctt ccaagattcc ttcagaggct tcttcttttg gattaccac	1440
50	cagatagggt gacacttttc cttcacaaca acgagggttt ccacgagcca cacattgctg	1500
	attcttggcc acagcttcag gatcatttct ctgctgtgaa gttgggtggg ccagaagaag	1560
	ctctttctcc aggagaagct agggatatgg ctatggattt gtgcaggcag gatccagagt	1620
55	gcgagttcta cttctctctt gatgctgatg ctgtgcttac taaccttcag actcttagga	1680
	ttcttattga ggagaacagg aaagtgattg ctccaatgct ttctaggcac ggaaagtgtg	1740

EP 3 312 282 B1

ggtctaattt ctggggtgct ctttctcctg atgagtacta cgctagatca gaggactacg 1800
 tggagcttgt tcagagaaag agagtgggag tttggaacgt tccttatatt tctcaggctt 1860
 5 acgtgattag gggagatact cttaggatgg agcttccaca gagggatggt ttctctggat 1920
 ctgatactga tccagatatg gctttctgca agtctttcag ggataaggga attttccttc 1980
 acctttctaa ccagcatgag ttcggaagat tgcttgctac ttcaagatac gatactgagc 2040
 10 accttcatcc tgatctttgg cagattttcg ataaccaggt ggattggaag gagcagtaca 2100
 ttcacgagaa ctactctagg gctcttgaag gagaaggaaat tgtggagcaa ccatgccag 2160
 atgtttactg gttcccactt ctttctgagc aaatgtgcga tgagcttggt gctgagatgg 2220
 15 agcattacgg acaatggagt ggaggtagac atgaggattc taggcttgct ggaggatacg 2280
 agaacgttcc aactgtggat attcacatga agcaagtggg atacgaggat caatggcttc 2340
 20 agcttcttag gacttatgtg ggaccaatga ctgagtctct tttcccagga taccacacta 2400
 aggctagggc tgttatgaac ttcgttgtga ggtatcgtcc agatgagcaa ccatctctta 2460
 ggccacacca cgattcttct actttcactc ttaacgtggc tcttaaccac aagggaacttg 2520
 25 attatgaggg aggaggatgc cgtttcctta gatacgattg cgtgatttct tcaccaagaa 2580
 agggatgggc tcttcttcat ccaggaaggc ttactcatta ccacgaggga cttccaacta 2640
 cttggggaac tagatatatt atggtgtctt tcgtggatcc atgactgctt taatgagata 2700
 30 tgcgagacgc ctatgatcgc atgatatttg ctttcaattc tgttgtgcac gttgtaaaaa 2760
 acctgagcat gtgtagctca gatccttacc gccggtttcg gttcattcta atgaatatat 2820
 35 caccogttac tatcgtattt ttatgaataa tattctccgt tcaatttact gattgtccag 2880
 aattcgcg 2888

40 <210> 23
 <211> 764
 <212> PRT
 <213> Artificial sequence

45 <220>
 <223> Synthetic sequence containing the vascular signal sequence of barley gene for Thiol protease aleurain precursor fused to the human Lysyl hydroxylase 3 and flanking regions

<400> 23

50 Met Ala His Ala Arg Val Leu Leu Leu Ala Leu Ala Val Leu Ala Thr
 1 5 10 15

55 Ala Ala Val Ala Val Ala Ser Ser Ser Ser Phe Ala Asp Ser Asn Pro
 20 25 30

Ile Arg Pro Val Thr Asp Arg Ala Ala Ser Thr Leu Ala Gln Leu Arg

EP 3 312 282 B1

	35					40					45					
5	Ser	Met	Ser	Asp	Arg	Pro	Arg	Gly	Arg	Asp	Pro	Val	Asn	Pro	Glu	Lys
	50						55					60				
10	Leu	Leu	Val	Ile	Thr	Val	Ala	Thr	Ala	Glu	Thr	Glu	Gly	Tyr	Leu	Arg
	65					70					75					80
15	Phe	Leu	Arg	Ser	Ala	Glu	Phe	Phe	Asn	Tyr	Thr	Val	Arg	Thr	Leu	Gly
					85					90					95	
20	Leu	Gly	Glu	Glu	Trp	Arg	Gly	Gly	Asp	Val	Ala	Arg	Thr	Val	Gly	Gly
				100					105					110		
25	Gly	Gln	Lys	Val	Arg	Trp	Leu	Lys	Lys	Glu	Met	Glu	Lys	Tyr	Ala	Asp
			115					120					125			
30	Arg	Glu	Asp	Met	Ile	Ile	Met	Phe	Val	Asp	Ser	Tyr	Asp	Val	Ile	Leu
	130						135					140				
35	Ala	Gly	Ser	Pro	Thr	Glu	Leu	Leu	Lys	Lys	Phe	Val	Gln	Ser	Gly	Ser
	145					150					155					160
40	Arg	Leu	Leu	Phe	Ser	Ala	Glu	Ser	Phe	Cys	Trp	Pro	Glu	Trp	Gly	Leu
					165					170					175	
45	Ala	Glu	Gln	Tyr	Pro	Glu	Val	Gly	Thr	Gly	Lys	Arg	Phe	Leu	Asn	Ser
				180					185					190		
50	Gly	Gly	Phe	Ile	Gly	Phe	Ala	Thr	Thr	Ile	His	Gln	Ile	Val	Arg	Gln
			195					200					205			
55	Trp	Lys	Tyr	Lys	Asp	Asp	Asp	Asp	Asp	Gln	Leu	Phe	Tyr	Thr	Arg	Leu
	210						215					220				
60	Tyr	Leu	Asp	Pro	Gly	Leu	Arg	Glu	Lys	Leu	Ser	Leu	Asn	Leu	Asp	His
	225					230					235					240
65	Lys	Ser	Arg	Ile	Phe	Gln	Asn	Leu	Asn	Gly	Ala	Leu	Asp	Glu	Val	Val
					245					250					255	
70	Leu	Lys	Phe	Asp	Arg	Asn	Arg	Val	Arg	Ile	Arg	Asn	Val	Ala	Tyr	Asp
				260					265					270		
75	Thr	Leu	Pro	Ile	Val	Val	His	Gly	Asn	Gly	Pro	Thr	Lys	Leu	Gln	Leu
			275					280					285			

EP 3 312 282 B1

	Asn	Tyr	Leu	Gly	Asn	Tyr	Val	Pro	Asn	Gly	Trp	Thr	Pro	Glu	Gly	Gly	
	290						295					300					
5	Cys	Gly	Phe	Cys	Asn	Gln	Asp	Arg	Arg	Thr	Leu	Pro	Gly	Gly	Gln	Pro	
	305					310					315					320	
	Pro	Pro	Arg	Val	Phe	Leu	Ala	Val	Phe	Val	Glu	Gln	Pro	Thr	Pro	Phe	
10					325					330					335		
	Leu	Pro	Arg	Phe	Leu	Gln	Arg	Leu	Leu	Leu	Leu	Asp	Tyr	Pro	Pro	Asp	
				340					345					350			
15	Arg	Val	Thr	Leu	Phe	Leu	His	Asn	Asn	Glu	Val	Phe	His	Glu	Pro	His	
			355					360					365				
	Ile	Ala	Asp	Ser	Trp	Pro	Gln	Leu	Gln	Asp	His	Phe	Ser	Ala	Val	Lys	
20		370					375					380					
	Leu	Val	Gly	Pro	Glu	Glu	Ala	Leu	Ser	Pro	Gly	Glu	Ala	Arg	Asp	Met	
25	385					390					395					400	
	Ala	Met	Asp	Leu	Cys	Arg	Gln	Asp	Pro	Glu	Cys	Glu	Phe	Tyr	Phe	Ser	
					405					410					415		
30	Leu	Asp	Ala	Asp	Ala	Val	Leu	Thr	Asn	Leu	Gln	Thr	Leu	Arg	Ile	Leu	
				420					425					430			
	Ile	Glu	Glu	Asn	Arg	Lys	Val	Ile	Ala	Pro	Met	Leu	Ser	Arg	His	Gly	
35			435					440					445				
	Lys	Leu	Trp	Ser	Asn	Phe	Trp	Gly	Ala	Leu	Ser	Pro	Asp	Glu	Tyr	Tyr	
	450						455					460					
40	Ala	Arg	Ser	Glu	Asp	Tyr	Val	Glu	Leu	Val	Gln	Arg	Lys	Arg	Val	Gly	
	465					470					475					480	
	Val	Trp	Asn	Val	Pro	Tyr	Ile	Ser	Gln	Ala	Tyr	Val	Ile	Arg	Gly	Asp	
45					485					490					495		
	Thr	Leu	Arg	Met	Glu	Leu	Pro	Gln	Arg	Asp	Val	Phe	Ser	Gly	Ser	Asp	
50				500					505					510			
	Thr	Asp	Pro	Asp	Met	Ala	Phe	Cys	Lys	Ser	Phe	Arg	Asp	Lys	Gly	Ile	
			515					520					525				
55	Phe	Leu	His	Leu	Ser	Asn	Gln	His	Glu	Phe	Gly	Arg	Leu	Leu	Ala	Thr	
	530						535					540					

EP 3 312 282 B1

	Ser	Arg	Tyr	Asp	Thr	Glu	His	Leu	His	Pro	Asp	Leu	Trp	Gln	Ile	Phe
	545					550					555					560
5	Asp	Asn	Pro	Val	Asp	Trp	Lys	Glu	Gln	Tyr	Ile	His	Glu	Asn	Tyr	Ser
					565					570					575	
10	Arg	Ala	Leu	Glu	Gly	Glu	Gly	Ile	Val	Glu	Gln	Pro	Cys	Pro	Asp	Val
				580					585					590		
15	Tyr	Trp	Phe	Pro	Leu	Leu	Ser	Glu	Gln	Met	Cys	Asp	Glu	Leu	Val	Ala
			595					600					605			
20	Glu	Met	Glu	His	Tyr	Gly	Gln	Trp	Ser	Gly	Gly	Arg	His	Glu	Asp	Ser
	610						615					620				
25	Arg	Leu	Ala	Gly	Gly	Tyr	Glu	Asn	Val	Pro	Thr	Val	Asp	Ile	His	Met
	625					630					635					640
30	Lys	Gln	Val	Gly	Tyr	Glu	Asp	Gln	Trp	Leu	Gln	Leu	Leu	Arg	Thr	Tyr
				645						650					655	
35	Val	Gly	Pro	Met	Thr	Glu	Ser	Leu	Phe	Pro	Gly	Tyr	His	Thr	Lys	Ala
				660					665					670		
40	Arg	Ala	Val	Met	Asn	Phe	Val	Val	Arg	Tyr	Arg	Pro	Asp	Glu	Gln	Pro
			675					680					685			
45	Ser	Leu	Arg	Pro	His	His	Asp	Ser	Ser	Thr	Phe	Thr	Leu	Asn	Val	Ala
	690						695					700				
50	Leu	Asn	His	Lys	Gly	Leu	Asp	Tyr	Glu	Gly	Gly	Gly	Cys	Arg	Phe	Leu
	705					710					715					720
55	Arg	Tyr	Asp	Cys	Val	Ile	Ser	Ser	Pro	Arg	Lys	Gly	Trp	Ala	Leu	Leu
				725						730					735	
60	His	Pro	Gly	Arg	Leu	Thr	His	Tyr	His	Glu	Gly	Leu	Pro	Thr	Thr	Trp
				740					745					750		
65	Gly	Thr	Arg	Tyr	Ile	Met	Val	Ser	Phe	Val	Asp	Pro				
			755					760								

<210> 24

<211> 45

<212> PRT

<213> Artificial sequence

<220>

EP 3 312 282 B1

<223> Vacuole signal sequence of barley gene for Thiol protease aleurain precursor

<400> 24

5 Met Ala His Ala Arg Val Leu Leu Leu Ala Leu Ala Val Leu Ala Thr
1 5 10 15

10 Ala Ala Val Ala Val Ala Ser Ser Ser Ser Phe Ala Asp Ser Asn Pro
20 25 30

15 Ile Arg Pro Val Thr Asp Arg Ala Ala Ser Thr Leu Ala
35 40 45

<210> 25

<211> 24

<212> DNA

<213> Artificial sequence

20

<220>

<223> Single strand DNA oligonucleotide

<400> 25

25 atcaccagga gaacagggac catc 24

<210> 26

<211> 29

<212> DNA

<213> Artificial sequence

30

<220>

<223> Single strand DNA oligonucleotide

<400> 26

35 tccactcca aatctctatc cctaacaac 29

<210> 27

<211> 23

<212> DNA

<213> Artificial sequence

40

<220>

<223> Single strand DNA oligonucleotide

<400> 27

45 aggcattaga ggcgataagg gag 23

<210> 28

<211> 27

<212> DNA

<213> Artificial sequence

50

<220>

<223> Single strand DNA oligonucleotide

<400> 28

55 tcaatccaat aatagccact tgaccac 27

Claims

1. A method of producing collagen in a plant or an isolated plant cell comprising expressing in the plant or the isolated plant cell at least one type of a collagen alpha chain which comprises a signal peptide for targeting to a vacuole and exogenous P4H which comprises a signal peptide for targeting to a vacuole in a manner enabling accumulation of said at least one type of said collagen alpha chain and said exogenous P4H in a subcellular compartment devoid of endogenous P4H activity, thereby producing the collagen in the plant.
2. The method of claim 1, further comprising expressing exogenous LH3 in said subcellular compartment devoid of endogenous P4H activity.
3. The method of claim 1, wherein said exogenous P4H is devoid of an ER retention sequence.
4. The method of claim 1, wherein said at least one type of said collagen alpha chain includes a C-terminus and/or an N-terminus propeptide.
5. The method of claim 1, wherein the plant is selected from the group consisting of tobacco, maize, alfalfa, rice, potato, soybean, tomato, wheat, barley, canola, carrot and cotton.
6. The method of claim 1, wherein said exogenous P4H is human P4H.
7. The method of claim 1, wherein the plant is subjected to a stress condition.

Patentansprüche

1. Verfahren zum Erzeugen von Kollagen in einer Pflanze oder einer isolierten Pflanzenzelle, umfassend das Expressieren mindestens eines Typs einer Kollagen-Alpha-Kette, die ein Signalpeptid zum Richten auf eine Vakuole umfasst, und von exogenem P4H, das ein Signalpeptid zum Richten auf eine Vakuole umfasst, in der Pflanze oder der isolierten Pflanzenzelle auf eine Weise, die eine Akkumulation des mindestens einen Typs der Kollagen-Alpha-Kette und des exogenen P4H in einem subzellulären Kompartiment ohne endogene P4H-Aktivität ermöglicht, wodurch das Kollagen in der Pflanze erzeugt wird.
2. Verfahren nach Anspruch 1, ferner umfassend das Expressieren von exogenem LH3 in dem subzellulären Kompartiment ohne endogene P4H-Aktivität.
3. Verfahren nach Anspruch 1, wobei das exogene P4H ohne ER-Retentionssequenz ist.
4. Verfahren nach Anspruch 1, wobei der mindestens eine Typ der Kollagen-Alpha-Kette am C-Terminus und/oder am N-Terminus ein Propeptid aufweist.
5. Verfahren nach Anspruch 1, wobei die Pflanze ausgewählt ist aus der Gruppe bestehend aus Tabak, Mais, Alfalfa, Reis, Kartoffeln, Sojabohnen, Tomaten, Weizen, Gerste, Raps, Karotten und Baumwolle.
6. Verfahren nach Anspruch 1, wobei das exogene P4H humanes P4H ist.
7. Verfahren nach Anspruch 1, wobei die Pflanze einem Belastungszustand unterworfen ist.

Revendications

1. Procédé de production de collagène dans une plante ou une cellule végétale isolée comprenant l'expression dans la plante ou la cellule végétale isolée d'au moins un type d'une chaîne alpha de collagène comprenant un peptide signal pour cibler une vacuole et de P4H exogène comprenant un peptide signal pour cibler une vacuole d'une manière permettant d'accumuler ledit au moins un type de ladite chaîne alpha de collagène et ladite P4H exogène dans un compartiment subcellulaire dépourvu d'activité P4H endogène, produisant ainsi le collagène dans la plante.
2. Procédé selon la revendication 1, comprenant en outre l'expression de LH3 exogène dans ledit compartiment

subcellulaire dépourvu d'activité P4H endogène.

3. Procédé selon la revendication 1, dans lequel ladite P4H exogène est dépourvue de séquence de rétention dans le RE.

5

4. Procédé selon la revendication 1, dans lequel ledit au moins un type de ladite chaîne alpha de collagène comprend un propeptide C-terminal et/ou N-terminal.

10

5. Procédé selon la revendication 1, dans lequel la plante est choisie dans le groupe constitué par le tabac, le maïs, la luzerne, le riz, la pomme de terre, le soja, la tomate, le blé, l'orge, le canola, la carotte et le coton.

6. Procédé selon la revendication 1, dans lequel ladite P4H exogène est une P4H humaine.

15

7. Procédé selon la revendication 1, dans lequel la plante est soumise à une condition de stress.

20

25

30

35

40

45

50

55






Fig. 1a



Cloning scheme, Level 3



Vacuole	Cytoplasm	Appoplasm
2 Cole a1 (I) Cole a2 (I)	1 Cole a1 (I) Cole a2 (I)	7 Cole a1 (I) Cole a2 (I)
3 Cole a1 (I) P4Hb Cole a2 (I) P4Ha	5 Cole a1 (I) P4Hb Cole a2 (I) P4Ha	8 Cole a1 (I) P4Hb Cole a2 (I) P4Ha
4 Cole a1 (I) P4Hb Cole a2 (I) P4Hplant	6 Cole a1 (I) P4Hb Cole a2 (I) P4Hplant	9 Cole a1 (I) P4Hb Cole a2 (I) P4Hplant
10 Protease C Protease N	11 Protease C Protease N	12 Protease C Protease N
13 Cole a1 (I) P4Hb LH3 Cole a2 (I) P4Ha	14 Cole a1 (I) P4Hb LH3 Cole a2 (I) P4Ha	15 Cole a1 (I) P4Hb LH3 Cole a2 (I) P4Ha
20 P4Hb LH3 P4Ha		21 P4Hb LH3 P4Ha

Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6a




Fig. 6b




Fig. 7




Fig. 8

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6617431 B [0007]
- WO 0134647 A [0011]
- US 2004018592 A [0011]
- US 4855237 A [0067]
- EP 67553 A [0067]
- JP 63014693 A [0067]
- EP 194809 A [0067]
- EP 278667 A [0067]
- WO 8706261 A [0067]
- US 5316931 A [0070]
- US 4945050 A [0076]
- US 5693507 A [0076]
- US 4666828 A [0096]
- US 4683202 A [0096]
- US 4801531 A [0096]
- US 5192659 A [0096]
- US 5272057 A [0096]
- US 3791932 A [0096]
- US 3839153 A [0096]
- US 3850752 A [0096]
- US 3850578 A [0096]
- US 3853987 A [0096]
- US 3867517 A [0096]
- US 3879262 A [0096]
- US 3901654 A [0096]
- US 3935074 A [0096]
- US 3984533 A [0096]
- US 3996345 A [0096]
- US 4034074 A [0096]
- US 4098876 A [0096]
- US 4879219 A [0096]
- US 5011771 A [0096]
- US 5281521 A [0096]
- US 05789469 A [0120]
- US 60613719 B [0120]

Non-patent literature cited in the description

- **OLSEN DAVID et al.** Recombinant collagen and gelatin for drug delivery. *ADVANCED DRUG DELIVERY REVIEWS*, 28 November 2003, vol. 55 (12), ISSN 0169-409X, 1547-1567 [0012]
- Hydroxylated human homotrimeric collagen I in *Agrobacterium tumefaciens*-mediated transient expression and in transgenic tobacco plant. **MERLE C et al.** *FEBS LETTERS*. ELSEVIER, 27 March 2002, vol. 515, 114-118 [0013]
- *Biochim Biophys Acta.*, 16 July 1984, vol. 800 (1), 59-65 [0042]
- **POTRYKUS, I.** *Annu. Rev. Plant. Physiol., Plant. Mol. Biol.*, 1991, vol. 42, 205-225 [0060]
- **SHIMAMOTO et al.** *Nature*, 1989, vol. 338, 274-276 [0060]
- **KLEE et al.** *Annu. Rev. Plant Physiol.*, 1987, vol. 38, 467-486 [0062]
- Cell Culture and Somatic Cell Genetics of Plants. **KLEE ; ROGERS.** *Molecular Biology of Plant Nuclear Genes*. Academic Publishers, 1989, vol. 6, 2-25 [0062]
- **GATENBY.** *Plant Biotechnology*. Butterworth Publishers, 1989, 93-112 [0062]
- Cell Culture and Somatic Cell Genetics of Plants. **PASZKOWSKI et al.** *Molecular Biology of Plant Nuclear*. Academic Publishers, 1989, vol. 6, 52-68 [0062]
- **TORIYAMA, K. et al.** *Bio/Technology*, 1988, vol. 6, 1072-1074 [0062]
- **ZHANG et al.** *Plant Cell Rep.*, 1988, vol. 7, 379-384 [0062]
- **FROMM et al.** *Nature*, 1986, vol. 319, 791-793 [0062]
- **KLEIN et al.** *Bio/Technology*, 1988, vol. 6, 559-563 [0062]
- **MCCABE et al.** *Bio/Technology*, 1988, vol. 6, 923-926 [0062]
- **SANFORD.** *Physiol. Plant.*, 1990, vol. 79, 206-209 [0062]
- **NEUHAUS et al.** *Theor. Appl. Genet.*, 1987, vol. 75, 30-36 [0062]
- **NEUHAUS ; SPANGENBERG.** *Physiol. Plant.*, 1990, vol. 79, 213-217 [0062]
- **DEWET et al.** *Experimental Manipulation of Ovule Tissue*. 1985, 197-209 [0062]
- **OHTA.** *Proc. Natl. Acad. Sci. USA*, 1986, vol. 83, 715-719 [0062]
- **HORSCH et al.** *Plant Molecular Biology Manual*. Kluwer Academic Publishers, 1988, vol. A5, 1-9 [0063]
- **GLUZMAN, Y. et al.** *Communications in Molecular Biology: Viral Vectors*. Cold Spring Harbor Laboratory, 1988, 172-189 [0067]
- **DAWSON, W. O. et al.** *Virology*, 1989, vol. 172, 285-292 [0068]

- **TAKAMATSU et al.** *EMBO J.*, 1987, vol. 6, 307-311 [0068]
- **FRENCH et al.** *Science*, 1986, vol. 231, 1294-1297 [0068]
- **TAKAMATSU et al.** *FEBS Letters*, 1990, vol. 269, 73-76 [0068]
- **SAMBROOK et al.** *Molecular Cloning: A laboratory Manual*. 1989 [0096]
- *Current Protocols in Molecular Biology*. 1994, vol. I-III [0096]
- **AUSUBEL et al.** *Current Protocols in Molecular Biology*. John Wiley and Sons, 1989 [0096]
- **PERBAL**. *A Practical Guide to Molecular Cloning*. John Wiley & Sons, 1988 [0096]
- *Recombinant DNA*. **WATSON et al.** *Scientific American Books* [0096]
- *Genome Analysis: A Laboratory Manual Series*. Cold Spring Harbor Laboratory Press, 1998, vol. 1-4 [0096]
- *Cell Biology: A Laboratory Handbook*. 1994, vol. I-III [0096]
- *Current Protocols in Immunology*. 1994, vol. I-III [0096]
- *Basic and Clinical Immunology*. Appleton & Lange, 1994 [0096]
- *Selected Methods in Cellular Immunology*. W. H. Freeman and Co, 1980 [0096]
- *Oligonucleotide Synthesis*. 1984 [0096]
- *Nucleic Acid Hybridization*. 1985 [0096]
- *Transcription and Translation*. 1984 [0096]
- *Animal Cell Culture*. 1986 [0096]
- *Immobilized Cells and Enzymes*. IRL Press, 1986 [0096]
- **PERBAL, B.** *A Practical Guide to Molecular Cloning*, 1984 [0096]
- *Methods in Enzymology*. Academic Press, vol. 1-317 [0096]
- *PCR Protocols: A Guide To Methods And Applications*. Academic Press, 1990 [0096]
- **MARSHAK et al.** *Strategies for Protein Purification and Characterization - A Laboratory Course Manual*. CSHL Press, 1996 [0096]
- **VAN ENGELEN et al.** *Transgenic Res*, 1995, vol. 4, 288-290 [0097]
- **GALILI et al.** *Nucleic Acids Res*, 1987, vol. 15, 3257-3273 [0097]
- **BULLEID NJ ; JOHN DC ; KADLER KE.** Recombinant expression systems for the production of collagen. *Biochem Soc Trans.*, 2000, vol. 28 (4), 350-3 [0119]
- **HARE PD ; CRESS WA.** Metabolic implications of stress-induced proline accumulation in plants. *Plant Growth Regulation*, 1997, vol. 21, 79-102 [0119]
- **HIETAR ; MYLLYHARJU J.** Cloning and characterization of a low molecular weight prolyl 4-hydroxylase from *Arabidopsis thaliana*. Effective hydroxylation of proline-rich, collagen-like, and hypoxia-inducible transcription factor alpha-like peptides. *J Biol Chem.*, 28 June 2002, vol. 277 (26), 23965-71 [0119]
- **HULMES DJ.** Building collagen molecules, fibrils, and suprafibrillar structures. *J Struct Biol.*, January 2002, vol. 137 (1-2), 2-10 [0119]
- **INKINEN K.** Connective tissue formation in wound healing. An experimental study. University of Helsinki, September 2003 [0119]
- **MERLE C ; PERRET S ; LACOUR T ; JONVAL V ; HUDAVERDIAN S ; GARRONE R ; RUGGIERO F ; THEISEN M.** Hydroxylated human homotrimeric collagen I in *Agrobacterium tumefaciens*-mediated transient expression and in transgenic tobacco plant. *FEBS Lett.*, 27 March 2002, vol. 515 (1-3), 114-8 [0119]
- **OLSEN D ; YANG C ; BODO M ; CHANG R ; LEIGH S ; BAEZ J ; CARMICHAEL D ; PERALA M ; HAMALAINEN ER ; JARVINEN M.** Recombinant collagen and gelatin for drug delivery. *Adv Drug Deliv Rev.*, 28 November 2003, vol. 55 (12), 1547-67 [0119]
- **RUGGIERO F ; EXPOSITO JY ; BOURNAT P ; GRUBER V ; PERRET S ; COMTE J ; OLAGNIER B ; GARRONE R ; THEISEN M.** Triple helix assembly and processing of human collagen produced in transgenic tobacco plants. *FEBS Lett.*, 03 March 2000, vol. 469 (1), 132-6 [0119]
- **TANAKA M ; SATO K ; UCHIDA T.** Plant prolyl hydroxylase recognizes poly(L-proline) II helix. *J Biol Chem.*, 25 November 1981, vol. 256 (22), 11397-400 [0119]
- **WANG C ; LUOSUJARVI H ; HEIKKINEN J ; RISTELI M ; UITTO L ; MYLLYLA R.** The third activity for lysyl hydroxylase 3: galactosylation of hydroxylysyl residues in collagens in vitro. *Matrix Biol.*, November 2002, vol. 21 (7), 559-66 [0119]